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ABSTRACT
This thesis describes investigations into Placental Protein 14 (PP14), a immunomodulator 
involved in human reproduction. The studies included the development of a purification 
procedure and an investigation of the activity of the protein. In addition the cDNA coding for the 
protein was cloned and expressed as a recombinant fusion protein and the molecular structure of 
the protein was predicted and analysed using computer-assisted modelling. Finally the clinical 
significance of the protein was studied in a range of patient groups.
The purification scheme consisted of ion exchange, hydrophobic interaction and gel filtration 
chromatography, and the pure protein obtained was analysed by SDS-PAGE and Western 
blotting. The results demonstrate that the purification procedure is a suitable method to obtain 
PPM in large quantity and with high purity. PPM purified by this method retained its activity 
and was shown to suppress, in a dose-dependent manner, the uptake of 3H-Thymidine by 
peripheral blood mononuclear cells stimulated with interleukin-2. Purified PPM was also shown 
to suppress the uptake of 3H-Thymidine by the cell line U937, also in a dose-dependent manner. 
This suppression could be removed by the incubation of the PPM sample with an 
immunoabsorbent gel linked to monoclonal antibodies against PPM, demonstrating that PPM 
was the molecule responsible for the observed activity. Based on the suppression by PPM of 
U937 cell growth a bioassay for PPM was developed, this assay was used to express the specific 
activity of PPM in Units/ml.
To obtain recombinant PPM, mRNA was purified from a tissue sample and reverse transcription 
used to prepare cDNA. Specific primers were used to amplify the portion of cDNA coding for 
PPM which was then ligated into the plasmids pUC 18 and pGEX-KG. Recombinant PPM was 
then expressed as a fusion protein with glutathione-S-transferase. The expression conditions were 
optimised and the fusion protein was purified using affinity chromatography.
The structure of PPM was investigated using computer assisted modelling. PPM is a member of 
the lipocalin family of proteins which share the feature of binding small hydrophobic molecules. 
The X-ray coordinates of two lipocalins known to share sequence homology with PPM were used 
as a basis to model a predicted structure for PPM. An analysis of the structural motifs of the 
protein was carried out, and it was established that PPM shares many of the characteristic 
features of this family of proteins including the presence of a binding pocket. The model was 
then used to predict potential ligands for PPM.
PPM was measured by radioimmunoassay in uterine flushings from fertile women, women with 
unexplained infertility and women suffering from recurrent miscarriages, and in plasma samples 
from fertile and infertile women. The results from the uterine flushings from fertile women 
showed that PPM levels rose during the second half of the menstrual cycle reaching pg/ml levels 
by the end of the cycle. These physiological concentrations are in the same range as the 
concentrations at which the immunomodulatory activity of PPM was observed in vitro. The 
levels of PPM measured in uterine flushings were lower in infertile women than in fertile women, 
indicating that a deficiency in PPM may be associated with infertility. The levels measured in 
plasma samples from these two groups of women did not pick up this difference. These results 
suggests that the measurement of proteins such as PPM in uterine flushings instead of plasma 
samples may be a more sensitive indicator of local uterine function. In women suffering from 
recurrent miscarriage a significant lack of secretion of PPM was observed around the time of 
implantation. This may be conected with the failure of implantation in these patients. A 
correlation was observed between the PPM levels measured in uterine flushings from recurrent 
miscarriage patients and the level of endometrial development.
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CHAPTER ONE: INTRODUCTION
Pregnancy is a unique physiological situation in which a partly foreign tissue survives and 
develops within the maternal body. During the process of implantation the fetal 
trophoblast containing paternal genes invades deep into the maternal decidual tissue, 
which is immunologically active and contains many leukocytic cells, some of which 
appear to be specific populations found only during pregnancy. Despite the expression 
by some trophoblast cells of paternal antigens, there is no evidence for rejection of the 
fetus by the maternal immune system in normal pregnancy. The specific leukocytic cell 
populations may play a role in limiting the invasion of the trophoblast and in the 
protection against maternal rejection. Decidual tissue also contains immunosuppressive 
molecules which may also contribute to the local down-regulation of the maternal 
immune system. A situation in which either the leukocytic cells are over-activated or the 
protective immunosuppressive environment is compromised may lead to immunological 
imbalance causing trophoblast lysis and miscarriage (Hill, 1990).
One of the candidate molecules for a role in the modulation of the local immunological 
activity in the decidua during pregnancy is placental protein 14 (PPM). This molecule is 
present in substantial quantities in the uterine environment at the time of implantation 
and during the first trimester of pregnancy (Julkiinen et al., 1985) and has been shown to 
have immunosuppressive activity (Bolton et al, 1987).
Chapter 1 of this thesis reviews the immunological interactions that occur in the 
endometrium and decidua leading up to and during the first stages of pregnancy. This 
background information gives a context for the role of PPM, which may be involved in 
the regulation of these interactions.
The work described in Chapters 2 and 3 relates to the purification and biological activity 
of PPM. Chapters 4 and 5 describe recombinant expression and studies of the molecular
1
structure of PPM. Chapter 6 describes the measurement of PPM in fertile women, 
patients with unexplained infertility and patients with recurrent miscarriage.
2
1.1 IMPLANTATION AND THE ESTABLISHMENT OF PREGNANCY
Implantation depends on the successful synchronisation and completion of a number of 
processes including the development and release of the ovum and the preparation of the 
endometrium to provide an optimum environment for the dividing blastocyst. After 
fertilisation the presence of the embryo is signalled to the endometrium. The embiyo 
must then undergo adhesion, attachment and penetration to establish a blood supply to 
access nutrients from the mother.
1.1.1 The menstrual cycle
In humans the endometrium undergoes a constant cyclical process of breakdown 
regeneration and growth during the menstrual cycle. This cycle lasts between 26 and 30 
days in most women and is under hormonal control. The cycle starts with menstruation 
and the first day of bleeding is designated day 1 of the cycle. For the next 14 days until 
ovulation the cycle is under the influence of oestrogen, during the second half of the 
cycle until day 28, progesterone is the dominant hormone.
1.1.2 The Endometrium
The uterus consists of a thick myometrium of smooth muscle arranged in layers. Lining 
the muscle is the endometrium consisting of a stromal matrix over which lies a layer of 
epithelial cells facing the uterine cavity. Glands lined with epithelial cells penetrate the 
stromal cell layer. Within the endometrium are spiral arteries which provide it with a rich 
blood supply and venous lakes (Figure 1.1).
The first 14 days of the menstrual cycle are a phase of endometrial cellular proliferation. 
At the beginning of the menstrual cycle, proteases break down the stroma and the 
endometrium is shed leaving a denuded surface with only the cups forming the bottom of 
the glands left. The blood vessels are also lost in this process. Within 5 days the 
endometrium is re-epithelialised, and by day 21 the stroma and glands have regrown and
3
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Figure 1.1: The changes in human endometrium during the menstrual 
cycle. The underlying hormone changes are also shown. Redrawn from 
Johnson & Everitt (1988).
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the tissue surface is covered with microvilli which provide a receptive environment for 
implantation (Nilsson etal., 1980).
The second 14 days of the cycle are a secretory phase during which proliferation slows 
down and the epithelial cells secrete a watery fluid, containing proteins and nutrients for 
the growing embryo, into the uterine lumen (Nilsson et al, 1980). The function of many 
of these molecules is unknown but some may be involved in the regulation of 
endometrial or trophoblastic growth.
After day 14 if fertilisation has occurred, the stromal compartment of the endometrium 
undergoes the process of decidualisation as the cells enlarge and become glycogen and 
lipid rich (Noyes et al, 1950; Wewer et al, 1985). The surface microvilli of the 
epithelial cell layer become flattened and bulbous cytoplasmic projections appear 
(Lindenberg, 1991). The tissue is known as the decidua from this point on. If 
fertilisation has not occurred the endometrium still undergoes these changes but to a 
lesser degree in a process known as pre-decidualisation.
In a conception cycle the pre-embryo passes through the fallopian tube into the uterus 
and implants into the decidualised endometrium which will continue to develop. This 
development is dependent on progesterone, secreted from the corpus luteum in response 
to chorionic gonadotrophin released from the embryo. In a non-conception cycle the 
unfertilised egg is passed out of the reproductive tract and the endometrium is shed at 
day 28 as a consequence of the drop in progesterone levels.
1.1.3 Ovulation
While the endometrium develops during the proliferative phase of the cycle, the ovary 
undergoes a phase of follicular development. Oocytes are formed before birth, and 
undergo mitotic proliferation then meiotic division. Shortly after birth the follicles arrest 
in the first meiotic prophase as primordial follicles (Peters et al, 1975). These follicles
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remain in arrested meiotic prophase awaiting the signal to resume development until 
puberty, when they recommence growth at the rate of a few a day.
When development restarts, the oocytes increase in diameter and the granulosa and 
thecal cells that surround them divide and become several layers thick. The granulosa 
cells secrete glycoproteins that form a layer, the zona pellucida, between themselves and 
the oocyte. Gap junctions formed by cytoplasmic processes that penetrate the zona 
maintain contact between the granulosa cells and the oocyte. These developing follicles 
are now termed preantral follicles and their fate depends entirely on the hormonal 
environment in which they find themselves (Johnson & Everitt, 1988). For continued 
development there must be adequate levels of luteinising hormone (LH) and follicle 
stimulating hormone (FSH) present in the circulation to bind to receptors on the follicles 
and induce conversion to antral follicles. If these hormones are not available the oocytes 
will become atretic.
At the end of the previous menstrual cycle the fall in oestrogen and progesterone allows 
the secretion of LH and FSH to rise, providing an environment in the beginning of the 
cycle permissive for the development of antral follicles. This stage of development is 
characterised by the continued proliferation of the granulosa cells and outer thecal cells. 
Fluid appears between the granulosa cells and collects around the oocyte forming 
follicular fluid. A week before ovulation the leading follicle begins to dominate, 
exhibiting a higher mitotic rate and a rapid expansion of the volume of follicular fluid 
(Adashi, 1994). At this point the follicle is again dependent on the environment for its 
continuing development. Development will only continue if a surge of LH coincides 
with the appearance of LH receptors on the outer granulosa cells. The LH surge causes 
terminal growth changes that result in ovulation and the expulsion of the oocyte from the 
follicle.
LH also continues to affect the post-ovulation follicle which becomes a corpus luteum 
producing progesterone. The corpus luteum declines 9-11 days after ovulation unless
chorionic gonadotrophin (hCG) released from the trophoblast intervenes (Hearn, 1986). 
This hormone is released into the bloodstream and travels to the ovary where it binds to 
the luteinising hormone receptors in the corpus luteum and promotes the continued 
progesterone production by luteal cells which in turn supports the endometrium and 
prevents its breakdown.
1.1.4 Implantation
Fertilisation occurs in the fallopian tube and the conceptus remains at this site for a few 
days before being passed down the tube to the uterus by the action of the cilia. During 
this time the morphology of the conceptus changes as it compacts to form a morula. At 
the 32-64 cell stage, the morula undergoes a rapid series of mitoses during its transition 
to a blastocyst. The blastocyst consists of an outer rim of trophectoderm cells 
surrounding a blastocoelic cavity with an inner cell mass placed against one side of the 
cavity. Transcriptional activity increases as growth factors become active in the embryo 
(Edwards, 1994).
The trophectoderm gives rise to the trophoblast which is the tissue concerned with the 
interaction with the mother and the nutrition and support of the foetus. Before 
implantation, while the embryo is still lying free in the uterine luminal fluid, interactions 
are necessary between the conceptus and the maternal tissue (Lindenberg, 1991), 
involving extracellular signals which pass both ways (Heald\ 1976; Hearn, 1986; Heap 
et al, 1979). In humans the embryo begins to implant around day 6 after fertilisation. It 
has been shown in mice that there is a period of optimal endometrial sensitivity when 
conditions for implantation are most favourable (Finn, 1982). This window of 
opportunity is dependent on the decidualisation of the endometrium, which is stimulated 
by the presence of the embryo before physical contact occurs (Lnndkvist & Nilsson, 
1984). One of the molecules involved in this interaction may be leukaemia inhibitory 
factor (LIF) as the expression of this molecule in the endometrium of mice on the fourth 
day of pregnancy, is essential for implantation which occurs a few hours later (Stewart et 
al., 1992).
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Implantation can be split into two phases (Lindenberg, 1991). First there is the 
positioning and adhesion of the trophoblast cells to the uterine surface. The polarity of 
the embryo has already developed by the stage at which it attaches to the endometrium 
(Lindenberg et al, 1986; 1989), and the embryo orientates itself so that the site of 
attachment is on the side of the inner cell mass. The polar trophectoderm cells involved 
with primary adhesion to the endometrial cell express specific cell surface adhesion 
molecules to facilitate this process (Edwards, 1994). There are also changes in the 
carbohydrates on the luminal uterine surface (Chavez & Anderson, 1985; Anderson et 
al, 1986) which may enable the endometrium to recognise and bind the adhesion 
molecules expressed by the trophoblast.
The second phase is the penetration of the uterine epithelium. There are three main 
mechanisms of penetration which vary between species: 1. fusion, found in rabbits
where the trophoblast fuses with the epithelial cells, 2. intrusive, found in ferrets, where 
the trophoblast cells extend cytoplasmic protrusions between epithelial cells and 3. 
displacement, found in humans, rats and mice, where the epithelial cells are lifted off 
from the stroma and pile up on either side of the implantation site. Because of these 
species differences, comparisons between implantation in humans and that in other 
species can only be made with care (Ramsey et al., 1976) All these types of implantation 
have specialised cell-cell contact between trophoblast and surface epithelium of the 
uterus.
1.1.5 Trophoblast invasion
In humans the trophblastic tissue invades the wall of the uterus within 24 hours of 
adhesion first occurring (Lindenberg et al., 1986; 1989). The trophectoderm penetrates 
the basement membrane underlying the uterine epithelium by breaking down the extra­
cellular matrix of the maternal tissues with metalloproteases and collagenases to reach 
the maternal blood supply. The cells of the trophectoderm proliferate rapidly as the 
conceptus migrates through the endometrium into the spiral arteries, replacing the 
maternal endothelial and smooth muscle cells in the vessel walls (Brosens et al., 1967;
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Pijnenborg et al, 1980; Robertson et al, 1986). However, the invading trophoblast 
cells do not appear to have cytolytic activity since degenerating epithelial cells have not 
been observed next to the trophoblast cells (Lindenberg, 1991).
During implantation, the trophoblast cells differentiate into a number of sub-types 
(Figure 1.2). Some of the outer layer of trophectoderm cells fuse to form a multi­
nucleated syncytium, the syncytiotrophoblast, across which blood gases and nutrients 
diffuse to the foetus and waste products to the maternal circulation. Other trophoblast 
cells remain as single cells and form the cytotrophoblast.
The surface of the fetal tissue is made up of branched villi which anchor it in the maternal 
decidua. At the tips of the villi there is a break in the syncytiotrophoblast layer and 
cytotrophoblast cells proliferate from these villi into the maternal spiral arteries eroding 
the vessel walls so that later in pregnancy they will be able to expand and accommodate 
the increased maternal blood flow to the foetus.
The invasion of maternal tissue occurs in two stages, one at this first encounter between 
the embryo and mother in the first trimester, and a second stage in the second trimester, 
when the cytotrophoblast cells invade the myometrium underlying the decidual tissue. 
The failure of the first wave of invasion can lead to first trimester miscarriage (Khong et 
al, 1987), and failure of the second to inter-uterine growth retardation or pre-eclampsia 
(Robertson et al., 1986; Khong et al, 1986).
In addition to the invasion of the spiral arteries cytotrophoblast cells break off from the 
villi and migrate deep into the maternal tissue becoming extravillous trophoblast cells. 
The reason for this is unclear, but these cells may be involved in signalling the presence 
of the foetus to the maternal immune system.
The only fetal tissues in direct contact with the maternal blood and tissues are the 
syncytiotrophoblast, cytotrophoblast and extravillous trophoblast cells.
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Figure 1.2: Schematic representation of implantation.
(a) 4-5 days after fertilisation, free-living blastocyst; (b) 6 days, trophectoderm 
transforms to trophoblastic tissue and attaches to epithelial cells then starts to 
penetrate epithelium; (c) 9 days, decidualisation in underlying stromal tissue 
spreads out from the attachment site, trophoblast erodes epithelium and invades 
decidual tissue becoming embedded. Redrawn from Johnson & Everitt, (19KX)
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Syncytiotrophoblast is bathed by the maternal blood supply, and the extravillous 
cytotrophoblast cells are in contact with the maternal decidua.
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1.2 IMMUNOLOGY OF THE MATERNO-FETAL RELATIONSHIP
The decidual and trophoblastic tissues interact in an immunologically active environment 
in which there appear to be a number of conflicting demands placed on the maternal 
immune system. The need for surveillance against disease is the same for these tissues as 
for the rest of the body, however the unique presence of a tissue bearing foreign antigens 
residing within this setting seems to have led to the evolution of distinct immune cell 
populations with multi-purpose roles.
1.2.1 Overview of the immune system
The immune system consists of leukocytic cells which are categorised by their function 
and by the surface CD (cluster of differentiation) markers they express. In any immune 
response two components are present; recognition of the foreign material and action to 
eliminate it. The mechanisms by which these actions are brought about fall into two 
main categories, many immune responses involve both types of response.
One arm of the immune system is an adaptive system, highly specific for a particular 
pathogen, involving the memory of previous encounters with the pathogen. This 
requires the production of antibodies against the pathogen and the response is more 
effective with subsequent exposure. The major cell types involved in this arm of the 
immune system are B lymphocytes, which synthesise antibodies; monocyte-macrophages 
which recognise foreign antigens then ingest and process them; and T lymphocytes which 
have a range of functions including stimulating B cells, retention of memory of pathogens 
and cytotoxicity.
The second method is non-specific and involves a faster but less focused approach. This 
defence process relies on the leukocytes identifying surface molecules on the target cells 
as foreign, then binding to and ingesting or lysing those cells. The major cell types 
involved in this process are the phagocytes, including polymorphonuclear leukocytes and
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monocyte-macrophages which attack microorgansims; and natural killer cells which 
recognise tumour cells.
T cells recognise antigens after macrophages have ingested them, processed them and 
then presented peptides derived from them in association with major histocompatibility 
complex (MHC) molecules expressed on the surface of the macrophage. There are two 
classes of MHC antigens, class I which are expressed on all nucleated cells and are 
involved in recognition of non-self and class II which are only expressed on activated 
antigen-presenting cells such as macrophages and are involved in the recognition of 
pathogens.
An essential part of the processes described above is the secretion by leukocytes of 
cytokines. These are polypeptide molecules which signal between cells. They have a 
range of functions, most of which activate or regulate aspects of the immune system and 
provide a communication system which is involved with every aspect of the immune 
response.
1.2.2 Leukocytic cells present in the endometrium.
In non-pregnant endometrium leukocytes are a major cell population comprising up to 
50% of the total cell numbers. Leukocytes are found scattered in the stromal tissue and 
as cell aggregates (Bulmer et al, 1991) and in an intraepithelial position (Kamat & 
Isaacson, 1987). In proliferative endometrium there are three major populations of 
stromal leucocytes: CD56+ CD3- CD 16- lymphocytes (decidual large granular
lymphocytes), CD 14+ macrophages and CD3+ T lymphocytes.
The number of endometrial leukocytes remains fairly constant through the proliferative 
phase and early secretory phase of the cycle but in the late secretory phase the number of 
stromal leukocytes increases mostly due to an increase in the number of CD56+ CD3- 
CD16- lymphocytes (Bulmer et al, 1991). This increase is probably in part due to 
proliferation, since cells observed in pre-menstrual endometrium are often in mitosis
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(Bulmer et al, 1991). Leukocytes continue to make up a significant proportion of the 
cell population of the decidua. In early pregnancy up to 40% of the cells in the decidua 
are positive for the leukocyte marker CD45 (Bulmer, 1988; Bulmer & Sunderland,
1984).
1.2.2.a Decidual large granular lymphocytes
By the time of implantation the decidua contains a significant population of natural killer 
(NK)-like cells, decidual large granular lymphocytes (LGLs), the only known non- 
pathological situation in which NK cells are found in large numbers in tissues. The rapid 
rise in their numbers at this time is in part due to proliferation and part due to infiltration 
(Bulmer et al, 1991).
These cells bear an unusual phenotype found in less than 1% of the peripheral blood 
lymphoid cell population (Lanier et al, 1986) and they appear to be an organ-specific 
subset related to but distinct from classic circulatory NK cells which are large granular 
lymphocytes (LGLs). They have been termed decidual LGLs because of this 
resemblance. They stain intensely positive for CD56, which is an NK marker weakly 
expressed by peripheral blood NK cells, but do not stain for other NK markers such as 
CD 16, CD57 and CD lib. They have cytoplasmic granules that contain perforin and 
granzyme A, cytolytic molecules indicating that these cells are potentially capable of 
killer activity. Suspensions of decidual cells enriched with these cells have been shown 
to have cytotoxic activity against the NK target cell K562, although this activity is lower 
than that seen with peripheral NK cells.
In the first trimester these cells represent 50% of the decidual leukocytes but their 
numbers decline in the second trimester (Bulmer & Sunderland, 1984; Bulmer et al, 
1988a) until they are undetectable at term. They are present throughout the decidua but 
aggregate particularly around endometrial glands and arterioles (Bulmer et al, 1991). 
They are also found associated with the trophoblast - the regions of the decidua proximal 
to fetal tissue have high concentrations of these cells.
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From their cell surface markers decidual LGLs appear to be highly activated in 
comparison to circulating NK cells, and have a pattern of activation marker expression 
characteristic of interleukin-2 (IL-2) stimulated NK cells.
1.2.2.b Macrophages
Macrophages are a major cell population in the uterus and placenta throughout 
pregnancy making up 25% of the total leukocytic cell population (Hunt et al., 1984; 
Lessin et al., 1988). These cells are identified by their positive staining for the 
monocyte-macrophage marker CD 14+ (Bulmer & Johnson, 1984; Kabawat et al., 1985) 
and are often associated with extravillous trophoblast (Bulmer et al., 1988a; 1988b) 
indicating a possible interaction with fetal tissue during and after implantation rather than 
a passive presence. These macrophages do not express CD 15 - a marker of blood 
macrophages - and therefore seem to be a specific cell population distinct from 
monocyte-macrophages found in the peripheral circulation. Most of these cells stain 
intensely for the class II MHC antigens (Sutton et al., 1983; Bulmer & Johnson, 1984) 
and many express CD1 lc. The expression of these markers indicates that they are in an 
activated state (Robbins et al., 1988), are capable of secreting cytokines (Nathan, 1987; 
Hunt, 1989) and could be involved in antigen presentation to T lymphocytes. Isolated 
decidual macrophages are capable of antigen presentation in mixed lymphocyte reactions 
(MLRs) with cells from pregnant women as responder cells and their partners cells as 
stimulators (Mizuno et al, 1994). They can be further stimulated by endotoxin or 
gamma interferon (y-IFN) from lymphocytes to release interleukin -1 (IL-1) and tumour 
necrosis factor (TNF) (Hill & Anderson, 1988), both of which are products of 
macrophages involved in the up-regulation of inflammatory responses.
In addition to releasing pro-inflammatory cytokines, macrophages are also a source of 
two immunosuppressive molecules, prostaglandin E2 (PGE2) and transforming growth 
factor- P (TGF-p.). Both of these molecules suppress the proliferation of lymphocytes 
(Lala et al, 1988; Matthews & Searle, 1987) and the generation of activated killer cells.
Decidual macrophages contain enzymes, hydrogen peroxide and free radicals suggesting 
a phagocytic role (Bulmer & Johnson, 1984), perhaps involving the destruction of 
invading organisms (Redline & Lu, 1988). Phagocytosis in the decidua may also be 
required to remove tissue debris present as a by-product of the tissue remodelling that 
takes place after the invasion of the decidua by the trophoblast.
1.2.2.C CD3+ T lymphocytes
A third group of leukocytes found in the decidua are lymphocytes which stain positive 
for the lymphocyte marker CD3. Most of these cells additionally stain positive for CD8,
identifying them as members of the cytotoxic subset of T lymphocytes involved in MHC
class I interactions. These cells may be conventional T lymphocytes involved in 
interactions with macrophages and memory of pathogens rather than specific pregnancy 
related functions. However this group of cells is also capable of suppressor activity 
(Bulmer, 1989) and may be another cell type involved in creating an immunosuppressive 
environment in the decidua.
1.2.2.d B lymphocytes
There are very few B-lymphocytes in the endometrium or decidua and they are unlikely 
to play a significant role in the process of pregnancy.
1.2.3 Cytokines in the endometrium and decidua
Many cytokines have been identified as present in the endometrium and decidua and their 
role is not confined to activities solely concerned with the immune system. Table 1.1 
lists some of these cytokines and their proposed roles in the uterine environment.
1.2.3.a Pro-inflammatory cytokines
Several of the cytokines involved in the upregulation of inflammatory responses have 
been described in the endometrium and decidua. These include IL-1, TNF, ylFN and IL- 
6. The release of any of these molecules may initiate a cascade reaction resulting in the
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CYTOKINE CELLULAR
ORIGIN
ACTIVITY PROPOSED ROLE  
IN ENDOMETRIUM  
OR DECIDUA
REFERENCE
IL-1 Activated
macrophages
T-cell activator, 
induces IL-2 
secretion, pyrogen, 
inflammatory reaction 
stimulator, induces 
PGE, release.
Regulation of  
hormones,
inflammatory reaction 
against infection, 
menstruation
(Tabibzadeh, 
1990)
IL-2 Activated 
T lymphocytes
Activates NK cells Can cause trophoblast 
cytolysis by activating 
NK cells
(Parhar et al., 
1989)
IL-3 Activated 
T lymphocytes
Multi-purpose growth 
factor
Growth promoter (Armstrong & 
Chaouat, 1989)
IL-6 Macrophages,
fibroblasts
Mediator of 
inflammation
Local signalling 
between hormones and 
cytokines
(Tabibzadeh et 
al, 1989)
GM-CSF Activated
T-cells
Growth promoter Growth promoter (Chaouat et al, 
1990)
CSF-1 Macrophages, 
fibroblasts, 
endothelial cells
Growth promoter Growth promoter (Arceci et al, 
1989)
y-IFN Activated 
T-cells, NK 
cells,
macrophages
MHC class I and II 
induction, NK cell 
stimulation, anti viral,
May cause trophoblast 
antigen recognition by 
upregulating MHC 
class I
(Hill, 1992)
TNF-a Activated 
macrophages, 
activated 
T lymphocytes
IL-2 receptor 
induction, y-IFN 
production, cytotoxic 
proinflammatory
Toxic to sperm, 
trophoblast, involved in 
menstruation
(Philippaeaux & 
Piguet, 1993)
TGF-p Macrophages Inhibitory and 
stimulatory
Immunosuppression, 
growth modulator
(Tabibzadeh, 
1994)
Table 1.1: Cytokines in the endometrium and decidua and their proposed functions
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secretion of the others and additional cytokines not usually found in large quantities in 
the decidua such as interleukin 2 (IL-2).
In non-pregnant endometrium IL-1 and TNF-a are found during the late secretory phase 
(Tabibzadeh, 1990; Philippaeaux &Piguet, 1993). The process of menstruation at the 
end of a non-conception cycle is reminiscent of an inflammatory reaction (Tabibzadeh, 
1994) and IL-1 and TNF-a may be mediators of this process. Prostaglandins are 
involved in the onset of menstruation (Singh et al, 1975) and IL-1 increases PGE2 
synthesis by the epithelial cells of the endometrium (Tabibzadeh, 1990) providing a 
pathway by which cytokines may interact with the endometrium. In decidual tissue IL-1 
levels rise during early pregnancy (Kauma et al, 1990) released by stromal cells and 
macrophages.
IL-2 is released by activated lymphocytes and stimulates the release of IL-1, TNF-a and 
y-IFN and activates natural killer cells. Decidual cells can be induced to secrete IL-2 in 
vitro (Sato et al, 1990) but in vivo the release of this molecule appears to be blocked 
and IL-2 is not normally found in measurable quantities in endometrial or decidual tissue 
(Lala, 1989).
IL-6 is secreted by endometrial stromal cells in response to IL-1, TNF or ylFN and is a 
major mediator of inflammatory responses. IL-6 levels can be also be modulated by 
oestrogens providing a link between hormones and the cytokine network (Tabibzadeh et 
al., 1989).
Placental tissue contains high levels of interferons (IFNs) (Chard et al., 1986; Duc- 
Goiran et al., 1986), the function of this is unknown although receptors for ylFN, which 
induces class I antigens, are also present (Branca, 1986).
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1.2.3.b Growth-modulating cytokines
Colony-stimulating factor 1 (CSF-1) and GM-CSF are secreted by the epithelial cells of 
the endometrium in the peri-implantation period (Arced et al., 1989; Robertson et al., 
1992). These factors stimulate DNA synthesis in murine trophoblast cells in culture 
although they may not stimulate trophoblast cell proliferation (Drake & Head, 1994), 
and if administered to pregnant mice they reduce the fetal reabsorption rate and increase 
the placental weight observed (Chaouat et al., 1990). However GM-CSF also appears 
to suppress the growth of the trophoblast-like cell line Jeg-3. IL-3 is secreted by 
activated lymphocytes and stimulates the growth and differentiation of a broad range of 
cells. In vitro studies show IL-3 has only a mild stimulatory effect on the growth of 
trophoblast cells (Drake & Head, 1994). The three cytokines may be involved in growth 
promotion and differentiation of trophoblast cells but the extent of their effect is still to 
be fully identified.
TGF-p is involved in the endometrial tissue growth and remodelling that occurs during 
the proliferative phase of the menstrual cycle. It modulates epithelial cell proliferation 
and enhances gland formation. It also promotes the activation and proliferation of 
fibroblasts and the deposition of extracellular matrix (Tabibzadeh, 1994; Sporn & 
Roberts, 1990), both processes are required for the regrowth of the stromal matrix. 
Another important attribute of TGF-P is its potent immunosuppressive activity. The 
secretion of TGF-P by decidual macrophages may be an important component of the 
mechanisms which regulate and prevent IL-2 release in the decidua.
1.2.4 The role of leukocytic cells in the endometrium
The presence of leukocytic cells in the endometrium and early pregnancy decidua is not 
due to a passive infiltration but the result of an active recruitment process of specific cell 
populations. It can therefore be assumed that these cells have a role to play in the 
establishment and maintenance of successful pregnancy. There have been a number of 
theories put forward to explain the presence of these cells.
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1.2.4.a Surveillance
One likely role these cells fulfil is that of surveillance. The female reproductive tract is 
exposed to several types of foreign antigens including microorganisms, sperm and fetal 
tissue. Although the uterus is a normally sterile environment with the cervix as a 
protective barrier (Ansbacher et al, 1967; Larson & Galask, 1982) there are occasions 
when it is invaded by bacteria such as listeria or viruses such as rubella, therefore the 
presence of immunologically active cells may be a pre-emptive guard against the 
possibility of infection. Decidual macrophages and the CD3+ T lymphocytes are 
probably involved if infection occurs.
Sperm can be seen as invading cells, but although they are antigenically foreign to the 
female they are able to pass to the fallopian tube to fertilise the ovum, and some at least 
are not eliminated by the maternal leukocytic cells. After intercourse there is a massive 
influx of leukocytes into the female cervix, the function of which may be to remove 
abnormal sperm, microorganisms and debris (Thompson et al., 1992). Decidual 
macrophages with their phagocytic ability may continue this process in the uterine cavity.
1.2.4.b Recognition
Another role of decidual leukocytic cells may be antigen presentation, to signal the 
presence of the fetus to the maternal immune system and induce recognition. This may 
be an important step in provoking a muted matemal-anti-fetal response which then gives 
a subsequent advantage to the fetus (Edwards et al., 1985; Sutton et al, 1986, Lessin et 
al, 1988), by the induction of blocking antibodies or the release of growth factors.
It appears that the trophoblast has developed a system for allowing maternal recognition 
to occur without activating a cascade of immune reactions that may result in cytolytic 
responses. There may however be occasions when this immunological balance breaks 
down and the trophoblast cells do come under attack.
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In 1953 Medawar proposed that the fetus was a semi-allograft analogous to a transplant. 
This led to many studies investigating the expression by trophoblast cells of the MHC 
antigens involved in the recognition and rejection of transplants. The expression of these 
molecules by trophoblast depends on the anatomical location of the cells, the stage of 
differentiation of the cells and whether they are exposed to maternal or fetal blood.
Preimplantation embryos do not express class I MHC antigens (Desoye et al, 1988). 
Syncytiotrophoblast which is exposed to the maternal blood also does not express class I 
antigens (Faulk & Temple, 1976; Goodfellow et al, 1976) and express low to 
undetectable levels of class I mRNA (Hunt & Hsi, 1990). Cytotrophoblast within the 
villi which is not exposed to any maternal tissue contains class I mRNA (Hunt & Hsi, 
1990) but the antigen is not expressed in situ (Sunderland et al, 1981; Bulmer & 
Johnson, 1985), although if the tissue is released from the villous structure and cultured 
the cells do express class I proteins (Loke & Burland, 1988). Extravillous trophoblast 
which proliferates and invades deep into the maternal decidua contains class I mRNA 
and expresses the antigen (Sunderland et al, 1981). This antigen was later shown to be 
expressed on chorion membrane as well (Hsi et al, 1984). None of the trophoblast cell 
populations express class II MHC antigens (Loke, 1989; Faulk & McIntyre, 1983), 
usually only expressed by leukocytic cells.
The class I antigen expressed by the extravillous trophoblast is a non-classical molecule, 
with a small heavy chain (Ellis et al, 1986) and has been identified as HLA-G by in situ 
hybridisation and by purification of first trimester cytotrophoblast cells (Kovats et al, 
1989). Cultured cytotrophoblast cells can be induced to express class I antigens by ylFN 
in vitro (Loke & Burland, 1988; Feinman et al, 1987). This make trophoblast cells 
susceptible to recognition when in an environment which contains yLFN and antigen- 
presenting cells. Under these conditions there is a possibility that, in vivo, class I 
antigens are induced and that cytolysis follows the recognition of the trophoblast cells.
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Cells from first trimester decidua have been shown to act as accessory cells for mitogen 
induced lymphoproliferation and the presentation of antigens to T cells (Oksenberg et 
al, 1986). The MHC II positive activated macrophage cells are prime candidates for 
this role.
This evidence demonstrates that there is the possibility of recognition of fetal antigens by 
maternal leukocytes in the decidua. The reasons for this and the mechanisms that control 
the process are still unclear.
1.2.4.C Growth stimulation
The theory of immunotrophism was originally proposed by Wegmann and co-workers 
(Athanassakis et al., 1987). The basis of this hypothesis is that there is an advantage for 
the feto-placental unit to be in close proximity to maternal leukocytes. It is suggested 
that an interaction between the fetal membranes and the leukocytes provoke a 
recognition response stimulating the leukocytes to release growth factors including 
interleukin-3 (IL-3), GM-CSF and CSF-1. These cytokines then stimulate the 
development of the fetus and the placenta. This idea is supported by experiments that 
demonstrate that depletion of maternal T cells reduces placental cell proliferation in 
placental-trophoblast co-cultures as measured by 3H-Thymidine and that some of these 
growth factors stimulate murine trophoblast growth in culture (Athanassakis et al.,
1987).
1.2.4.d Growth regulation
The most likely function of the LGL cells in human decidua is a role in control of 
trophoblast invasion (King et al., 1993). The LGLs are candidates for this role because 
of their proximity to the regions of trophoblast invasion. These cells are able to kill 
trophoblast cells in vitro (Parhar et al., 1989), although in vivo there is little evidence of 
trophoblast cell lysis. Decidual LGLs contain cytolytic enzymes including perforin, and 
granzyme A, both of which are involved in the induction of apoptosis (Shiver et al, 
1992). Based on this observation it has been proposed that the mechanism by which the
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decidual LGLs lyse aberrant trophoblast cells is through the release of these molecules 
and the induction of apoptosis (King et al, 1993), a process which can occur with little 
histological evidence (Ellis et al, 1991).
Further evidence for the theory of LGL involvement in trophoblast control is the 
observation that trophoblast invades more deeply into ectopic sites lacking decidual 
LGLs (King et al, 1993). When an embryo implants in the fallopian tube a patchy 
decidualisation reaction takes place in the tube with LGLs only found in these areas, but 
the embryo invades beyond these regions. The main immune reaction at the ectopic site 
resembles an inflammatory response, while decidualisation still occurs in the 
endometrium, despite the remoteness of the embryo.
Decidual macrophages are another pregnancy-specific cell group that may be involved in 
the regulation of trophoblast growth. They are capable of the secretion of potent 
immunosuppressive molecules such as TGF-P and PGE2 and are also clustered round 
areas of trophoblast invasion. These molecules may have a direct role in the suppression 
of trophoblast growth, or they may be part of a control loop that suppresses overactive 
LGLs preventing a cascade inflammatory reaction form occurring.
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1.3 MECHANISMS OF FETAL PROTECTION
The evidence shows that there are a large number of activated maternal leukocytic cells 
in close proximity to the fetal-placental tissues. They are capable of recognising the 
trophoblast cells and under certain specific conditions of lysing and killing them, a 
process which may be a feature of normal pregnancy. However their presence also poses 
a considerable threat to the foetus. Various mechanisms have been proposed to explain 
how this potentially hostile environment is controlled to prevent any attack and there is 
the possibility that the breakdown of control mechanisms provides an explanation for 
recurrent miscarriage and other fertility problems.
1.3.1 Immunosuppression
Decidual tissue has been shown to contain potent immunosuppressive molecules (Bolton 
et al., 1987; Bulmer et al, 1991). This activity is usually attributed to TGF-P (Clark et 
al, 1988). Although decidual macrophages are a potential source of TGF-P, other cells 
have been described as responsible for its secretion. Clark and co-workers proposed that 
the mechanism to protect the fetus from leukocytes involves suppressor cells (Daya et 
al, 1985). In mice some of these cells have been shown to be small non-T, non-B 
granulated lymphocytes which release a soluble factor related to TGFp2 which blocks 
responses to IL-2 (Clark et al, 1988).
Suppressor cells have been found mice in the endometrium after ovulation and in the 
decidua of successful pregnancies. In mice with a deficiency of these cells there is a high 
abortion rate (Clark et al, 1986) and in human IVF and embryo transfer there is a 
mononuclear infiltrate deficient in suppressor cells in the endometrial tissue removed 
after failed pregnancies (Daya et al, 1985). The human equivalent of Clark's suppressor 
cells may be the NK-like decidual LGLs (Bulmer, 1988; Bulmer et al, 1991) but NK- 
like cells have been found in murine decidua (Croy et al, 1985) and seem to be a 
different population from the small and large suppressor cells. There is little evidence of 
human decidual LGLs exhibiting immunosuppressive activity. A more likely human
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equivalent is the decidual lymphocytes which stain positive for CD3 and CD8. These 
cells are theoretically capable of suppressor activity but this has not yet been 
demonstrated, nor is it known whether they secrete TGF-p.
There have been reports of suppression of mixed lymphocyte reactions by the 
supernatants of endometrial epithelial cell cultures. (Bulmer et al, 1991). It is possible 
that the immunosuppression observed in decidual lymphocyte preparations may in fact be 
due to contaminating epithelial cells (Bulmer, 1988). Semi-purified suppresser cells from 
human decidua show lower levels of suppression of mitogen-induced lymphocyte 
proliferation than unfractionated decidual cell suspensions, so they are not responsible 
for the total immunosuppressive activity found in decidual tissue extracts (Bulmer, 
1988). Separation of the various cell types appear to show that no single cell population 
is responsible for the immunosuppressive activity of decidual tissue.
The maintenance of an IL-2-free environment in the decidua is important for fetal 
survival (Lala, 1989). This is because the activation of T cells, NK-like large granular 
lymphocytes, lymphokine activated (LAK) cells, and macrophages is a threat to the fetus, 
and is IL-2 dependent. When IL-2 is injected into pregnant mice it causes pregnancy 
failure (Tezabwala et al, 1989). LGLs are able to lyse trophoblast cells after exposure 
to IL-2, and the release of ylFN, which is stimulated by IL-2, can induce the expression 
of MHC class I antigens on trophoblast (Feinman et al, 1987), permitting their 
recognition. Therefore the activation of an inflammatory response by IL-2 would initiate 
a range of potentially damaging processes that may lead to cytolysis of the trophoblast 
cells.
TGF-p suppresses the generation of IL-2 activated killer cells, cytotoxic T cell activity 
and IL-1 dependent T cell proliferation, and its presence in the endometrium may prevent 
these IL-2-dependent reactions from occurring. PGE2 also inhibits several 
immunostimulatory activities including mitogen proliferation of T cells, activation of NK
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cells and generation of lymphokine activated killer (LAK) cells (Lala, 1989) and may 
contribute to the maintenance of an IL-2-free environment.
Other molecules implicated in immunosuppressive activity in the endometrium include 
progesterone, a-feto protein, and chorionic gonadotrophin (hCG). Of these only 
progesterone is widely accepted as having true immunosuppressive activity.
Supernatants of IVF embryos suppress lymphocyte proliferation (Daya & Clark, 1986) 
however IVF medium alone has been shown to have immunosuppressive activity and the 
presence of immunosuppressive acivity does not correlate with successful implantation of 
these embryos. One of the molecules responsible may be early pregnancy factor, a 
protein that is still ill-defined and is measured by the inhibition of lymphocyte rosette 
formation (Morton et al, 1974; Shu-Xin & Zhenm-Qnn, 1993).
There is clear evidence for immunosuppression in decidual tissue and TGF-P and PGE2 
are probably responsible for some, but not all of this activity. The other contributing 
factors have not yet been totally characterised. The immunosuppressive activity released 
by epithelial cells observed by Bulmer (1988) may be due to placental protein 14 (PP14), 
the subject of this thesis. This will be discussed in more detail in section 1.5.
1.3.2 Blocking antibodies
The theory of blocking antibodies is based on the idea that during pregnancy the mother 
secretes antibodies that block the response between maternal leukocytes and paternal 
antigens, protecting the fetus (Rocklin et al., 1976; 1982). These antibodies are 
demonstrated using mixed lymphocyte cultures (MLC) with male lymphocytes as 
stimulator cells and maternal lymphocytes as responder cells. This reaction can be 
inhibited by maternal plasma or serum. However, these antibodies are not a clinical 
index of successful pregnancy, and blocking activity is not always detected in the serum 
of women with normal pregnancy, therefore they do not appear to play a significant role 
in the course of normal pregnancy.
26
1.3.3 TLX
The concept of TLX (trophoblast-lymphocyte-cross-reacting) antigens was originally 
proposed by McIntyre and Faulk (Faulk et al, 1978) This was based on the observation 
that a polyclonal antibody raised against a set of trophoblast antigens also recognised 
antigens on lymphocytes and some other cell types including monocytes, PMNLs, and a 
weak interaction with platelets. (Johnson et al, 1981; Bulmer et al, 1984; Bulmer & 
Johnson, 1985). These antibodies can inhibit in vitro mixed lymphocyte reactions 
(McIntyre & Faulk, 1979). The same antigens are found in the serum of some patients 
suffering recurrent miscarriages. The theory is that the TLX antigen allows the 
trophoblast cells to participate in the local immune environment (Bulmer, 1988) maybe 
by stimulating the mother to mount an immune response which is beneficial to fetal 
development, and this explains both the role of immune cells in the endometrium and 
why they do not pose a threat to the foetus. The significance of these antigens has not 
been satisfactorily established and their relevance in spontaneous miscarriage is still 
controversial. It has also been suggested that successful pregnancy depends on a balance 
between TLX-Ag and blocking antibodies.
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1.4 MODELS OF PREGNANCY FAILURE
Only 30% of embryos survive to birth, of the 70% that do not survive 15% end in 
recognisable miscarriage and 55% are lost in the early stages (Lindley, 1979). 91.7% of 
the early stage losses are without the mothers knowledge (Edmonds et al., 1982).
Although a high number of these early pregnancy losses are attributable to chromosomal 
abnormality (30-60%), the remaining 40-70% of embryo mortality is not due to grossly 
abnormal karyotype (Flamigni et al., 1991). There have been a number of theories put 
forward to explain this wastage.
1.4.1 Endometrial, oocyte and hormonal factors
It has been proposed that implantation is the crucial event which differentiates fertile and 
non-fertile cycles, (Navot et al., 1989) and that endometrial receptivity is the most 
important factor differentiating between successful and unsuccessful implantation 
(Flamigni et al., 1991). Data from in vitro fertilisation (IVF) supports this view; a 70- 
90% fertilisation rate results in only a 15-25% pregnancy rate (Navo et al., 1986) despite 
the replacement of multiple embryos. On average only 3-5% of embryos transferred 
after IVF successfully complete implantation (Flamigni et al, 1991), the rates of 
spontaneous miscarriage for IVF patients are higher than average and this reduces the 
live birth rate to below 10%. The timing of embryo replacement could be critical, as the 
endometrium may be hostile to out of phase embryos (Edwards et al., 1981). This is an 
important consideration in IVF, since embryos that are fertilised outside the body, 
cultured in vitro, and replaced develop more slowly than in the normal in vivo situation 
and therefore no longer match the dating of the endometrium into which they are 
replaced.
The drop in fecundity with age has been attributed by some to uterine ageing, and others 
to oocyte ageing. With advances in assisted reproductive technology these theories have 
been tested in oocyte donation programmes. The results are ambiguous with some
28
studies demonstrating uterine age as a parameter in successful pregnancy (Flamigni et 
al, 1993; Meldrum, 1993). Other studies report a restoration of fertility in older women 
when donor eggs are used, independent of the age of the recipients (Abdalla et al., 1993; 
Navot et al, 1994). Both factors are likely to play a role and the balance may vary 
between different women.
Hormonal imbalance and endometrial retardation (histological dating behind LH dating 
by 2 or more days) are major factors in the aetiology of recurrent miscarriage (Horta et 
al, 1977). Recurrent miscarriage is defined as three or more consecutive fetal losses 
before the gestational age of 20 weeks and 15% of all pregnancies are lost through 
miscarriage spontaneously therefore 3-4 out of every 1000 women will have 3 or more 
consecutive losses by chance alone. Even in these patients the chance of success in the 
next pregnancy is 40-70%. This makes it very hard to assess the efficacy of any 
treatment. Hormonal therapy can improve the pregnancy outcome in these patients but 
emotional support and counselling can be equally as effective (Stray-Pederson & Stray- 
Pederson, 1988). A combination of the two can restore the probability of successful 
pregnancy to that of the normal population i.e. 85%, in the majority of patients (T.C. Li, 
personal communication).
1.4.2 Blocking factors
An absence of blocking antibodies has been observed in recurrent miscarriage (Rocklin et 
al., 1976). But the lack of antibodies may be the result of the pregnancy failure not the 
cause. Immunotherapy has been carried out as a treatment for recurrent miscarriage 
based on the theory that blocking antibodies must be induced to block a matemal-anti- 
fetal immune response. This treatment involves the immunisation of the patient with 
paternal (Beer et al., 1985) or third-party (Taylor & Faulk, 1981) leukocytes. A 
variation is immunisation with trophoblast vesicles (Johnson et al., 1988). Although 
success rates of up to 78% have been reported, the placebo effect of entering a trial and 
having careful monitoring and medical attention must not be underestimated (Stray- 
Pederson & Stray-Pederson, 1988). In addition some of these trials were restricted to
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secondary recurrent miscarriage patients, based on the assumption that these were the 
most likely group to be suffering from a reaction to their partners antigens rather than 
their secondary recurrent miscarriage being due to another cause. While this is a logical 
step to take in the design of such a trial it further complicates analysis of the efficiency of 
the treatment and comparisons with the general population of recurrent miscarriers may 
imply that the treatment is more successful than it actually is. Until the results from a 
number of controlled trials currently being carried out are known the role of blocking 
factors remains controversial.
1.4.3 Immunological imbalance
There may be an immunological imbalance in recurrent miscarriage patients, either the 
leukocytes of the decidua are over-activated and prevent implantation or initiate rejection 
of the fetus or the natural immunosuppressive factors may be absent (Hill, 1990).
In spontaneous miscarriage the decidua shows large areas of necrosis and the fetal tissue 
is infiltrated by cytotoxic T lymphocytes (Cray et al, 1982), the cells which are activated 
by IL-2. These cells may have been activated due to a rise of cytokines in response to 
immunological imbalance, clinical or sub-clinical infection such as Listeria or because of 
recognition of the paternal antigens expressed by the fetus. In humans the presence of 
raised levels of TNF or IL-2 at the time of implantation has detrimental effects on the 
embryo (Hill et al., 1987; Tezabwala et al, 1989) and can cause miscarriage. In mice 
these cytokines can totally block pregnancy. However it is difficult to demonstrate that 
the cytotoxic cells are the cause of the fetal demise, their presence may only be a 
consequence of another mechanism already in process. In humans inevitably the 
evidence is only available after both cause and effect have already taken place.
The concept of immunologically mediated miscarriage is still controversial. However the 
evidence points to a system of immunological balance between activated leukocytes and 
immunosuppressive mechanisms during successful pregnancy. The breakdown of this 
system is likely to account for fertility problems in some women.
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1.5 PLACENTAL PROTEIN 14
Placental protein 14 (PPM) is the major secretory product of the endometrium during 
the secretory phase of the menstrual cycle and the first trimester of pregnancy, by the 7th 
week of gestation PPM forms 10% of the total soluble protein extracted from the 
decidua (Julkunen et al, 1985).
1.5.1 Background
PPM was first isolated by Bohn and colleagues (Bohn et al., 1982) and has since been 
shown to be structurally similar or identical to a number of other molecules discovered 
by different groups of workers. These include chorionic a-2 microglobulin (Petrunin et 
al, 1976; Petrunin et al, 1978), alpha uterine protein (Sutcliffe et al, 1980), 
progestogen-dependent protein (Joshi et al, 1980), pregnancy associated endometrial 
a -2  globulin and endometrial protein 15 (Bell et al, 1985a; 1985b). Bohn's original 
preparation was described as having a molecular weight of 42,000 daltons but this was 
later revised to 56,000 daltons made up of two identical subunits each having a 
molecular weight of 28,000 daltons (Julkunen et al, 1988). The isoelectric point of 
PPM is 4.8 (Julkunen et al, 1988). The cDNA sequence of PPM has been published 
(Julkunen et al., 1988), this shows that PPM is coded for by a 1 kilobase mRNA and is 
made up of 180 amino acids including a hydrophobic rich 18 amino acid signal sequence. 
This gives a predicted molecular weight of 18,787 daltons for the mature protein. The 
carbohydrate content of PPM is generally quoted as 17.5%, however this calculation 
appears to have been made using a molecular weight of 21,000 daltons for the subunits 
of PPM. Using the revised subunit weight of 28,000 daltons the carbohydrate content 
can be calculated as 33%.
1.5.2 PP14 is a lipocalin
PPM is a member of a family of proteins that has been named the lipocalins (Pervaiz & 
Brew, 1985). The name comes from the greek word calyx meaning pocket and has been 
coined because all the members of the family so far identified have a binding pocket
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which binds a small hydrophobic molecule. PPM has 53.4% homology with equine P- 
lactoglobulin (Bell et al, 1987; Huhtala et al, 1987) and 22.7% homology with retinol 
binding protein (Seppala et al, 1988). PPM does not bind to retinol (Westwood et al,
1988) although p-lactoglobulin does (Futterman & Heller, 1972). Bohn originally 
proposed that PPM is a prostaglandin metabolising enzyme (Bohn et al, 1982). 
However the secretion pattern of PPM does not fit with this hypothesis. PPM is 
secreted mainly during the late secretory phase of the menstrual cycle and the first 
trimester of pregnancy, a secretion pattern which doesn't correspond to that of 
prostaglandins, the levels of which gradually rise throughout pregnancy. Another 
possible ligand for PPM is progesterone which is immunosuppressive and essential for 
pregnancy. The lipocalin family is reviewed in greater detail in the introduction to 
chapter 5.
1.5.3 PP14 in the reproductive tract
PPM is secreted from the epithelial cells of the glandular endometrium into the uterine 
luminal fluid (Bell & Dore-Green, 1987) PPM is found in follicular fluid (Seppala,
1985) fallopian tubes (Julkunen et al, 1986a), and amniotic fluid, where the 
concentration of PPM at 8-10 weeks gestation is 100-1000 times that found in serum 
(Julkunen et al, 1985). In the male, seminal plasma has been found to contain high 
levels of PPM up to 800pg/ml forming 2.5% of the total protein content (Bell & Patel, 
1987; Bolton et al, 1986).
Serum levels of PPM vary during the menstrual cycle in a pattern which reflects 
ovulation (Joshi et al., 1982; 1986; Julkunen et al, 1986b) There are basal levels of 
PPM detectable throughout the cycle. This pattern reflects the development of the 
endometrium which is proliferating during the period leading up to ovulation and then 
secreting proteins in the second half of the cycle in preparation for the implantation of 
the fertilised ovum. In situ hybridisation studies show that mRNA for PPM is detectable 
in the basal glands of early proliferative phase endometrium, virtually undetectable in the 
late proliferative phase and early secretory phase and abundant after day 17 of the
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menstrual cycle, but only in the epithelial glandular cells (Seppala et al, 1988b). PP14 
mRNA was also detected in the fallopian tubes in the mucosal epithelial cells in the late 
secretory phase. Immunohistochemistry confirms this picture with PPM first detectable 
from day 19-21 in epithelial glands, with the levels reaching a maximum at the end of the 
secretory phase (Waites et al, 1988). In conception cycles the levels of PPM in serum 
rise dramatically, doubling every 2.5 days (Joshi, 1987), reaching a peak at 7-9 weeks 
then dropping after 8-10 weeks (Bell et al, 1985a; Joshi et al, 1982).
This pattern of secretion led to the assumption that PPM is progesterone dependent 
(Joshi et al, 1980) as some of the synonyms imply. Oral contraceptives containing 
progesterone can cause an increase in PPM (Seppala et al, 1987), but this may only be 
an indirect effect. There is a 6 day gap between the rise in progesterone and that of 
PPM which is unusual for a tissue release response to a hormone. There is no fall in 
PPM when RU386, a progesterone receptor antagonist is administered (Howell et al,
1989). The levels of PPM begin to fall after 9-10 weeks of pregnancy, at this time the 
levels of progesterone are still rising, although the drop in PPM secretion may reflect the 
changes in the secretory pattern of the endometrium at this time. It now appears that 
PPM secretion is dependent on oestrogen priming of the endometrium and ovarian 
hyperstimulation in IVF treatment causes a proportional rise in PPM secretion.
1.5.4 The role of PP14
PPM has been the focus of much interest and study to try and elucidate the role it plays 
in the endometrium. The clinical data are contradictory and lead to conflicting 
conclusions. Subjects with inadequate luteal responses as assessed by histology have 
low levels of PPM (Joshi et al, 1986) and in IVF treatment there is an association 
between implantation and a rise in PPM (Than et al, 1988; Wood et al, 1990). Yet 
PPM does not appear completely essential for pregnancy since Turner's syndrome 
patients are able to carry pregnancies to term after embryo transfer and hormone 
supplement despite having normal levels of progesterone and subnormal levels of PPM 
(Johnson et al, 1993). Similar findings have recently been reported in patients with
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premature ovarian failure. These findings seem dependent on the hormone regime 
followed.
It has been proposed that PPM has an immunosuppressive role in the protection of the 
feto-placental tissue from the potentially hostile maternal immune system. Decidual 
tissue extracts inhibit mixed lymphocyte reactions and the mitogen stimulated 
proliferation of lymphocytes (Bolton et al, 1987; Pockley et al, 1988). This activity can 
be removed using a specific monoclonal immunoadsorbent to PPM and purified PPM 
alone has the same activity. PPM suppresses the release of IL-1 and IL-2 from 
mitogenically stimulated mononuclear cells (Pockley & Bolton, 1989; 1990). This may 
show that the key action of PPM in suppressing lymphoproliferation is through the 
inhibition of the production and/or the release of IL-1.
PPM has also been shown to suppress natural killer cell activity (Okamoto et al, 1991) 
an interesting observation in the light of the presence of the large number of NK-like 
large granular lymphocytes in decidual tissue during pregnancy. NK cells secrete EL-1 
when activated and therefore the action of PPM to suppress IL-1 release may not be 
restricted to monocyte-macrophages.
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1.6 AIMS OF THE STUDY
The overall aim of this study was to investigate, from a number of perspectives, the 
possible role of PP14 as an immunomodulator involved in reproduction.
Chapter 1 has described the background context of the adtive immunological 
environment in which PP14 is found. A case has been made for the need of 
immunosuppressive molecules in this environment. PP14 has been suggested as a 
candidate molecule for this role.
The remaining chapters of this thesis describe studies which contribute to furthering the 
understanding of the role of PPM. These studies focus on three particular areas.
1.6.1 Purification and activity studies
Much of the work on the activity of PPM has been carried out on crude decidual 
extracts (Bolton et al, 1987). Although the purification of PPM has been reported 
(Westwood et al., 1988; Riittinen et al., 1991), the quantities obtained are of the order of 
a few milligrams. In addition the second method involves the use of acidic buffers which 
may denature the protein. To carry out further activity studies a method that yielded 
larger quantities of PPM was desirable, provided the risks of denaturation were 
minimised.
The ability of PPM to suppress the response of peripheral blood mononuclear cells to 
mitogen stimulation, in mixed lymphocyte reactions and in natural killer assays has 
previously been investigated. The cell stimulation that is the basis for all these assays is 
dependent on the response of the cells to IL-2. It is known that PPM suppresses the 
release of IL-2 in vitro but its direct effect on the response to exogenous IL-2 is not 
known. This is an important physiological question since the activation of the NK-like 
cells in the decidua is dependent on their response to IL-2.
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Previous in vitro studies on the activity of PPM have involved primary cell cultures, of 
either peripheral blood mononuclear cells (Bolton et al., 1987; Pockley et al., 1990) or 
natural killer cells (Okamoto et al., 1991). The variability observed in these studies has 
been singled out for particular mention (Pockley et al., 1990). This variation is 
attributed to the use of blood samples from different donors taken on different days, an 
inherent problem in primary cell cultures. The study of certain aspects of PPM has been 
hampered by this difficulty. Investigations into the stability of the activity, for instance, 
are hard to interpret when the natural variation from one experiment to the next may be 
higher than the activity changes under investigation.
Many assays that measure the activity of immunomodulatory molecules are based on the 
effect of that molecule on the growth of a cell line or on the release of another molecule 
by a cell line. For example, the activity of the immunosuppressive molecule transforming 
growth factor-P is measured by its ability to suppress the growth of the mink lung cell 
line Mv-l-Lu (Meagher et al., 1991).
The development of a similar bioassay for PPM using a cell line would eliminate many of 
the problems of primary cell assays and provide a reproducible way of relating the 
activity observed from one assay to the next.
1.6.2 Expression of PP14 as a recombinant protein and molecular modelling of 
PP14
If PPM is found to be an important immunomodulatory molecule in human reproduction 
there are two areas of study which also become significant. The first is the question of 
its use as a possible treatment. If PPM has a role in normal pregnancy it is likely that a 
lack of it could result in problems, which the therapeutic administration of PPM might 
resolve. Recombinant PPM protein would be essential for therapeutic administration. 
Recombinant PPM would also be an additional source of PPM for other studies.
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A second area of interest is the mechanism of action of the protein. PP14 is a member of 
the lipocalin family, a group of carrier molecules that bind small, hydrophobic molecules. 
The significance of this is unknown, as is the cofactor or ligand that PP14 binds. The 
molecular structure of some of the lipocalins is known, but it is not known how PP14 
resembles these molecules. Insights into the structure of PPM would help in identifying 
its mode of action. In addition, information about the identity of the cofactor may be 
essential for an active form of recombinant PPM to be developed.
1.6.3 Clinical significance of PP14
Many attempts have been made to ascertain the clinical significance of PPM. Almost all 
of these studies have relied on the measurement of PPM in serum or plasma. It has 
generally been accepted that the results from these experiments are unlikely to accurately 
reflect the PPM levels in the local environment of the endometrium or decidua.
If PPM has an important role as an immunomodulator during pregnancy, a lack of this 
protein may be associated with unexplained infertility or recurrent miscarriage. A 
method of examining the local levels of PPM may provide the opportunity of 
investigating the clinical relevance of PPM in these conditions.
1.6.4 Summary of aims
The studies described in this thesis had four aims:
1. To purify PPM and use this to set up an activity assay.
2. To clone the cDNA coding for PPM and express PPM as a recombinant protein.
3. To model the structure of PPM.
4. To investigate the clinical relevance of PPM.
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CHAPTER 2: PURIFICATION OF PP14
2.1 INTRODUCTION
In order to carry out the activity studies described in Chapter 3 it was essential to have a 
source of pure, active PP14. Several methods have been published describing the 
purification of PPM, however these use reagents which risk denaturation of the protein 
(Riittinen et al, 1991; Westwood et al., 1988), or introduce reagents such as 
Concanavalin A (Bell et al, 1987) which may contaminate the preparation and affect later 
immunological assays.
Using the published methods as a starting point the aim of this study was to develop a 
purification which reduced the risk of denaturation but yielded sufficient quantities of 
active PPM from each run (75-100 mg) at an acceptable level of purity (>95%).
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2.2 MATERIALS AND METHODS
All reagents, suppliers and equipment are listed in Appendix I.
2.2.1 Ethical aspects
Approval for this study was obtained from the local ethics committee.
2.2.2 Purification strategy
The method of Westwood et al. (1988) described an ion-exchange based purification 
procedure for PPM using first trimester decidual tissue as the source material. Decidual 
tissue has the advantage that up to 10% of the total soluble protein content consists of 
PPM (Julkunen et al, 1985). It is also easy to obtain in quantity. The tissue will be 
contaminated with blood, and so haemoglobin and albumin are major contaminants. 
Initial optimisation experiments established that up to 500pg of PPM could be purified in 
one step on a Mono Q ion exchange column as used in the method of Westwood et al. 
(1988). The sample obtained ran as one band using SDS-PAGE gels. However this 
method did not provide enough material for functional studies so additional steps were 
incorporated to increase the capacity of the procedure. Based on the observation that 
crude decidual extract lost some immunosuppressive activity if left at room temperature 
for several hours, the protein preparation was kept at 4°C or below throughout the entire 
purification procedure. All the buffers were pre-cooled to 4°C and the columns were run 
with water chilled to 4°C passing through the outer water jackets.
2.2.3 Optimisation of the purification procedure
2.2.3.a Step 1
A DEAE ion exchange column was incorporated as the first step, due to the high capacity 
of the gel (lOOmg total protein/ml gel) (Pharmacia, technical information). A pH of 7.2 
was selected because this is the pi of haemoglobin, which would therefore pass through 
the column without binding, significantly reducing the total protein load required on 
subsequent columns and reducing the contamination of these columns. This step also
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allowed a large volume of tissue extract (up to 4 litres) to be reduced to 500 ml in one 
step. Initial studies showed that the yield of PP14 after this step was reproducibly over 
90% and the majority (over 90% by SDS-PAGE gel analysis) of the haemoglobin was 
removed. A NaCl concentration of 0.25M was chosen to elute the protein from the 
column. This concentration was decided from the results of the test run on the Mono Q 
column which indicated that PPM was eluted at 0.15M, the concentration was increased 
by 0.1M to ensure that all the PPM was recovered.
2.2.3.b Step 2
The major contaminating protein remaining after the first ion-exchange step was albumin. 
Some of the properties of PPM and albumin are similar, for example, the pi of PPM is 
4.5 and that of albumin 4.8 so a separation by isoelectric focusing would not separate 
them satisfactorily. In addition, the molecular weights are within 10,000 kD. One classic 
way to purify albumin is to use dyes to bind albumin. However, in a pilot experiment 
over 60% of PPM was found to also bind to the dye substituted agaroses that bound 
albumin.
Hydrophobic interaction chromatography was used in the method of Riittinen et al. 
(1991) so this was explored as a possible step to separate PPM from albumin. An 
optimisation experiment was carried out to investigate different hydrophobic resins. The 
binding of albumin to the resins was monitored using SDS-PAGE, the binding of PPM 
was followed by measurement using the radioimmunoassay descibed in Appendix II. A 2 
ml sample of the eluent from the DEAE step, containing 1.25 mg of PPM, was applied to 
2ml test columns of each of the gels in phosphate buffer (pH 7.0, lOmM) containing 1M 
ammonium sulphate. If the sample bound it was then eluted by the following buffers in 
succession:
(a) 10 mM phosphate, 1M ammonium sulphate
(b) 10 mM phosphate
(c) 50% isopropanol
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The elution conditions and recovery of PPM were noted for each column and compared 
to the elution conditions for albumin. The results are summarised in Table 2.1
From the results of this experiment hexyl agarose was chosen as the resin which was 
most likely to separate albumin and PPM because albumin and PPM both bound to it but 
could be eluted in non-denaturing conditions. When scaled up as described in the final 
method protocol separation between PPM and albumin was observed.
2.2.3.C Step 3
Next a gel filtration step was added which removed some further albumin along with 
high and low molecular weight contaminants. After the hydrophobic interaction step the 
sample volume was between 50 and lOOmls. This sample was concentrated to reduce 
the volume before loading onto the gel filtration column. A Superdex 200 HR column 
was chosen because it combines a fast flow rate with high resolution, allowing a run to 
be carried out in 1.5 hours. 150mM NaCl was added to the buffer to prevent non­
specific binding of proteins to the column.
2.2.3.d Step 4
Finally the Mono Q step used in the method of Westwood et al. (1988) was replaced 
with a Hiload Q Sepharose ion exchange column with similar resolution but higher 
capacity (25mg total protein/ml gel). The flow rate and gradient volume of this final step 
were optimised to obtain a peak of pure PPM.
All the chromatography steps were carried out using Fast Protein Liquid 
Chromatography (FPLC) equipment from Pharmacia. At all stages in the purification 
procedure the fractions were assayed for their PPM content using radioimmunoassay as 
detailed in Appendix II.
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RESIN PP14
BINDING
PP14 ELUTION BUFFER PP14
RECOVERY
ETHYL not bound 1M ammonium sulphate 100%
BUTYL not bound 1M ammonium sulphate 85%
PROPYL not bound 1M ammonium sulphate 100%
PENTYL 25% bound 1M ammonium sulpliate/lOmM Phosphate 100%
HEXYL bound lOmM Phosphate 70%
OCTYL bound lOmM Phosphate 52%
DECYL bound 50% isopropanol 26%
DODECYL bound irreversibly bound 0%
RESIN ALBUMIN
BINDING
ALBUMIN ELUTION BUFFER
ETHYL not bound 1M ammonium sulphate
BUTYL not bound 1M ammonium sulphate
PROPYL not bound 1M ammonium sulphate
PENTYL 25% bound 1M ammonium sulphate/lOmM Phosphate
HEXYL 75% bound 1M ammonium sulphate/lOmM Phosphate
OCTYL bound lOmM Phosphate
DECYL bound 50% isopropanol
DODECYL bound irreversibly bound
Table 2.1: PP14 and albumin binding to hydrophobic resins. A protein 
sample after the initial ion exchange step was applied to each resin sample 
as detailed in the text and the binding, elution conditions and recovery of 
PP14 for each resin were determined. PPM bound to hexyl agarose and 
could be eluted under non-denaturing conditions with resolution from 
contaminating albumin.
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2.2.4 Final method protocol
A flow diagram of the final purification scheme is shown in Figure 2.1.
2.2.4.a Collection and preparation of decidual tissue samples
Decidual tissue was obtained from women undergoing elective termination of pregnancy, 
frozen immediately and stored at -20°C until used. The tissue was thawed overnight at 
4°C in thawing buffer (20mM phosphate pH 7.2, O.lmM dithiothreitol, O.lmM 
ethylenediamine tetraacetic acid, O.lmM phenylmethylsulphoxide). Dithiothreitol was 
added to stabilise disulphide bridges and retain protein folding, ethylenediamine 
tetraacetic acid was added to chelate metal ions required by metalloproteinases and 
phenylmethylsulphoxide was added as a proteinase inhibitor. The aim of the addition of 
these reagents was to protect the protein from denaturation.
Typically 25Og of tissue was thawed in 3 litres of buffer. The freezing and thawing 
process had the effect of lysing the cells and releasing PP14 which is a secreted protein. 
Recovery of PP14 was not significantly improved if the tissue was homogenised, and 
contamination from other proteins increased. The mixture of thawed tissue and buffer 
was centrifuged (10,000g, 30 minutes, 4°C) and the supernatant passed through a funnel 
of glass wool to remove lipids. The supernatant was dialysed overnight at 4°C against 
thawing buffer to remove low molecular weight substances and to ensure the removal of 
any salt which would reduce the binding of the protein to the ion-exchange resin. 
Typically 500ml of supernatant was dialysed against 3 changes of 25 litres of buffer. 
Following dialysis the extract was re-centrifuged using the same conditions as before and 
stored at -70°C until required.
2.2.4.b Ion exchange chromatography
Up to 2500 mis of decidual extract was applied at a flow rate of 5mls/minute to a 300ml 
column (15cm x 50mm) of DEAE Sepharose Fast Flow equilibrated in 20mM phosphate 
buffer pH 7.2 (buffer A). The column was washed with two column volumes of buffer A
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Defrost decidual tissue in buffer
Centrifuge extract and discard tissue debris 
vp
Dialyse supernatant and re-centrifuge
Apply supernatant to ion-exchange column and elute with
0.25M NaCl
*
Mix with ammonium sulphate and centrifuge
Apply supernatant to hydrophobic interaction column in 
2M ammonium sulphate and elute with decreasing 
_______ ammonium sulphate gradient (1-OM)_______
4/
Concentrate sample and apply to gel filtration column
*
Dilute sample to reduce salt content and apply to ion 
exchange column. Elute with increasing NaCl gradient (0- 
____________________Q.35M)____________________
Figure 2.1: Flow diagram of the final PPM purification procedure
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at the same flow rate and the bound protein eluted in one step by washing with buffer A 
containing 0.25M NaCl.
2.2.4.C Hydrophobic interaction chromatography
Saturated ammonium sulphate (4M, pH adjusted to 7.2)) was added to the eluted protein 
pool and then mixed for 30 minutes at 4°C on an end-over-end mixer to make a final total 
salt concentration of 1.5M. The mixture was centrifuged (10,000g, 30 minutes, 4°C) and 
the supernatant applied to a 300ml (15cm x 50mm) hexyl agarose column previously 
equilibrated with buffer A containing 1.5M ammonium sulphate at a flow rate of 
5ml/minute. The column was then washed with two column volumes of equilibration 
buffer. A 1.5M ammonium sulphate concentration was found to be required to ensure all 
the protein bound to the column, but once it had bound no protein was eluted at 
ammonium sulphate concentrations between 1.5 and 1.0M. Therefore a gradient of 1M- 
0M ammonium sulphate was applied in 2 column volumes to elute the protein. The 
eluted protein was collected in 10ml fractions which were assayed for PPM content and 
the peak fractions were pooled.
2.2.4.d Concentration of pooled fractions
The sample was concentrated using Amicon Centriprep-10 concentrators. Each 
concentrator had a capacity of 15mls. The pooled sample was centrifuged at 4°C for 40 
minutes at 1500g. Typically a pool of250ml would be concentrated to 25mls.
2.2.4.e Gel filtration
The concentrated PPM was applied to a Superdex 200 HR column equilibrated with 
Buffer A containing 150mM NaCl. The sample was applied in 5ml aliquots and the 
experiment repeated for as many times as needed, typically 5 times. The flow rate of the 
column was 4ml/minute and 5ml fractions were collected. The peak fractions containing 
PPM identified by radioimmunoassay were pooled from all the column runs.
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2.2.4.f Ion exchange chromatography
The pool of PP14 fractions from the gel filtration was diluted with 4 volumes of water to 
reduce the salt concentration and was then applied at 5ml/minute to a 60ml Q Sepharose 
HiLoad column (2.6cm x 10cm) equilibrated with 5 volumes of buffer A. The column 
was washed with 2 column volumes of buffer A and then a gradient.of 0-0.3 5M NaCl in 5 
column volumes was applied. The PPM peak was pooled.
2.2.5 SDS-Polyacrylamide gel electrophoresis
The purity of the PPM was assessed by analysing samples using standard SDS- 
polyacrylamide gel electrophoresis (Laemmli, 1970) details of the method are in 
Appendix IV.
2.2.6 Western blotting
Western bloting was carried out on the SDS-PAGE gels. The blots were probed with 
polyclonal and monoclonal antibodies. The monoclonal antibody has previously been 
described as specifically immunoreactive with PPM (Bolton et al, 1987). The details of 
this method are in Appendix IV. The polyclonal antibody was used at a dilution of 1/500 
and the monoclonal at a dilution of 1/100 The monoclonal antibodies were subcloned, 
expressed and purified as detailed in Appendix III.
2.2.7 Protein assay
The total protein content of the samples obtained during the purification process was 
measured using a Pierce BCA protein assay kit. The details of this method are in 
Appendix V.
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2.3 RESULTS
The results detailed here are from a typical purification of PP14.
2.3.1 Chromatography steps
The elution profiles from the hydrophobic interaction, gel filtration and ion exchange 
chromatography steps as identified by absorption at 280nm, and the PP14 concentrations 
measured by radioimmunoassay are shown in Figures 2.1, 2.2 and 2.3.
2500mls of decidual extract was loaded onto the ion exchange DEAE Fast Flow 
Sepharose column. Contaminating haemoglobin passed through the column and after 
washing the column, PPM was eluted in one step with 0.25M NaCl. The volume of the 
eluent was 500ml and the total PPM content 190 mg. After this step the degree of purity 
was 6% (Table 2.2).
500mls of eluent was mixed with 250mls of 4M ammonium sulphate, centrifuged for 30 
minutes at 4°C at 10,000g, then the supernatant loaded onto the hydrophobic interaction 
hexyl agarose column (Figure 2.1). There was no PPM detected by radioimmunoassay in 
the pellet obtained from the centrifugation. All the protein loaded bound to this column. 
An ammonium sulphate gradient was applied and the protein bound was eluted as a broad 
peak. PPM was measured as a distinct peak within this broader peak. The volume of the 
fractions containing PPM was 70ml and the purity after this step was 22% (Table 2.2).
After concentrating the pooled fractions they were loaded onto a gel filtration Superdex 
200 HR column in 5 aliquots each of 5mls (Figure 2.2). PP14 was eluted in fractions 21- 
25 at 210-235 mis.
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Figure 2.2: The trace obtained from the hydrophobic interaction
chromatography step. 10ml fractions were collected, the absorbance is 
indicated by the closed squares and the PP14 concentration measured in 
each fraction by radioimmunoassay is indicated by the open squares. The 
dotted line indicates the salt concentration.
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Figure 2.3: The trace obtained from the gel filtration
chromatography step. 5ml fractions were collected, the void 
volume was llOmls. The absorbance is indicated by the closed 
squares and the PPM concentration measured in each fraction by 
radioimmunoassay is indicated by the open squares.
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The fractions containing PPM were loaded onto a ion exchange Hiload Q Sepharose 
column (Figure 2.3). PPM was eluted with a salt gradient at 0.15M. The PPM peak was 
distinct from the other peaks obtained, in particular the albumin peak.
The results of the SDS-PAGE analysis of the steps of the method are shown in Figure
2.4. The band of albumin appears to have migrated slightly faster in the lanes containing 
protein at a later stage of purification, the reason for this is not known.
The results, recovery and degree of purity obtained from each step in the purification are 
summarised in Table 2.2. The final pool of PPM had a volume of 50mls containing 76mg 
of PPM with 97% purity.
2.3.2 SDS-PAGE and Western blotting
The results of the SDS-PAGE and Western blots are shown in Figure 2.5. The PPM 
obtained was 97% pure by total protein estimation and ran as a single band on SDS- 
PAGE gels at 28,000 Da. The protein was immunoreactive with polyclonal and 
monoclonal antibodies previously shown to be reactive for PPM (Bolton et al., 1983; 
1987)
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Figure 2.4: The trace obtained from the ion exchange
chromatography step. 10ml fractions were collected. The 
absorbance is indicated by the closed squares and the PPM 
concentration measured in each fraction by radioimmunoassay is 
indicated by the open squares. The dotted line indicates the salt 
concentration.
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-t 5 6
Figure 2.5: SDS-PAGE analysis of the steps of the purification. The 
molecular weight markers are listed on the right. The band of PPM  is 
arrowed.
Lane 1: Crude decidual extract
Lane 2: Sample after the first step, ion exchange
Lane 3, 4, 5, 6 : Samples after the second and third steps, hydrophobic 
interaction and gel filtration, fractions from the gel filtration column.
Lane 7: Molecular weight markers
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Purification Step Volume
(ml)
Total protein 
(mg/ml)
PPM
(ug/ml)
Total PPM  
(mg)
Recovery o f  
PPM (%)
Purit 
y (%)
Decidual Extract 2500 16 80 200 100 0.5
Ion exchange eluent 500 6.8 380 190 95 6
Hydrophobic interaction eluent 70 10.8 2357 165 82.5 22
Gel Filtration eluent (5 runs) 125 1.8 920 115 57.5 51
Ion exchange eluent 50 1.6 1518 76 38 97
Table 2.2: Details of the total protein content, PPM content, recovery and purity of 
PPM at each step in the purification procedure.
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116-
97-
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Figure 2.6: SDS-PAGE gels and Western blots of purified PP14. The 
molecular weight markers are listed on the left. The band of PP14 is 
arrowed.
Lane 1: Molecular weight markers (kD)
Lane 2: PP14 
Lane 3: PP14
Lane 4: Western blot of PP14 probed with polyclonal antibody to 
PP14
Lane 5: Control blot of molecular weight markers probed with 
polyclonal antibody to PPM
Lane 6: Western blot of PPM probed with monoclonal antibodies 
to PPM
Lane 7: Control blot of molecular weight markers probed with 
monoclonal antibody to PPM
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2.4 DISCUSSION
Several methods have been published detailing the purification of PP14 (Westwood et al, 
1988; Bell et al., 1987; Riittinen et al, 1991). However these methods either have yields 
of a few pg of PPM or use harsh or unsuitable reagents in the method.
The method described here overcomes these problems to some degree. Although this 
method has several steps, it is possible to complete an entire run from tissue to purified 
protein in 3 days, including the overnight dialysis step at the beginning of the method. 
The method was designed to enable the steps to follow on from each other without 
interupting the method to assay fractions or dialyse the sample. The rationale behind the 
use of DEAE column at the beginning of the method was that it would remove 
haemoglobin, clean up the sample and concentrate it. To simplify the identification of 
PPM, protein bound to this column was eluted in one step, eliminating the need to assay 
fractions for PPM. Subsequent steps were relied on for further resolution of the bound 
proteins.
The hexyl agarose column requires a high salt concentration for proteins to bind to it, and 
so it was natural to place this step after the ion-exchange step which leaves the protein in 
a high salt buffer. This step was not sufficiently reproducible to enable the prediction of 
the eluted fractions containing PPM, and a radioimmunoassay was routinely set up after 
this step to determine which fractions to pool for the gel filtration step. This step 
removed much of the albumin in the sample.
The gel filtration step was an essential part of the purification to remove high and low 
molecular weight contaminants.
The final ion exchange column separated PPM from other remaining proteins, resulting in 
a pure sample that ran as one band on SDS-PAGE.
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Results from this study demonstrate a method capable of purifying 75mg of active PPM 
in one run with a final purity of 97%. This provided ample PPM for activity 
investigations. The purity of the protein was confirmed independently using an HPLC 
column and acetonitrile elution (SJ Yewdall, personal communication).
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2.5 CONCLUSION
PP14 was purified in high yield and purity using a combination of chromatography 
techniques. On SDS-PAGE gels the protein ran at 28,000 Da, the published molecular 
weight of PPM. The isolated protein was demonstrated to be immunologically identical 
to PPM by the binding of characterised antibodies to a Western blot of the purified 
protein.
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CHAPTER THREE: ACTIVITY STUDIES
3.1 INTRODUCTION
3.1.1 Immunosuppressive activity of PP14
Previous studies on PP14 have established that it has immunosuppressive activity. This 
activity was initially observed in mixed lymphocyte reactions (MLRs) (Bolton et al., 
1987) and mitogen-stimulation assays (Pockley & Bolton, 1990) where the 
immunosuppressive activity of crude decidual extract could be removed with an 
immunoadsorbent gel coupled to monoclonal antibodies against PP14.
In immune responses the activation of lymphocytes and accessory cells such as 
monocyte-macrophages is increased by a process of mutual stimulation. Lymphocytes 
respond to mitogen or antigen stimulation by releasing cytokines including interleukin-2 
(EL-2), interferon-y (y-IFN) and tumour necrosis factor (TNF). These cytokines, in 
particular IL-2, activate lymphocytes and stimulate their proliferation. TNF and y-IFN 
also activate monocyte-macrophages which in turn release interleukin-1 (IL-1), 
interleukin-6 (IL-6) and TNF. These cytokines act on the lymphocytes causing further 
activation and a positive feedback loop is created. It has been suggested that the 
immunosuppressive activity of PP14 observed against lymphocytes may be mediated 
through the suppression of IL-1 release from monocyte-macrophages (Pockley & Bolton, 
1989). This would create a break in the positive feedback cycle, and limit the continued 
activation of lymphocytes.
In the uterine environment the presence of activated NK-like decidual large granular 
lymphocytes and activated macrophages is a potential risk to the fetus. The release of 
IL-2, in particular, would be detrimental to fetal tissue because IL-2 is a crucial molecule 
in the activation response. Secretion of IL-2 activates lymphocytes to release ylFN, 
which stimulates the expression of MHC antigens. Class I antigens are present on some
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trophoblast cells and their expression may lead to recognition and rejection by the 
maternal leukocytes. PP14 is proposed as one of the molecules that keeps the 
immunological environment of the decidual tissue in balance by preventing the release of 
IL-2.
Previous studies established that PP14 suppresses the proliferation of peripheral blood 
mononuclear cells in response to mitogen stimulation and in MLRs. It also has been 
shown to suppress the release of IL-2 in mitogen stimulation experiments.
In the study described here this work was extended to investigate the ability of PP14 to 
affect PBMCs directly stimulated by IL-2. This may be more relevant to the situation in 
decidual tissue. Although mitogen-stimulation of the decidual leukocytes may occur, it 
is unlikely to be a factor in the process of normal pregnancy. Similarly mixed 
lymphocyte reactions as a model for matemo-fetal interactions may not accurately 
parallel the physiological situation. However the lymphocytes found in the decidua are 
activated and could be expected to release IL-2, the fact that this does not appear to lead 
to immune activation in normal pregnancy could indicate a role for.PPM in suppression 
of the response of these cells to IL-2. Therefore it is important to establish if PPM can 
suppress the direct effect of IL-2.
3.1.2 U937 cell line
The growth of the cell line U937 is ELI dependent. This cell line is from a patient with 
histocytic lymphoma (Sundstrom & Nilsson, 1976) and shows some monocyte-like 
charateristics including the secretion of IL-1 (Palacios et al, 1982). This attribute made 
it a suitable cell line to investigate further the activity of PPM. If the theory that PPM 
suppresses IL-1 secretion is true, it can be expected that the growth of this cell line 
would be suppressed in the presence of PPM.
If PPM were to suppress the growth of U937 cells there would be advantages to its use 
as a way to study PPM activity, and it could be used to develop a bioassay for PPM.
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The previous methods of investigating the activity of PP14 have involved the isolation of 
peripheral blood mononuclear cells. The use of these methods immediately introduces 
variations into the study. There is a natural variation between the responses of the cells 
from different donors and variations are also found in the responses from day to day with 
the same donor. The preparation of the cells afresh for each experiment introduces 
further opportunities for day to day differences. The use of a cell line as the source of 
cells for the experiments to study the activity of PPM removes many of these varaibles 
and should provide a more reproducible response.
An additional consideration is the time consuming nature of lymphoproliferation assays. 
The doubling time of U937 is less than 48 hours. Unlike primaiy cell cultures which take 
several days to undergo stimulation and then enter a phase of growth, cell lines can be 
maintained in a constant logarithmic growth phase. Thus assays using cell lines can be 
carried out with shorter incubation times since the cells are already growing strongly, 
and without the preliminary separation procedures involved in primary cell culture.
3.1.3 Aims of the study
There were three aims to this part of the study:
1. To investigate the effect of PPM on IL-2 stimulated PBMCs.
2. To investigate the effect of PPM on U937 cells.
3. To develop a bioassay for PPM based on the U937 cell line.
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3.2 MATERIALS AND METHODS
The reagents and equipment used are listed in Appendix I. All assays were carried out in 
triplicate and all procedures were carried out using aseptic technique.
3.2.1 Isolation of peripheral blood mononuclear cells from whole blood.
Venous blood was collected from healthy volunteers into vacutainers containing lithium 
heparin as an anticoagulant. After gentle mixing the blood was diluted 1:1 with RPMI 
medium and separated as described by Boyum (1968) by layering 20mls of blood onto 
lOmls of lymphopaque separation medium then centrifuging at 400g‘ for 20 minutes. The 
layer containing the PBMC was carefully removed and washed by centrifugation 3 times 
with RPMI. Finally the cells were resuspended in 1ml of AIM V medium and the cell 
numbers and viability assessed by Trypan Blue dye exclusion. Equal volumes (20pl) of 
cell suspension and 0.2% Trypan Blue in PBS were mixed and a portion of the sample 
counted using a haemocytometer. The cells were resuspended at a concentration of 1 x 
106/ml in AIM V medium.
3.2.2 Stimulation of peripheral blood mononuclear cells with interleukin-2
PBMCs were isolated as described and cells suspended in lOOpl aliquots of AIM V 
medium were placed into each of the central 60 wells of 96 well plates (1 x 
105cells/well). The surrounding wells were filled with culture medium to prevent 
evaporation from the plate. The cells were cultured with 50pl of interleukin-2 (IL-2) 
diluted in AIM V at concentrations of 0.5-500U/ml. The volume in each well was made 
up to 250pl with 50pl of PBS and 50pl of AIM V. Control wells contained AIM V 
instead of IL-2. The cells were incubated at 37°C in 5% C02 and 100% humidity for 24, 
48, 72 and 96 hours. 24 hours before the end of the incubation time 25pi of AIM V 
medium containing lpCi of 3H-Thymidine was added to each well. At the end of the 
experiment the cells were harvested using a semi-automatic cell harvester. The cell 
harvester aspirates the cells onto filter mats and rinses the wells with 0.9% NaCl to 
ensure all the cells are removed. The filters were left to dry then were transferred into
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scintillation vials, 2mls of liquid scintillation fluid was added to each tube and after 
thorough mixing the samples were counted in a liquid scintillation counter for 10 
minutes.
3.2.3 Addition of PP14 to IL-2 stimulated PBMCs
PBMCs were isolated and cultured as described in the previous section, but this time 
with the addition of PPM to the cells. PPM purified using the method in chapter 2 and 
diluted in PBS was added to the cells to achieve final concentrations in the range 12.5- 
800|ig/ml. The PPM samples were added in 50pl, replacing the 50ffi of PBS added in 
the previous experiment except for the control wells which contained PBS instead of 
PPM. The cells were cultured and harvested as in the previous experiment.
3.2.4 Maintenance of U937 cells
U937 cells were maintained in continuous culture in RPMI medium supplemented with 
10% foetal calf serum, 200U/ml penicillin 200|_ig/ml streptomycin and 2mM glutamine 
(RPMI+). The cells were maintained as a stock culture in 75cm2 flasks and were 
subcultured twice a week at a split density of 1:10, with additional flasks seeded as 
necessary to grow up larger numbers of cells. This regime maintained the cells at a 
density of between 5 x 104/ml and 5 x 105/ml and ensured that the cells remained in the 
log phase of growth.
3.2.5 Culture of U937 cells
U937 cells were removed from the 75cm2 flasks, centrifuged for 5 minutes at lOOg at 
room temperature then resuspended in fresh RPMI+ medium at the cell concentrations 
indicated in the figures. Cells suspended in IOOjj.1 aliquots of RPMI+ medium were 
placed into each of the central wells of a 96 well plate as described for the PBMC assays. 
50fil of PBS was added to each well. Finally lpCi of 3H-Thymidine in lOOjil of RPMI+ 
was added to each well to make a final volume of 250}fi. The cells were cultured 
overnight at 37°C in 5% C02 and 100% humidity and harvested and counted as 
described for the PBMC experiments.
62
3.2.6 Addition of PP14 to U937 cells
U937 cells were cultured as described in the previous section with the addition of PP14. 
50pl of PP14 sample diluted in PBS was added to each well at concentration in the range 
1.5-200|ig/ml, PBS was added to the control wells.
3.2.7 Immunoabsorption of PP14
Controls for the experiments described were the removal of PPM from the samples by 
immunoabsorption. The samples before and after treatment were added to U937 cells as 
described in the previous section. Monoclonal antibodies to PPM were generated as 
detailed in Appendix III and linked to cyanogen-bromide activated Sepharose 4B gel. 
The difference in activity between absorbed and unabsorbed samples was analysed 
statistically using Student's /-test. The level of statistical significance was chosen at 
P<0.05.
3.2.7.a Preparation of immunoadsorbent
Monoclonal antibodies were dialysed against coupling buffer (Sodium carbonate, pH 8.3,
0.5M NaCl) and diluted to a concentration of 1 mg/ml. Cyanogen bromide activated 
Sepharose 4B gel was equilibrated in ImM HC1 then washed with 250mls of ImM HC1 
for each ml of gel. The gel was then washed quickly with coupling buffer and mixed 
with the dialysed antibody solution for 2 hours end-over-end at room temperature, 
2.5mg of antibodies were mixed with each ml of gel. Any remaining reactive molecules 
on the activated gel not bound to antibodies were blocked with 0.2M glycine by end- 
over-end mixing for 2 hours at room temperature. The gel was then washed alternately 
with coupling buffer and sodium acetate buffer (0.1M, pH 4.0, 0.5M NaCl), by 
resuspending the gel in 30mls of buffer then centrifuging it for 5 minutes at 2000g at 
room temperature. This washing cycle was repeated four times. Finally the gel was 
washed 5 times with PBS, and stored in PBS containing 0.1% NaN3 until required. 
Before use, the gel was rewashed with PBS 5 times to remove the preservative.
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3.2.7.b Treatment of samples
Samples containing up to 1 mg/ml PP14 were immunoadsorbed by mixing with an equal 
volume of immunoadsorbent gel on an end-over-end mixer for two hours at 4°C.
3.2.7.C Effectiveness of immunoabsorbent
The effectiveness of the immunoabsorption was checked by running the sample before 
and after on SDS-PAGE gels. Control samples were incubated with Sepharose 4B 
blocked with glycine only. This was to demonstrate the specificity of the
immunoabsorbent as well as the successful removal of PPM. Therefore, a sample with 
some minor contaminating bands was chosen to demonstrate these bands did not bind to 
the gel. The samples were also assayed using the radioimmunoassay to confirm the 
removal of PPM.
3.2.8 Viability of U937 cells
To confirm that PPM did not have a cytotoxic effect on the U937 cells parallel 
experiments were set up with PPM added to the cells at the highest concentrations. 
Instead of harvesting the cells, at the end of the incubation period the cells in each well 
were resuspended using a 1ml pipette, a portion was mixed with an equal volume of 
Trypan blue and a viable cell count carried out microscopically using a haemocytometer.
3.2.9 U937 bioassay for PP14
The U937 cell line was used to develop a bioassay for PPM. Samples were incubated 
with cells as described in the previous sections but instead of adding the samples at 
specific concentrations they were incubated with the cells at a fixed range of sample 
dilutions. The results were plotted as titration curves and used to express the activity of 
the PPM samples in Units/ml as described in the results section. 2 samples were 
analysed 4 times each to establish the inter- and intra-assay variation, and the assay 
detection limit.
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3.2.10 Effect of temperature on the activity of PP14
To test the temperature stability of the activity a sample of PPM was divided into 4 
portions. These were treated as follows:
1. 4°C for 30 minutes
2. 20°C for 30 minutes
3. 37°C for 30 minutes
4. Boiled for 5 minutes at 100°C
3.2.11 Effect of pH on the activity of PP14
A sample of PPM diluted in PBS was split into 4 portions. High and low pH buffers 
were made up (0.5M Tris, pH 11.0, 0.5M sodium acetate, pH 2.5) and added to the 
samples. It had previously been calculated how much of each buffer needed to be added 
to the PPM samples to achieve test pH values of 3.0, 5.0 and 9.0 by adding the high and 
low buffers drop by drop to samples of PBS while measuring the pH. The PPM samples 
were stored at the test pH values at 4°C for 30 minutes and then the pH of each sample 
was adjusted, with the appropriate buffer, to pH 7.2, the starting pH. The samples were 
then made up to a constant volume with water, and incubated with U937 cells. As 
additional controls neutralised buffers alone were added to U937 cells..
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3.3 RESULTS
3.3.1 The effect of incubation time on the response of peripheral blood 
mononuclear cells to a range of IL-2 concentrations
Peripheral blood mononuclear cells (PBMCs) were stimulated with IL-2 for 24, 48, 72 
and 96 hours at concentrations of 500, 100, 50, 10, 5 and 1 units/ml. The results of this 
experiment are shown in Figure 3.1. IL-2 stimulated uptake of 3H-thymidine by the cells 
in a dose-dependent manner, with the extent of stimulation increasing with time. From 
these results 72 hours was chosen as a adequate stimulation period, with an IL-2 
concentration of lOOU/ml.
3.3.2 The effect of PP14 on 3H-Thymidine uptake by peripheral blood 
mononuclear cells (PBMCs) in response to IL-2
PPM was added at different concentrations to PBMCs stimulated with IL-2. The results 
are shown in Figure 3.2. There was a dose-dependent suppression of the uptake of 3H- 
thymidine by the cells when they were incubated with PPM at concentrations in the 
range 12-800pg/ml. There was a wide variation in the immunosuppressive activity 
observed in different samples, this can be seen by the large standard error of the mean 
(S.E.M.) values.
3.3.3 The effect of PP14 on 3H-Thymidine uptake by U937 cells
Figure 3.3 shows the suppression of the growth of the cell line U937 when incubated 
with PPM at the concentrations indicated. There is a dose-dependent response between 
the concentration of PPM and the suppression in the range 1.5-100pg/ml with a slight 
drop in suppressive activity at the highest concentration of 200jj.g/ml. As with the 
results seen with IL-2 there is wide variation seen between PPM samples at the same 
concentration.
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Figure 3.1: Time course of the uptake of 3H-thymidine by
peripheral blood mononuclear cells stimulated by IL-2 at 
concentrations in the range 0.5-500U/ml.
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Figure 3.2: The effect of PPM concentration on the uptake of 
3H-thymidine by PBMC stimulated with IL-2. (n=3). Results are 
expressed as means ± S.E.M.
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Figure 3.3: The effect of PPM concentration on the uptake of 
3H-thymidine by the cell line U937 (n=6). Results are expressed 
as means + S.E.M.
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3.3.4 Viability of U937 cells
The viability of U937 cells with or without PPM was over 95%. Therefore the 
suppression of the uptake of 3H-Thymidine by U937 cells was not due to a cytotoxic 
effect of PPM.
3.3.5 The effect of cell number on the suppression of the growth of the cell line 
U937 by PP14
U937 cells were incubated at three different cell concentrations with the same sample of 
PPM to establish the effect of cell concentration on the extent of growth suppression. 
The results are shown in Figure 3.4 and show that the pattern of dose-dependent 
suppression is independent of the cell concentration. The results from this experiment 
were used to determine a cell concentration for later experiments. One of the purposes 
of investigating the U937 cell line as a basis for an assay was to develop a rapid method 
of measuring the activity of PPM. The 3H-Thymidine counts obtained with a cell 
concentration of 1 x 106/ml were approximately 10 x higher than with 1 x 105/ml in 
proportion to the number of cells. Therefore the samples with more cells could be 
counted for a shorter time since 10,000 counts should be accumulated to minimise the 
radioactive counting error. A cell concentration of 1 x 106/ml was chosen for 
subsequent experiments.
3.3.6 Removal of activity by immunoadsorbent gel against PP14
After treatment of the PPM samples with the immunoabsorbent gel the activity against 
U937 dropped as shown in Figure 3.5. The removal of activity was significant at all 
concentrations (50-12.5pg/ml, P<0.0005; 6.25pg/ml, P<0.001; 3.1pg/ml, P<0.05).
3.3.7 SDS-PAGE analysis of the effectiveness of immunoabsorption with 
monoclonal antibody gel
Figure 3.6 shows the SDS-PAGE gel of the samples before and after treatment with the 
immunoabsorptive gel. In addition, the control gel blocked with glycine only was mixed
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Figure 3.4: U937 cells cultured overnight at three different
concentrations of cell/ml with the same sample of PPM. A: 1 x 
106/ml, B: 5 x 105/ml,C: 1 x lOVml.
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Figure 3.5: The effect of treating PPM samples with a
monoclonal antibody immunoabsorbent gel on its ability to inhibit 
the uptake of 3H-thymidine by U937 cells. The results are 
expressed as means ± S.E.M. (n=4) Closed squares are 
unabsorbed, open squares are immunoabsorbed.
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Figure 3.6: SDS-PAGE analysis of PP14 sample before and after
incubation with monoclonal antibody-substituted and glycine blocked 
Sepharose gel. The band of PP14 is arrowed.
Lane 1: Molecular weight markers
Lane 2: Sample before incubation with immunoabsorbent
Lane 3: Sample after incubation with monoclonal antibody Sepharose gel
Lane 4: Sample after incubation with control Sepharose gel
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with a portion of the sample and also run on the gel. The results demonstrate the 
effectiveness of the monoclonal antibody gel in specifically removing PPM from the 
sample and show that this is not a non-specific effect since the Sepharose blocked with 
glycine does not bind PPM (Figure 3.6).
3.3.8 Analysis of PPM samples measured in units of activity
In view of the wide variation observed between different samples of PPM it was decided 
to develop a method of expressing the immunosuppressive activity of PPM in terms of 
units of activity instead of concentrations. Samples of PPM were incubated with U937 
cells at a range of PPM dilutions as shown for 10 representative samples in Figure 3.7. 
One unit of activity was arbitarily defined as the PPM concentration required to suppress 
by 50% the uptake of 3H-Thymidine by U937 cells. This method of expressing units of 
activity of a growth-suppressing substance as 50% suppression has been used to define 
the activity of other molecules including TGF-(3 (Meagher, 1991). The final dilution at 
which a 50% suppression would be achieved is read off the graph and gives the Units/ml 
of PPM activity in that sample. The activity in all 10 of the samples shown on this graph 
was calculated and the results are shown in Table 3.1.
3.3.9 Inter- and Intra-assay variation
The inter-assay variation was 22.5%, the intra-assay variation was 12.5%. The detection 
limit of the assay was defined as the level of suppression of growth that was significantly 
different from the controls, and was found to be 25%.
3.3.10 The effect of temperature on the activity of PP14
The results of the experiment to investigate the effect of temperature on the stability of 
the activity of PPM are shown in Figure 3.8. These results show that heating PPM to 
100°C destroys much of its activity. Leaving PPM at 37°C or 20°C for 30 minutes also 
reduces the activity compared with an identical sample stored at 4°C for the same length 
of time.
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3.3.11 The effect of pH on the activity of PP14
The results of the exposure of PP14 to high and low pH are shown in Figure 3.9. When 
exposed to a pH of 3 for 30 minutes a substantial loss of PP14 activity was observed. 
There was also some loss of activity at pH 5 and 9.
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Figure 3.7: Inhibition of uptake of 3H-Thymidine by samples of PP14 
expressed as dilutions of the original samples. The dotted lines read off 
the units of activity for two of the samples.
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Sample Activity (Units/ml)
A 600
B 800
C 215
D 800
E 880
F 1350
G 1100
H 760
I 850
J 1800
Table 3.1 Analysis of 10 samples of PP14 expressed in Units of 
activity.
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Figure 3.8 The effect of temperature on the ability of PP14 to 
suppress the uptake of 3H-Thymidine by U937 cells.
A: 4°C, B: 20°C, C: 37°C (all 30 minutes incubation), D: 100°C (5 
minutes).
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Figure 3.9: The effect of pH on the ability of PPM to inhibit the 
uptake of 3H-Thymidine uptake by U937 cells. A: No treatment, 
B: pH 9, C: pH 5, D: pH 3.
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3.4 DISCUSSION
3.4.1 Inhibition of the response of peripheral blood mononuclear cells (PBMCs) to 
interleukin-2 (IL-2)
PPM has previously been shown to inhibit the response of PBMCs to mitogen 
stimulation and mixed lymphocyte reactions (MLRs) (Pockley & Bolton, 1988; Bolton et 
al., 1987). PPM has also been shown to suppress the release of IL-2 from PBMC 
cultures (Pockley et al., 1990). To explain this activity it has been suggested that the 
mode of action of PPM is via suppression of the release of interleukin-1 (IL-1). IL-1 
and IL-2 are released by monocyte-macrophages and lymphocytes respectively as part of 
a positive feedback mechanism. Suppression of the release of either of these cytokines 
will lead to a down-regulation of this response. The release of IL-2 by lymphocytes acts 
in a positive feedback loop and stimulates them to proliferate and release further IL-2 as 
well as other inflammatory cytokines including IL-6 and y-IFN which act on monocyte- 
macrophages and induce them to release IL-1 which also induces lymphocyte 
proliferation.
The results described here show that PPM suppresses the response of lymphocytes to 
exogenous IL-2. This may be through the secondary path of suppressing IL-1 or it may 
be a direct effect on the lymphocytes.
The concentrations of PPM which suppresses IL-2-induced proliferation (10-800jig/ml) 
are in the same range as the concentrations described previously as suppressing mitogen 
stimulated proliferation or MLRs.
3.4.2 Inhibition by PP14 of 3H-thymidine uptake by U937 cells
The cell line U937 is dependent on IL-1 for its growth, therefore the observation that 
PPM suppresses this growth as measured by 3H-Thymidine uptake is further evidence 
that PPM may act through the supppression of IL-1 release. The removal of this activity
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by the immunoabsorption of the samples with a monoclonal antibody gel specific for 
PPM confirmed PPM as the molecule responsible for the activity. The optimisation of 
this experiment resulted in the development of a routine assay for the measurement of 
the activity of PPM. The variation of specific activity between different preparations of 
pure PPM has been a problem in the study of this molecule. However with the method 
of activity measurement based on the primary cell culture of PBMCs, the variability 
between different blood donors was a significant source of error. The U937 assay 
reduced this variability and provides a reproducible method of investigating the activity 
of PPM.
As an example of the type of experiments this assay could be used for, the temperature 
and pH stability of PPM was investigated. The observation that, on exposure to room 
temperature, a loss of activity can be measured after only 30 minutes may explain much 
of the variability between different samples.
One of the other immunosuppressive molecules in the endometrium is TGF-P, which is 
active at ng/ml concentrations, making it lOOOx more potent than PPM. Despite the 
evidence that the immunoabsorbent gel specifically both removes PPM and the 
immunosuppressive activity, a contamination of only 0.1% TGF-P would significantly 
interfere with the results. However TGF-P is acid stable, in fact it requires acid 
conditions for activation from its latent form (Meagher, 1991) and is often stored in acid 
conditions to preserve the biological activity. The total loss of activity observed with 
PPM samples treated at pH 3 establishes that contamination of the sample with TGF-p 
cannot be responsible for the immunosuppressive activity.
The use of U937 cells to assay the activity of PPM provides future opportunities for 
further study of the activity, receptors and mode of action of PPM. Although the assay 
is not specific for PPM, it can be made so by the use of the immunoabsorption gel to 
prepare control samples.
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3.5 CONCLUSION
PP14 suppresses the uptake of 3H-Thymidine by IL-2 stimulated peripheral blood 
mononuclear cells. As will be shown in Chapter 6 the concentrations at which PPM is 
active are physiological within the local enviroment of the endometrium. The activated 
leukocytic cells found in the endometrium and decidua are sensitive to IL-2 stimulation. 
Therefore these results show that PPM may play a role in suppressing the activation of 
leukocytic cells in the decidua.
The development of a bioassay for PPM will simplify future studies of the activity, 
receptors and mode of action of this molecule.
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CHAPTER FOUR: CLONING AND OVEREXPRESSION 
OF RECOMBINANT PP14 IN ESCHERICHIA COLI
4.1 INTRODUCTION
The treatment of patients with human-derived proteins is only ethical and practical if a 
recombinant form of the protein is available. PP14 is a potential therapeutic protein in 
the treatment of recurrent miscarriage, infertility and inflammatory disease, but the 
cloning and expression of PP14 in a recombinant form is a pre-requisite for the 
investigation of any clinical application. This chapter describes the expression of PP14 
as a recombinant protein.
4.1.1 Cloning strategy
Recombinant PP14 was cloned in E. coli by the insertion of cDNA for PP14 into the 
multiple cloning site of the pGEX-KG vector expression system (Guan and Dixon, 
1991). This enabled the expression of the protein in frame with glutathione ^-transferase 
(GST) as a fusion protein. This expression system allows the rapid and efficient 
purification of the fusion protein by affinity chromatography using glutathione agarose 
beads. pGEX-KG is a derivative of the pGEX-2T vector (Smith and Johnson, 1988) 
with an extra glycine-rich linker inserted next to the specific thrombin cleavage site 
between glutathione ^-transferase and the cloned protein. This linker increases the 
accessibility of the cleavage site and so improves the efficiency of thrombin in the 
cleavage reaction which splits GST from the desired recombinant protein. The 
expression of proteins as fusion products may also increase their solubility, which is 
often a limiting factor in the yield of recombinant proteins.
Proteins that contain more than 2.9% arginines are often expressed at very low levels in 
E. coli since the arginine codons AGA and AGG are rarely found in prokaryotic genes 
but are common in eukaryotic genes. When E. coli encounters these codons the cells 
stop transcribing the DNA. Brinkmann et al., (1989) found a correlation between the
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abundance of these codons and lack of protein expression in E. coli. If a protein had 
over 2.9% of AGA and AGG codons then the levels of expression were low or 
undetectable. PPM has a AGA+AGG content of 3.3% (Julkunen et al, 1988), and 
therefore there is a strong probability that the expression levels of this protein in E. coli 
may be low. This potential problem was overcome by transforming the E. coli argU 
gene encoding the rare arg t-RNA^GA^nt0 pPPM.GEX clone using the plasmid 
pUBS250 (Brinkmann et al, 1989) which carries the argU gene under the control of the 
lac promoter and is compatible with the pBR322 based vectors of which the pGEX 
derivatives are examples.
E. coli was chosen as the host organism for the cloning of PP14. There are some 
disadvantages to E. coli, including the lack of post-translational modifications such as 
glycosylation and folding which may be essential to obtain active protein. However, 
rapid, high level expression of recombinant proteins can be obtained in E. coli with low 
cost due to fast cell growth and cheap growth media.
cDNA coding for PPM was prepared using the reverse transcriptase reaction after 
mRNA purification. The leader sequence was included in the cloning procedure since 
sometimes this is important for the folding of the protein. Although less relevant when 
the expression is carried out in E. coli, it leaves the option open of transferring the clone 
to a mammalian expression system at a later date, when this may become important. The 
amino acids coded for by the leader sequence can be cleaved from the expressed protein 
after purification, but sometimes the presence of a leader amino acid sequence makes no 
difference to the activity and can be ignored. In the case of PPM the leader sequence 
consists of 18 amino acids, approximately 10% of the protein. The cDNA was amplified 
using the PCR reaction and then inserted into the cloning vector pUC 18 using blunt 
ended ligation. The initial use of a cloning vector facilitated the ligation subsequently 
into the expression vector pGEX-KG. The use of pUC 18 enabled the identification of 
clones containing the PPM gene using the blue/white selection technique. This is based 
on the design of the position of the multiple cloning site in pUC 18, which is situated in
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the lacZ gene. LacZ codes for P-galactosidase which converts 5-Bromo-4-chloro-3- 
indolyl-p-D-galactoside (X-Gal) blue when induced by isopropyl-thio-p-D-galactoside 
(IPTG) and is inactivated when a gene is inserted into it. Colonies containing religated 
vector without the inserted PP14 cDNA still have the active lacZ gene and will be blue, 
while colonies containing the insert will be white. A schematic representation of this 
ligation is shown in Figure 4.1.
The PP14 cDNA was then religated into the expression vector pGEX-KG. The vector 
used was a derivative of pGEX-KG containing cDNA coding for the human zona- 
binding protein (hZP3) inserted into the Eco RI and Hindlll sites in the multiple cloning 
site. Both vectors were digested with Eco RI and Hindlll and the hZP3 cDNA in the 
pGEX-KG vector replaced with the PPM cDNA. A schmatic representation cloning 
strategy is shown in figure 4.2.
The argU gene carrying plasmid pUBS250 was then inserted into the clone. The 
synthesis of recombinant PPM as a fusion protein with glutathione ^-transferase in 
pGEX-KG is controlled by the tac promoter (Amann et al., 1983) which is normally 
repressed by the lac repressor located on the plasmid until induction with IPTG. The 
expression conditions were optimized by investigating different induction times, 
temperatures, and IPTG concentrations. The effect of these conditions on the solubility 
of the fusion protein was also investigated.
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Figure 4.1: Schematic representation of the ligation of cDNA coding for 
P P M  into pUC18. Sma I  indicates the cloning site into which the P P 1 4  
gene was inserted, amp indicates the gene coding for ampicillin 
resistance, lacZ indicates the P-galactosidase gene.
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Figure 4.2: Schematic representation of the cloning of the gene for PP14 
into the expression vector pGEX-KG. EcoRI, Hindlll indicate the 
restriction sites into which the PP14 gene was cloned, lacZ indicates the 
P-galactosidase gene, amp indicates the ampicillin resistance gene, ori 
indicates the origin, ptac indicates the tac promoter gene, lac indicates 
the lac repressor, gst indicates the gene for glutathione-S-transferase
4.2 MATERIALS AND METHODS
The reagents, equipment and suppliers used in this study are listed in Appendix I.
4.2.1 Collection of tissue sample
An endometrium biopsy sample was taken from a healthy, fertile woman after informed 
consent had been obtained. The sample was taken during the luteal phase of the 
menstrual cycle timed from the date of the last period because this is when the 
endometrium is reported to be maximally synthesising and secreting PP14 (Bell et al., 
1987). Thirty minutes before the sample was removed the patient was given a mild 
tranquilizer to act as a muscle relaxant. The sample was removed using a Sharman's 
curette from the fundus of the endometrium. The curette was inserted gently through 
the neck of the cervix and twisted round to remove the sample. The biopsy was placed 
into a small sterile container and snap frozen immediately in liquid nitrogen. It was then 
transferred to a -70°C freezer and stored until required.
4.2.2 Isolation of mRNA
All equipment and tubes in this part of the method were pre-treated with a 0.1% solution 
of diethyl pyrocarbonate (DEPC) for 2 hours at 37°C then rinsed thoroughly with 
RNAse free water before use.
mRNA was extracted from the biopsy sample using the method of Chomczynski & 
Sacchi (1987). lOOmg of biopsy sample was placed in a 1.5ml tube and kept on ice. 1ml 
of denaturing solution (4M guanidinium thiocyanate, 25mM sodium citrate, pH 7, 0.5% 
sarkosyl, lOOmM (3-mercaptoethanol) was added and the tissue gently homogenised by 
drawing it up and down into a 1ml syringe through a 19 gauge needle until the tissue had 
broken down and a uniform suspension had been obtained. This tissue suspension was 
then split into 2 aliquots and each portion placed in a 1.5ml tube. lOOpl of 2M sodium 
acetate buffer pH 4.0 was added to each tube. After mixing by inversion, 1ml of phenol 
saturated with water was added, the tubes were again mixed by inversion and 200jil of
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chloroform:isoamyl alcohol mixture (49:l,v/v) was added. The tubes were shaken 
vigorously for 10 seconds, then chilled on ice for 20 minutes. After centrifuging at 
10,000g for 20 minutes at 4°C the upper aqueous layers containing RNA were 
transferred to fresh tubes. An equal volume (650pl) of ice-cold isopropanol was added 
to each tube and the samples were cooled at -20°C for 1 hour to precipitate the RNA. 
The RNA was pelleted by centrifuging the tubes at 10,000g for 20 minutes at 4°C then 
the supernatant was removed and discarded. The pellets were each resuspended in 300p 
1 of denaturing solution, then 300pl of isopropanol was added and after mixing the tubes 
were again cooled at 20°C for 1 hour. After centrifuging at 10,000g for 10 minutes at 
4°C the supernatant was removed and discarded. lOOpl of 75% ethanol was added 
without resuspending the pellet and the samples were frozen at -70°C until required for 
the reverse transcriptase reaction.
4.2.3 Design of primers
Two synthetic oligonucleotides were designed from the published sequence of PPM 
(Julkunen et al., 1988). EcoRI and Hindlll sites were designed into the primers to 
enable the insertion of the PCR product into the multiple cloning site of the pGEX-KG 
expression vector
The primer sequences were:
5'-CGCGGAATTCGCATGCTGTGCCTCCTGCTC-3' specific for the 5' end 
incorporating an EcoRI site (underlined) and
5,-GCGCGAAGCTTCTAGAAACGGCACGGCTC-3' specific for the 3' end 
incorporating a Hindlll site (underlined).
The absorbance of a diluted solution of each of the primers was measured at 260nm in a 
spectrophotometer. The extinction coefficient of the primers was calculated using the 
total molarity of the oligonucleotides and from these the molarities of the primer 
solutions were calculated.
89
4.2.4 Reverse Transcription
The reverse transcriptase reaction was carried out using a First-strand cDNA synthesis 
kit (Pharmacia). One of the purified mRNA samples was thawed on ice, the 75% 
ethanol removed and the mRNA dried under vacuum in a rotary evaporator.
The pellet was resuspended in 8 pi of DEPC treated water. The sample was estimated to 
contain 3 mg total RNA. To this was added 5 pi of bulk strand reaction mixture 
(containing reverse transcriptase, bovine serum albumin, dATP, dCTP, dGTP and dTTP 
in aqueous buffer), lpl of 3' primer containing 20 pmol of DNA and lpl of 200mM 
dithiothreitol (DTT). The reaction was incubated for 1 hour at 37°C.
4.2.5 Polymerase chain reaction (PCR)
The cDNA obtained from the reverse transcriptase reaction was amplified using the 
polymerase chain reaction (PCR). The conditions were determined empirically and a 
variety of dilutions of cDNA were used as the template DNA.
PCR reactions were carried out in total volumes of lOOpl. Each reaction consisted of lp  
1 of PP14 cDNA (1/1? fyjQ, Vjoq, i^ooO’ dilutions), 2pl of lOmM dNTPs, 20 pmol of 3' 
primer, 20 pmol of 5' primer, lOpl lOx PCR buffer (lOOmM Tris-HCl, pH 9.0, 500mM 
KC1, 1% Triton X-100), lOpl of 25mM MgCl2, 3.75 units Taq Polymerase and Milli Q 
water to lOOpl.
All the reagents except the Taq polymerase were assembled in a 500pl tube and heated 
to 100°C for 5-10 minutes. After cooling on ice for a few minutes the tubes were 
vortexed briefly and centrifuged at 10,000g, then the Taq polymerase was added and 
after gentle mixing the reaction mixture was overlayed carefully with lOOpl of light 
mineral oil. The tubes were placed in the thermal cycler and the PCR reaction performed 
for 30 cycles. Each cycle consisted of a denaturing step at 94°C for 45 seconds, a primer 
annealing step at 50°C for 2 minutes and an extension step at 72°C for 90 seconds. The
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tubes were then kept at 4°C. The mineral oil was removed by adding lOOpl of ether to 
each tube and vortexing thoroughly. After centrifuging the tubes at 10,000g for 5 
minutes the top layer was removed.
4.2.6 Agarose gel electrophoresis
The PCR reaction components were separated by electrophoresis on an agarose gel. A 
1% gel was cast by melting 0.75g of agarose in 75ml of TAE buffer (40mM Tris- 
Acetate pH 8.0, ImM EDTA) in a conical flask. The gel mixture was cooled to 
approximately 60°C by holding the flask under a running cold tap, then the gel was 
poured into a casting frame sealed at either end with masking tape. The samples were 
prepared by adding 1 volume of sample to 5 volumes of sample buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll, Type 400 in water). After the 
gel had set, lOpl portions of the samples were loaded. The size of the DNA fragments 
separated by electrophoresis was estimated by comparison with known molecular weight 
standards run on the same gel. lOpl of 225pg/ml bacteriophage X DNA digested with 
Hindlll or .EcoRI and Hindlll was run as molecular weight markers. The gel was run 
for 1 hour at 100V with TAE as running buffer. The gel was removed from the mould 
and placed in a container with 100ml of water containing lOOpl of a lOmg/ml solution of 
ethidium bromide (EtBr) and gently agitated for 20 minutes. The EtBr solution was then 
washed off and the DNA visualised under UV light at 310 nm on a transilluminator and 
photographed.
4.2.7 Purification of DNA
The DNA was further purified using a 'GeneClean' kit. This method is based on the 
binding of DNA to glass beads.
The band containing the amplified DNA was carefully excised from the gel and placed in 
a pre-weighed 1.5 ml tube. The tube was reweighed and the weight of the gel 
calculated. 3mls of Nal solution (6M Nal, 160mM Na2SC>3) was added for every gram 
of gel and the tubes were incubated at 50°C until the gel had dissolved (approximately 15
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minutes). The tubes were then cooled on ice for 10 minutes. 5pi of 'glassmilk' was 
added and the tubes were left on ice for 15 minutes. During this time the tubes were 
vortexed every 5 minutes. The tubes were centrifuged for 5 seconds at 10,000g and the 
supernatants carefully removed. The pellet was resuspended in 500pl of 'newwash' 
(lOmM Tris-HCl, pH 8.0, lOmM NaCl, ImM EDTA in 75% Ethanol) and recentrifuged. 
The supernatant was again removed. This step was repeated a further 2 times. Finally 
the DNA was eluted from the glass beads by resuspending the pellet in lOpl of Milli Q 
water and incubating at 50°C for 5 minutes. After centrifuging for 10 seconds at 
10,000g the supernatant was removed and retained and the resuspension, incubation and 
centrifugation was repeated. The second supernatant was pooled with the first.
4.2.8 Formation of blunt ends and phosphorylation of PCR product
The purified PCR product was ligated into pUC 18 using a Sureclone kit from 
Pharmacia.
The quantity of DNA obtained after purification using the 'GeneClean' kit was estimated 
by running an agarose gel of the sample with markers of known quantity of DNA and 
comparing visually the intensity of the bands obtained. The PCR product was prepared 
for ligation using a blunting/kinasing reaction. This reaction removes single-base 3' and 
5' overhangs on the PCR product that may interfere with the subsequent ligation. At the 
same time the product is phosphorylated by T4 polynucleotide kinase. This reaction was 
carried out in a total volume of 20pl consisting of 16pl PCR product containing 100 ng 
of DNA, lpl Klenow fragment, 2pl lOx buffer (660mM Tris-HCl, pH 7.6, 50mM 
MgCl2, 50mM dithiothreitol, 1 mg/ml bovine serum albumin, lOmM hexaminecobalt 
chloride, 2mM ATP, 5mM spermidine HC1), and lpl Polynucleotide Kinase.
The reaction mixture was incubated at 37°C for 30 minutes then 20pl of 
phenol/chloroform was added and the mixture was vortexed then centrifuged at 10,000g 
for 1 minute. The upper layer was removed and purified by centrifugation it at 10,000g 
for 30 seconds through an Sephacryl S-200 Microspin column.
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4.2.9 Ligation into pUC 18
The purified blunt-ended DNA was ligated into pUC 18. This vector was provided in 
the SureClone kit pre-digested at the Sma I site and dephosphorylated. The ligation 
reaction was carried out in a total volume of 20pl and consisted of lOng DNA, lOpl lOx 
ligation buffer (300mM Tris-HCl, pH 7.8, lOOmM MgCl2, lOOmM dithiothreitol, lOmM 
ATP,), 50 ng of pUC 18 vector DNA, lpl DTT (200mM solution), 1 unit of T4 Ligase, 
Milli Q water up to 20pl. The reaction was carried out for 2 hours at 16°C.
A control ligation reaction treated in an identical manner contained all the reagents 
except the DNA which was replaced by water. After the ligation the reactions were 
placed on ice until required for the transformation of E. coli.
4.2.10 Preparation of competent E. coli JM109 cells
Competent cells were prepared by the method of Nishimura et al. (1990). 5ml of Luria 
Broth (LB) medium (lOg tryptone, 5g yeast extract and lOg NaCl in 1 litre H2O) was 
inoculated from an original stock of E. coli JM109 cells. The cells were grown 
overnight at 37°C with vigorous shaking in a loosely capped culture tube. A 100ml flask 
containing 50ml of LB containing lOmM MgS04 and 0.2% glucose (medium A) was 
inoculated with 500pl of the overnight culture. The flask was shaken vigorously at 37°C 
with good aeration for 2Vi hours. The cells were placed on ice for 10 minutes then 
pelleted by centrifuging at 1500g for 10 minutes at 4°C. The cells were resuspended 
gently in 500pml of medium A and 2.5ml of a storage medium of LB containing 36% 
glycerol, 12% PEG 8000 and 12mM MgS04 and lOOpl aliquots were placed in 1.5ml 
eppendorf tubes. The tubes were stored at -70°C until used. The viability of the cells 
was tested before using them for transformations by streaking a plate of LA (LB with 
15g of agar added per litre) with the cells and observing the growth at 37°C overnight.
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4.2.11 Transformation of Kcott
Competent JM 109 cells were transformed by removing them from the -70°C freezer and 
placing the tubes immediately on ice. The cells were allowed to thaw on ice for a few 
minutes, and 5pl of the ligation mixture added. Aliquots of cells containing the control 
ligation mixture without the insert, lpl of the vector only and no DNA at all were also 
prepared as controls. The tubes were gently mixed and left on ice for 15-30 minutes. 
The cells were then heat-shocked by placing them in a 42°C water bath for exactly 2 
minutes. After replacing the tubes on ice for 2 minutes 1ml of pre-warmed LB was 
added to each tube, the tubes were gently mixed by inversion and the cells were 
incubated at 37°C for 45-60 minutes. The tubes were centrifuged at room temperature 
for 15-40 seconds at 10,000g and most of the supernatant was removed to leave 200pl 
of medium in the tube. At this point for transformations of pUC 18 40pl of 200mM 
isopropyl-thio-P-D-galactoside (IPTG) and 40pl of 20 mg/ml 5-bromo-4-chloro-3- 
indolyl-p-D-galactoside (X-Gal) dissolved in dimethylformamide was added to each tube 
of cells. Transformations of pGEX-KG as described later did not have any further 
reagents added to the cells, since this plasmid does not have blue/white selection. Both 
pUC 18 and pGEX-KG select for ampicillin resistance so the cells were gently 
resuspended in the remaining medium and plated onto pre-warmed Lamp plates, lg of 
agar was dissolved in lOOmls of LB, the mixture was autoclaved and after cooling to 
60°C, ampicillin was added to make a final concentration of 50pg/ml. 25ml aliquots 
were dispensed into petri dishes and left to set. After plating out the transformed cells 
the plates were incubated overnight at 37°C.
4.2.12 Identification of transformants
The positive colonies could be identified from those containing only religated vector due 
to their inability to make p-galactosidase and convert X-Gal to a blue product. The 
production of P-galactosidase may cause the colonies containing this activity to grow 
slower than the white colonies positive for the insert, and appear as pinpoints rather than 
fully developed colonies, therefore some colonies that are in fact negative for the insert
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can initially appear as white positive colonies. The blue colour can be enhanced by 
placing the plates at 4°C for a few hours. After this incubation 36 white colonies from 
the plate with the ligation mixture containing the insert were picked off the plate using an 
inoculation loop and grown up overnight in 5ml of Lamp broth (LB containing 50pg/ml 
ampicillin) at 37°C with in loosely capped culture tubes with vigorous shaking.
4.2.13 Minipreparation of plasmid DNA
Minipreparations of DNA were prepared as described in Maniatis (Maniatis et al, 
1980). 1.5ml of each overnight culture was placed in a 1.5ml tube and the cells pelleted 
by centrifuging for 1 minute at 10,000g. The cells were resuspended by vigorous 
vortexing in lOOpl of ice-cold miniprep I solution (25mM Tris-HCl pH 8.0, 50mM 
glucose, lOmM EDTA). After leaving the tubes at room temperature for 5 minutes with 
the lids open 200pl of freshly made miniprep II solution (0.2M NaOH, 1% SDS in H2O) 
was added, the tubes mixed by inversion and placed on ice for 5 minutes. Following this, 
150pl of ice-cold miniprep III solution (60ml 5M potassium acetate, 11.5ml acetic acid, 
28.5ml water) was added and the tubes again left on ice for 5 minutes. After briefly 
vortexing the tubes were centrifuged for 5 minutes at 10,000g and the supernatants 
transferred to fresh tubes. An equal volume (450pl) of phenol was added, the tubes 
were vortexed thoroughly and centrifuged for 5 minutes at 10,000g. The supernatants 
were transferred to fresh tubes and 500pl of ether was added. The tubes were again 
vortexed and centrifuged at 10,000g for 2 minutes. The supernatants were removed and 
discarded and 1ml of ethanol at -20°C was added. The tubes were left on ice for 10 
minutes, then centrifuged for 7 minutes at 10,000g. The supernatants were removed and 
discarded and the pellet was washed with lOOpl of 70% ethanol. The pellet was dried 
using a rotary evaporator centrifuge and then resuspended in 20pl of Milli Q water.
4.2.14 Restriction digests
Plasmid DNA from the minipreps was digested with restriction enzymes to cut out the 
PCR product. The reaction mixture was carried out in a total volume of 20pl containing 
12 units of EcoRI, 12 units of Hindlll, 2pl of lOx incubation buffer (lOOmM Tris-HCl
pH 7.5, 50mM NaCl, 6mM MgC^, 6mM P-mercaptoethanol), lpl of 1 mg/ml RNase A 
(previously boiled for 15 minutes to remove DNase activity), lOpl of miniprep DNA and 
Milli Q water to make the volume up to 20pl. The reaction was carried out at 37°C for 
1 hour and then lOpl of the reaction mixture was electrophoresed on an agarose gel as 
before.
Clones that potentially contained the insert for PPM were identified from the gel by the 
presence of two bands, one with approximate size of the insert (543 base pairs) in 
addition to the plasmid band (5000 base pairs). Clones that did not contain an insert 
were identified by the presence of only one band.
4.2.15 Sequencing of DNA
The sequence of the insert now in the plasmid pUC 18 in the positive clones was 
checked using a USB sequencing kit. This was to confirm that the correct piece of DNA 
had been ligated and that the sequence agreed with the published sequence.
Three additional primers were used for sequencing, 2 were from the kit and were 
designed to be used to sequence DNA fragments in the Ml 9 range of vectors. The thrid 
primer was designed from the centre of the PPM sequence.
For each of the primers (5 in total) 7.5 pi of a miniprep containing 4pg of DNA was 
denatured by adding 2pl of 2M NaOH , vortexing and centrifuging at 10,000g briefly 
then incubating at room temperature for 10 minutes. 3 pi of 3M sodium acetate and 7pl 
of Milli Q water were then added and the DNA was precipitated by the addition of 60pl 
of 100% ethanol. After a 30 minute incubation at 70°C the DNA was centrifuged at 
10,000g for 10 minutes, the pellet was washed with 70% ethanol and then resuspended 
in lOpl of Milli Q water.
Sequencing reactions: lOpl of template DNA was annealed to lpmol of each primer in 2 
pi with 2pl of annealing buffer. After vortexing and centrifuging at 10,000g briefly the
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reaction tube was heated at 65°C for 5 minutes, then 37°C for 10 minutes. The tubes 
were then cooled to room temperature for at least 10 minutes, then centrifuged at 
10,000g briefly. For each primer 4 tubes were prepared labelled 'A', 'C', 'G' and T . 2.5pl 
of the A,C,G and T mixture were dispensed into the appropriate tubes. These tubes 
were pre-warmed at 37°C for at least 1 minute. An 'enzyme pre-mix' was prepared by 
mixing 2pl of T7 DNA Polymerase, 14pl of enzyme dilution buffer, 3 pi of labelling mix, 
13pi of water, 8pl of DTT and 8pl of 32P-dATP and kept on ice. 6pl of this mix was 
added to each annealed template and primer to carry out the labelling reaction. After 
mixing gently the tubes were incubated at room temperature for 10 minutes. 4.5pl of 
each labelling reaction was added to each of the tubes labelled A,C,G and T. After 5 
minutes incubation at 37°C the reactions were stopped by the addition of 5 pi of stop 
solution. The tubes were then stored on ice until they were loaded onto the gel. Just 
prior to loading the gel the reactions were heated to 75-80°C for 2 minutes.
The sequencing gel was prepared by washing the plates with water, then ethanol, then 
coating them with silicone. Spacers were placed acroos the bottom and down either side 
and then plates were held together with clamps. The gel mixture was prepared by gently 
heating 5.7g acrylamide, 0.3g bisacrylamide and 42g of urea in TBE (lOOmM Tris- 
Borate, 2mM EDTA) until the mixture was dissolved. After cooling to room 
temperature the mixture was filtered through a 0 .2pm filter, topped up to 100 ml with 
TBE. Immediately before use 1 ml of fresh 10% ammonium persulphate was added and 
then swirled to mix. 40pl of TEMED was then added and the gel mixture poured 
carefully into the prepared plate sandwich. The comb was inserted at the top and the gel 
left to set for at least 1 hour.
The gel was placed in the apparatus and the comb removed. TBE was washed along the 
top of the gel to remove the urea and the comb reinserted to form 40 wells across the 
gel. The gel was pre-run at 1800V for 1 hour prior to loading the samples. The gel was 
run in TBE buffer. 2.5pl of each of the 20 samples was loaded in the order A, C, G, T
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and the gel run for 2 hours. The samples were then reapplied to the remaining 20 wells 
and the running of the gel continued for a further 2 hours.
After running the gel was transferred onto filter paper and exposed to autoradiography 
film for 2  hours at -70°C in the dark.
4.2.16 Preparation of insert from positive colonies
5ml cultures of the positive clones were grown up in Lamp broth and the DNA prepared 
as before. The DNA was digested with restriction enzymes in a total volume of 80pl 
consisting of 40pl miniprep DNA, 36 units of EcoRI, 36 units of Hind\\\, 8 pi lOx buffer 
(lOOmM Tris-HCl pH 7.5, 50mM NaCl, 6mM MgCl2 , 6mM p-mercaptoethanol), made 
up to 80pl with Milli Q. The reaction was carried out at 37°C for IV2 hours.
The DNA was purified by running an agarose gel and the band containing the insert was 
excised and treatment with the 'GeneClean' kit as described before.
4.2.17 Preparation of pGEX-KG vector
The original pGEX-KG vector was a kind gift of Dr. A Bannister. The vector used to 
ligate the PP14 insert into was a modified version (pHZP3GEXl.l). This contains the 
insert hZP3 which codes for the human zona pellucida protein ZP3 ligated into the 
EcoRI and Hindlll sites.
An overnight culture of JM 109 containing the pHZP3GEXl. 1 vector was grown up in 2 
x 5ml loosely capped culture tubes overnight at 37°C with vigorous shaking. 
Minipreparations of plasmid DNA were made as described before.
4.2.18 Restriction digestion of pHZP3GEXl.l
The DNA was digested with restriction enzymes in a total volume of 80pl consisting of 
40pl DNA, 36 units of EcoRI, 36 units of Hind III, 8 pi lOx buffer (lOOmM Tris-HCl pH
7.5, 50mMNaCl,6mM MgCl2,6mM P-mercaptoethanol), Milli Q water up to 80pl.
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The reaction was carried out for IV2 hours at 37°C and then separated on an agarose gel 
and the band containing the plasmid carefully excised. The DNA was purified using the 
'GeneClean' kit as before.
4.2.19 Ligation of the insert into pGEX-KG
The PPM insert was ligated into the pGEX-KG vector in a total volume of 20pl 
consisting of lpl pGEX containing 12ng of DNA, lpl insert containing 16ng of DNA, 1 
pi lOx ligation buffer (300mM Tris-HCl, pH 7.8, lOOmM MgCl2, lOOmM DTT, lOmM 
ATP), 2.5 units of T4 DNA ligase, Milli Q water to 20pl.
The reaction was carried out at 4°C overnight. Control reactions were also carried out 
as described before. Competent cells were transformed with 5pl of each ligation mixture 
and Lamp plates inoculated as described before.
4.2.20 Identification of transformants
After overnight incubation at 37°C the plates were inspected for colonies. When cloning 
into pGEX-KG the incidence of false positives is much higher than in pUC 18 since there 
is no way of visually screening between positive and negative religated vector. 36 
colonies were picked off the plate inoculated with the cells containing the ligation 
mixture with the insert. These colonies were expanded in 5ml overnight cultures and 
minprepped and digested as described before. The potentially positive clones were 
identified by running a gel and looking for a band corresponding to the size of the insert.
4.2.21 Transformation of positive recombinant clones with plasmid pUBS250
Positive clones containing the PPM insert in pGEX-KG were used to prepare competent 
cells as previously described. The cells were transformed as described by the addition of 
lpl of the plasmid pUBS250 which codes for the argU gene. This time the cells were 
plated onto twin selection plates containing 25pg/ml ampicillin and 25pg/ml kanamycin,
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since the pUBS250 plasmid selects for kanamycin resistance. Colonies exhibiting 
kanamycin resistance were assumed to contain the pUBS250 plasmid.
4.2.22 Expression of recombinant protein
5ml cultures of positive clones were grown overnight at 37°C with shaking and good 
aeration in broth (LB containing 25pg/ml ampicillin and 25pg/ml kanamycin).
50pl of this overnight culture was inoculated into 5ml of fresh broth. The
cultures were grown up under the same conditions for 2 hours and 1ml of uninduced 
culture removed. Protein expression was induced by the addition of IPTG to a final 
concentration of ImM. 1ml of culture medium was removed every hour for 3 hours 
after induction. Control cultures with the plasmids pGEX-KG and pUBS250 without 
the insert were also induced. Control cultures of E. coli JM109 cells were also grown 
up in LB without antibiotics and induced. The samples were spun for 1 minute to pellet 
the cells and total cell extracts were prepared by resuspending the cells in lOOpl SDS- 
PAGE running buffer (50mM Tris-HCl, pH 6 .8, lOOmM dithiothreitol, 2% SDS, 0.1% 
bromophenol blue, 10% glycerol). SDS-PAGE was carried out as described in appendix 
IV.
4.2.23 Protein solubility
The solubility of the expressed protein was investigated by growing up further 5ml 
cultures of the positive clones and inducing them for 3 hours as before. 1ml of cells 
were pelleted and resuspended in lOOpl of PBS and sonicated on ice for 2 bursts of 10 
seconds each at an amplitude of lOp . The suspension was then centrifuged at 10,000g 
for 30 minutes and the pellet resuspended in SDS-PAGE running buffer as before. SDS- 
PAGE was run on the resuspended pellets and the supernatants to establish the 
proportion of expressed protein in the soluble fraction.
4.2.24 Optimisation of expression conditions
From the results of the previous experiment it was apparent that a substantial proportion 
of the expressed protein was in an insoluble form when expressed under the initial
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growth conditions described. A number of changes were made to increase the 
proportion of expressed protein in the soluble fraction. The growth temperature was 
investigated since it has been reported that lower expression temperatures increase the 
solubility of some pGEX-KG fusion proteins (Taylor et al., 1993). Cultures were grown 
as before for 3 hours at 37°C, 30°C and 25°C. Cells were sonicated as before and the 
supernatants and resuspended pellets run on SDS-PAGE.
The effect of the sarkosyl concentration on solubility was also investigated. Cell pellets 
were sonicated in 0.05%, 0.1% and 0.5% solutions of sarkosyl. The soluble and 
insoluble fractions obtained were electrophoresed and the amount of expressed protein in 
the soluble fraction assessed.
4.2.25 Scale-up of protein expression
The expression of recombinant PP14 was scaled up into 100ml flasks. Overnight 
cultures of the positive clones were grown in 10 ml aliquots of at 37°C.
Flasks containing 100ml Lamp/kana (up to 10 flasks) were each inoculated with 1ml of 
overnight culture. The flasks were placed on a shaker at 37°C for 2 hours. The flasks 
were then cooled on ice for 10 minutes before IPTG at a final concentration of 0.05mM 
was added. The cultures were induced at 25°C with shaking. The induction time was 
increased to 4 hours to take account of the slower growth rate of the cells at 25°C. The 
cells were harvested at 4°C by centrifuging at 3000g for 10 minutes, and each pellet was 
resuspended in 1ml sonication buffer (PBS, 0.5% sarkosyl, 0.1 mM PMSF). The cell 
pellets were each sonicated on ice for a total of 1 minute in 10 second bursts with 2 
minutes rest on ice between each sonication. The suspensions were then centrifuged at 
10,000g for 30 minutes at 4°C and the supernatants pooled.
4.2.26 Affinity purification of fusion protein
The fusion protein was purified by a modification of the method of Guan & Dixon 
(1991). The supernatant was applied to a 2ml glutathione-agarose column previously 
equilibrated with 40mls of ice-cold PBS. The column flow was stopped and the resin
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resuspended, and left on ice to resettle for 20 minutes. The flow was restarted and the 
eluent collected and then reapplied to the column. The column was then washed with 
40mls of ice-cold PBS, followed by 20mls of thrombin cleavage buffer (Tris-HCl, pH 
8 .0 , 150mMNaCl, 2.5mMCaCl2).
4.2.27 Western blotting
The identity of the band at 44kD as the fusion protein was confirmed by western blotting 
as described in appendix III. The nitrocellulose membrane was probed with polyclonal 
rabbit antibodies against glutathione ^-transferase at a dilution of 1/30,000 and against 
PPM at a dilution of 1/1000.
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4.3 RESULTS
4.3.1 Cloning of cDNA for PP14
mRNA was extracted from endometrial tissue and used in a reverse transcriptase 
reaction and then PCR. Figure 4.3 shows the results of the polymerase chain reaction. 
A band was obtained at approximately 546 bps, assumed at this point to be DNA coding 
for PP14, this reaction was carried out a number of dilutions of cDNA, as indicated on 
the figure. Positive results were obtained at dilutions of and ^ooo- The reaction
at a dilution of did not give a positive result, the reason for this is not known.
The band observed at 546 bps was cut out of the gel and used to prepare DNA to ligate 
into the cloning vector pUC18. The results of the ligation are shown in Figure 4.4. Two 
bands were obtained, one at 546 bps, presumed to be PP14 and the plasmid band at 
2635bps. Again the insert was cut out of the gel and used to prepare DNA to ligate into 
the expression vector pGEX-KG.
DNA was prepared from the PPM clone in pUC18 and sequenced to confirm that the 
insert definitely coded for PPM. Part of the sequencing gel obtained is shown in figure
4.5. The results from this experiment demonstrated that cDNA coding for PPM had 
been successfully cloned and that the sequence obtained agreed with the published 
sequence.
The method used to ligate the PPM cDNA into pGEX-KG was slightly unusual. Several 
attempts to ligate the PPM insert into pGEX-KG digested with EcoKL and Hmdlll were 
unsuccessful with no apparent reason for this failure discovered. A clone containing the 
gene coding for the zona pellucida binding protein ZP3 ligated into these sites in pGEX- 
KG was available in the laboratory. This clone was digested, run on a gel and the
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Figure 4.3: Agarose gel of PCR reactions. cDNA coding for 
PPM was amplified at different dilutions. The bands presumed to 
code for PPM are indicated.
Lane 1: PPM cDNA %
Lane 2: PPM cDNA hl0 
Lane 3: P P M cD N A V  
Lane 4: PPM cDNA l/lQ00 
Lane 5: PPM cDNA \
Lane 6 : Control PCR reaction
Lane 7: Molecular weight markers, 7JDNA cut with
LcoRI and Hin&lll
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Figure 4.4: Agarose gel of digested plasmids pPP14UC 18 and 
pPP14GEX-KG containing the PP14 insert. The plasmids and 
PPM insert are indicated by arrows (1: pGEX-KG, 2 : pUC 18, 3: 
PPM). The plasmids were digested with EcoRl and Hindlll.
Lanes 1 and 2: pPPMUC 18
Lanes 3,4,5,6,7,and 8 : pPPMGEX.KG
Lane 9: Molecular weight markers, ^DNA digested with
EcoKL and Hindlll.
Figure 4.5: Part of the sequence of PP14 as analysed by sequencing 
gel. The region sequenced in the four lanes to the extreme right 
corresponds to base pairs 150-225 as indicated.
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plasmid band cut out and used to prepare plasmid DNA to ligate with the PPM cDNA. 
The ligation reaction worked at the first attempt. The results of this ligation are shown 
in figure 4.4 alongside the results from the ligation into pUC18.
4.3.2 Expression of recombinant PP14
Having obtained a recombinant clone for PPM the expression of the protein was 
investigated. The fusion protein was induced by the addition to small-scale cultures of 
IPTG. Control cultures containing JM109 cells alone and pGEX-KG only without the 
PPM gene were grown up alongside the PPM clone. All cultures were controlled with 
non-induced cultures. The cells from these cultures were lysed, and samples run on 
SDS-PAGE. Figure 4.6 show the results obtained from the induction of GST-PP14. An 
additional band can be seen in the lane containing the induced PPM clone at 44kD. The 
molecular weight of GST is 26kD and that of the PPM monomer is predicted at 18,787 
(Jtilkunen et al., 1988), giving a predicted fusion protein weight of 45 kD, therefore the 
observed molecular weight of the induced band agrees well with the expected result. 
There is a clearly induced band at 26kD in the lane containing pGEX-KG only, 
corresponding to GST.
4.3.3 Optimisation of expression
The solubility of expressed recombinant proteins is often a problem therefore the effect 
of various conditions on the solubility of recombinant PPM was investigated. Three 
different expression temperatures were compared and the concentration of the 
solubilisation reagent sarkosyl was also studied. Several small-scale cultures were grown 
at each temperature and the cells sonicated and centrifuged in different concentrations of 
sarkosyl. The results of these experiments are shown in figure 4.7. Dropping the 
temperature from 37°C improved the solubility, in the top gel lanes 1-6 are of cells 
grown at 37°C, only lane 2 at the top concentration of sarkosyl shows significant soluble 
protein, and this is less than half the expressed protein. In comparison the lanes 
containing cell supernatants from the cultures grown at 30°C (top gel lanes 8-10  and
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Figure 4.6: SDS-PAGE gel of induced GST-PP14 fusion protein
Lane 1: Molecular weight markers
Lane 2: JM109 cells uninduced
Lane 3: JM109 cells induced with IPTG
Lane 4: pGEX.KG uninduced
Lane 5: pGEX.KG induced with IPTG
Lane 6 pPP14GEX.KG uninduced
Lane 7: pPP14GEX.KG induced with IPTG
PP14-GST is indicated by the arrow at 44kD
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Figure 4.7: SDS-PAGE gels o f optimisation o f temperature o f
expression and sarkosyl concentration in the expression o f the fusion 
protein GST-PP14
Top gel: Bottom gel:
Lane I : Molecular weight markers Lane 1: Molecular weight markers
Lane 2: 37°C, 0.5% sarkosyl, supernatant Lane 2: 30°C, 0.1% sarkosyl, pellet 
Lane 3: 37°C. 0.5% sarkosyl, pellet Lane 3: 30°C, 0.05% sarkosyl, supernatant
Lane 4: 37°C, 0.1% sarkosyl, supernatant Lane 4: 30°C, 0.05% sarkosyl, pellet 
Lane 5: 37°C, 0.1% sarkosyl, pellet Lane 5: 25°C, 0.5% sarkosyl, supernatant
Lane 6: 37°C, 0.05% sarkosyl, supernatant Lane 6: 25°C, 0.5% sarkosyl, pellet 
Lane 7: 37°C, 0.05% sarkosyl. pellet Lane 7: 25°C, 0.1% sarkosyl, supernatant 
Lane 8: 30°C, 0.5% sarkosyl, supernatant Lane 8: 25°C, 0.1% sarkosyl, pellet 
Lane 9: 30°C, 0.5% sarkosy l, pellet Lane 9: 25°C, 0.05% sarkosyl, supernatant
Lane 10: 30°C, 0.1% sarkosy l. supernatant Lane 10: 25°C, 0.05% sarkosyl, pellet
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bottom gel lanes 2-4) and 25°C (bottom gel lanes 5-10) both show higher proportions 
total expressed protein in the soluble fraction. At 30°C the greatest solubility was 
obtained at sarkosyl concentrations of 0.5% and 0.1%, but at 25°C the expressed protein 
could be solubilised at a sarkosyl concentration of 0.05%. At 25°C the higher two 
sarkosyl concentrations did not appear to solubilise the protein effectively, the reason for 
this is not known, however higher concentrations of sarkosyl can lead to micel formation 
and so chosing a lower concentration may be desirable. 25°C was therefore chosen as a 
optimum expression temperature, and 0.05% sarkosyl as the detergent concentration.
4.3.4 Purification of fusion protein
100ml volumes of cells were grown up at 25°C then centrifuged, resuspended in 0.05% 
sarkosyl, sonicated and recentrifuged. The supernatants obtained were then applied to a 
glutathione-agarose column. Figure 4.8 shows the results from an SDS-PAGE gel of 
this purification and a Western blot of some of the lanes of the gel probed with 
polyclonal antibody against GST. It can be seen from this gel that this purification 
method does not succeed in obtaining a pure preparation of fusion protein. There appear 
to be several other bands that co-purify. This may be the results of aggregates in the 
case of the higher molecular weight species and truncated protein expression in the case 
of the lower molecular weight species. The Western blot clearly shows the fusion 
protein band, and also picks up a few of the other bands confirming that they contain 
GST and therefore may be truncated fusion protein.
The GST expression system is designed to allow the straightforward cleavage of the 
expressed protein from its fusion partner GST with thrombin. In practice this reaction 
appears to be inefficient, and despite several attempts the cleavage reaction of GST from 
PP14 was unsuccessful. This problem has been encountered by other users of the GST 
expression system (Taylor et al, 1993).
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Figure 4.8: SDS-PAGE gel of purification of fusion protein GST-PP14 
using glutathione-agarose. Western blot of GST-PP14 fusion protein.
Lane 1: Molecular weight markers 
Lane 2: Pellet after sonication 
Lane 3: Supernatant after sonication
Lane 4: Supernatant after elution from giutathione-agarose column 
Lane 5: Western blot of Lane 3 
Lane 6: Western blot of Lane 4
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4.4 DISCUSSION
cDNA coding for PP14 has been cloned and over-expressed in E. coli as a fusion protuct 
with GST. cDNA was prepared from mRNA from endometrial tissue and amplified 
using the PCR reaction. The gene obtained was then ligated in to pUC18 followed by a 
cross-over ligation reaction into the expression vector pGEX-KG. This vector expressed 
PP14 as a fusion protein with GST in response to induction with IPTG. This fusion 
protein could be solubilised when grown at 25°C and resuspended in 0.05% sarkosyl. 
Although the fusion protein was partially purified using glutathione agarose, the cleavage 
reaction to separate the two proteins proved unsuccessful. This may have been due to 
protein aggregation, masking the cleavage site. The activity of this recombinant protein 
has not yet been studied due to the failure to obtain a pure preparation isolated from 
GST. However modifications to the cleavage procedure may yield isolated protein and 
then activity studies can be carried out. An additional factor to take into account when 
investigating recombinant PP14 is the possible requirement for a cofactor for activity. 
The next chapter considers this problem.
The availability of recombinant PP14 facilitates the possible future therapeutic use of this 
protein. It will also provide a source of protein for further investigations into the activity 
of this molecule.
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4.5 CONCLUSION
These results describe the successful cloning and expression of PPM as a recombinant 
protein. This provides a basis for further investigations into the clinical application of 
PPM, and the activity of this molecule.
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CHAPTER FIVE: MOLECULAR MODELLING OF PP14 
STRUCTURE
5.1 INTRODUCTION
Placental protein 14 (PPM) is a member of the lipocalin family of proteins. At present 
over 20 members of this family have been characterised, and with the help of 
computerised sequence analysis programs that identify sequence homology between 
molecules, the number of members assigned to the family is increasing steadily.
The first member was retinol-binding protein (RBP). The three-dimensional structure of 
RBP was resolved by X-ray crystallography revealing a novel folding pattern and it was 
suggested that it might be a member of a new family of proteins (Newcomer et al, 1984). 
When the structure of P-lactoglobulin (PLG) was determined a similar folding pattern 
was found (Godovac-Zimmermann et al., 1985; Sawyer et al, 1985), in fact the two 
structures can be super-imposed on each other, and this observation, together with some 
regions of sequence homology identified pLG as a second member of this new group of 
proteins (Papiz et al., 1986).
It was already known that pLG binds retinol (Fugate & Song, 1980) so this implied that 
the family was a group of of retinol-binding molecules. However the next proteins 
identified as members were a -1-microglobulin (Pervaiz & Brew, 1985), a-2- 
microglobulin and bilin-binding protein (Huber et al., 1987, Holden et al, 1987), which 
shared structural features with RBP and pLG but have very different ligand specificity. 
This widened the description of the proposed role of the lipocalins to that of a family of 
adaptable carrier molecules consisting of a group of proteins of similar size (150-200 
amino acid residues), (North, 1989), which share a common three-dimensional structure 
despite low overall sequence homology.
When the sequence of PPM was published (Julkunen et al, 1988) the presence of 
regions of sequence homology identified it as a lipocalin.
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5.1.1 Structural features
There are three features that identify a protein as a lipocalin: the characteristic folding 
pattern of the three-dimensional structure; the presence of a binding pocket or calyx lined 
with predominately hydrophobic residues; and the presence of specific, characteristic 
regions of sequence conservation. Analysis of the three-dimensional structure of RBP, P 
LG and major urinary protein (MUP) shows a conserved P-barrel structural motif of 
eight anti-parallel P-strands in a criss-cross pattern arranged as two p-sheets stacked on 
top of one another. This forms a compact, protease-resistant framework, surrounding a 
hydrophobic core which provides a protected binding site for labile and water insoluble 
hydrophobic molecules.
In addition there is a conserved a-helix motif at the carboxy end of the proteins, and a 
disulphide bridge linking this helix to the centre of the P-strands. The amino acid 
sequences of the lipocalins vary widely with no more than 30% sequence homology 
between any two members of the family (Akerstrom & Logdberg, 1990), but there are 
certain regions of the sequences that are highly conserved (Godovac-Zimmerman, 1988; 
Perviaz & Brew, 1985). The sequence Gly-X-Trp (where X is any amino acid) is 
conserved near residue 25 in all lipocalins identified so far (Nagata et a l, 1991) with 
regions on either side sharing some homology. In addition the sequence Thr-Asp-Tyr is 
conserved near residue 100 in the majority of lipocalins, though it is not universal, again 
with some further homology in the flanking regions. The Gly-X-Trp set of residues form 
part of the first P strand and the Thr-Asp-Tyr set form part of a loop between the sixth 
and seventh P strands (Godovac-Zimmermam, 1988), this loop crosses the same region 
in the three-dimensional structure as the first strand, forming a specific area in the 
molecule which is highly conserved. The Trp residue at 28 in PLG, 23 in MUP and 24 in 
RBP, is at the back of the proposed binding pocket, in the centre of this highly conserved 
region and has been suggested as the crucial residue in the binding site (Papiz et al., 
1986). An arginine residue around residue 125 positioned behind the tryptophan at the 
base of the binding pocket is another highly conserved feature.
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5.1.2 Receptors and specificity
The mammalian lipocalins have associated receptors (Sawyer, 1987), and the conserved 
area of the molecular structure has been proposed as the receptor binding site. However 
the RBP receptor has been described as interacting with the opening on the binding 
pocket which is on the opposite side of the molecule from the conserved area 
(Sivaprasadarao et al., 1993). There is wide sequence variation between lipocalins in 
this area of the molecule which would ensure specificity for the receptor. Therefore 
there appears to be a common protein structural framework with specific modifications 
to give the selectivity for different ligands (Godovac-Zimmerman, 1988). The variations 
to give the specificity may be at the opening to the binding pocket, which may also serve 
as a receptor binding site, or within the binding pocket, to select only the desired ligand. 
The area of sequence conservation may be a binding site common to all lipocalins, with 
variations to the surrounding sequences rendering the site specific for a particular 
receptor. The mode of action may be that a conformational change occurs upon ligand 
binding, enabling the lipocalin to bind to a receptor that it cannot bind without the ligand, 
and passing on a signal to the target cell, or the mechanism may be a ligand delivery 
system, and once the lipocalin is bound to the receptor the ligand is passed to the 
receptor, probably via the tryptophan and arginine residues at the back of the binding 
pocket.
5.1.3 Ligand binding
Individual members of the family bind a range of different molecules in the core region of 
their structure, these molecules include Vitamin A (retinol-binding protein), biliverdin 
(insectocyanin/bilin-binding protein) and pheromones (major urinary protein). The 
common pattern is the binding of hydrophobic molecules in an aqueous enviroment. 
There are many small hydrophobic molecules utilised by living organisms including 
steroids, vitamins, lipids, retinoids, pheromones and bilins (Godovac-Zimmerman, 1988). 
The conservation of the lipocalin family of proteins provides a transport and signalling 
system for these insoluble molecules in an aqueous environment. Some bind specifically
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and only to particular ligands, others may be multipurpose carrier molecules, PLG has 
been shown to bind to over 100 molecules. Table 5.1 lists most of the lipocalins 
discovered so far, the ligand they bind to if known and their suggested function.
5.1.4 Function
The lipocalins appear to cover a broad spectrum of functions. These can be roughly 
grouped, but much is yet to be discovered about their role and mode of action. Some 
lipocalins are simple carrier of vitamins or pheromones; some have enzymatic activity 
(prostaglandin D synthase); others exert influence on the immune system, 0 4 - 
microglobulin complexes with IgA (Akerstrom & Logdberg; 1990), has
immunosuppressive activity (Logdberg & Akerstrom, 1981; Logdberg et al, 1986). 
Complement C8y although not essential for the lytic activity of C8 in the complement 
pathway, enhances the binding of the C8P chain to C5b-7 complex.
The lipocalin family shares structural homology with another protein family that bind 
small hydrophobic ligands, the fatty acid-binding proteins (FABP) and with 
streptoavidin, a binding protein with affinity for the hydrophobic vitamin biotin. The 
main common structural feature all these proteins share is the folding pattern of the p 
barrel.
These proteins may provide the basis for a drug carrier system based on the structural 
motif of the family. The binding pocket could be modified using mutagenesis to provide 
a carrier molecule for a designed drug. The receptors for the majority of these molecules 
are as yet undiscovered but may provide the opportunity for highly specific drug delivery 
to particular groups of cells (Godovac-Zimmermann, 1988).
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Name Species; location Ligand Function References
PP14 Human endometrium Unknown Immunosuppression (Seppala et al, 1994)
ctr
microglobulin/HC
protein
Human, rat, monkey, 
rabbit, dolphin, pig; 
plasma, liver, kidney, 
urine, cerebrospinal 
fluid
yellow/brown 
chromophore/retino 
id, porphyrin
Mediation of neutrophil 
chemotaxis, IgA-binding, 
immunosuppressive
(AkerstrOm & 
Logdberg, 1990; Lee 
et al, 1987)
Retinol-binding
protein
Human, rat; plasma Retinol, retinoic 
acid, retinoyl 
acetate (narrow)
Retinol transport (Newcomer et al, 
1984; Laurent et al, 
1985; Cogan et al, 
1976)
(3-lactoglobulin Cow, sheep, horse, pig, 
dog, dolphin; milk whey
Retinol, +100 
others (broad)
Vitamin transport to the 
gut
(Futterman & Heller, 
1972)
Insecticyanin/bilin- 
binding protein
tobacco hornworm, 
butterfly
biliverdin IXy 
(narrow)
Camouflage,
photoreception?
(Holden et al, 1987; 
Huber et a l, 1987)
Apolipoprotein D Human plasma cholesteryl esters, 
lecithin (broad)
Lipid transport (Drayna et al, 1986)
BGprotein/Olfactoiy
neuroepithelium
protein
Frog olfactory 
epithelium, Bowman's 
gland
odorants (broad) Odorant transfer to 
receptor
(Lee et al, 1987)
a-2ji-globulin Rat urine pheromone Sexual signalling (Pervaiz & Brew, 
1985)
Major urinaiy 
protein
Mouse urine pheromone Sexual signalling (BOcskei et al, 1991)
androgen-dependent 
epididymal secretory 
protein
Rat Retinoic acid Sperm maturation (Brooks et al, 1986)
Crustacyanins A & 
C
Lobster Astaxanthin,
retinoids
Coloration, photo-reception (North, 1989)
Alpha-1-acid- 
glycoprotein
Human progesterone
(broad)
Platelet aggregation, 
immunosupppression
(Dente et al, 1985)
Prostaglandin D 
synthase
Human, Rat; brain, 
nervous system, retina, 
cochlea
prostaglandin 
D2 ,l-chloro-2,4- 
dinitrobenzene, 
bilirubin, 
indocyanine green
Biosynthesis of 
prostaglandin D2
(Nagataetal., 1991; 
Urade et al, 1989)
Protein 24p3 Mouse; activated 
macrophages, kidney
Unknown Defence mechanism 
against infection?
(Flower et a l, 1991; 
Meheus et a l, 1993)
Complement C8y Human plasma unknown/Retinol Complement-mediated
cytolysis
(Haefliger et al, 
1991)
Chorioid plexus 
secreted protein
Toad chorioid plexus Unknown Transport across the blood- 
brain barrier?
(Achen et al, 1992)
CH21
protein/quiescence- 
specific polypeptide
Chicken Unknown Cell regulation (Cancedda et al, 
1990; Bedard et al, 
1989)
Aphrodisin Hamster Pheromone? Sexual signalling (Henzel et a l, 1988)
Von Ebner's gland 
protein
Rat Unknown Taste reception (Schmale et al, 
1990)
Probasin Rat Unknown Unknown (Spence et a l, 1989)
Tear pre-albumin Human tear fluid unknown/retinol Hydrophobic molecule 
carrier
(Redl et al, 1992)
Table 5.1: Characteristics of members of the lipocalin family
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5.1.5 Aim of the study
The structure of PP14 was modelled using computer graphics. The purpose of this was:
1. To investigate the relationship of the structure of PP14 to that of other members of 
the lipocalin family, and from this determine which structural motifs are conserved 
in PP14 including the p-sheets, binding pocket and disulphide bridges. The 
structure obtained would also give a basis for analysing data from future X-ray 
crystallography experiments.
2. To analyse the binding pocket and model a potential ligands into the model of the 
protein, and so predict the structure of the ligand. This is particularly relevant to 
the activity of the recombinant protein which may require the ligand for activity.
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5.2 METHODS
5.2.1 Modelling strategy
The predicted structure for PPM was modelled using the molecular modelling 
programme FRODO (Jones, 1978) implemented on an Evans and Sutherland series 'V' 
workstation supporting 'crystal eyes' stereo graphics. The known X-ray structure 
coordinates for retinol-binding protein (RBP) and major urinary protein (MUP) were 
used as a framework around which to build the structure of PPM around (provided by 
Dr. SJ Yewdall). The areas of closest sequence alignment to RBP and MUP were the 
framework of the polypeptide chain with the most variable sequences found in the parts 
joining the loop regions to the P strands except for specific loops with conserved 
sequences. The PPM residues contributing to the framework were aligned first to the 
structure of MUP and, where possible, structural motifs were preserved with appropriate 
modifications due to sequence deletions and/or substitutions. Amino acid changes 
deemed of little consequence (e.g with respect to size or charge) were carried out first. 
Then the areas of less homology were worked on following the framework of RBP or 
MUP depending on which showed more homology in that particular region.
Idealised geometries, torsion (Ramachandran & Sasisekharan, 1968) and hydrogen- 
bond distances of 0.285 nm (2.85 A) were generated throughout. Side-chains were 
added and their orientations chosen to give good geometry and reasonable interactions. 
The final model was subjected to repeated cycles of geometrically restrained 
regularisation and energy minimisation.
5.2.2 Ligand modelling
Three potential ligands were chosen to model into the proposed binding pocket of PPM: 
Progesterone, hyaluronic acid and prostaglandin E2. These ligands were chosen as 
representative of some of the groups of molecules which are present in the reproductive 
tract. The ligands were positioned in the molecule by eye and adjusted to give the best
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orientation. The resulting models were then subjected to repeated cycles of energy 
minimisation to reduce conflicting interactions.
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5.3 RESULTS
5.3.1 Structural features of PP14
Figures 5.1 and 5.2 show the modelled predicted structure for PPM. The rainbow 
ribbon is coloured from red at the N-terminal to dark blue at the C-terminal. Both 
figures show the molecule in the same orientation to the horizontal plane but Figure 5.2 
has been rotated 90° from Figure 5.1 around a vertical axis through the centre of the 
molecule. This means that the same features are at the top of each of the pictures, the a- 
helix and the carboxy terminus, likewise the N-terminal is at the bottom of both pictures. 
The sharp bend shown in turquoise on the right of Figure 5.1 is pointing directly out of 
the picture in Figure 5.2.
These figures show that the predicted structure for PPM retains many of the features 
common to the lipocalin family. The eight anti-parallel P-sheets stacked on top of each 
other forming a calyx are present (labelled A-H from the N-terminal end), seven of the 
strands cross the width of the molecule, while the second strand (B) shown in yellow is 
truncated. The a-helix near the carboxy end is also conserved.
The significant residues and areas of the molecule are marked. These are the conserved 
triple amino acid sequence Thr-Asp-Tyr which in PPM is at residues 97-99, the 
tryptophan residue at the bottom of the binding pocket which is part of a conserved 
triplet Gly-X-Trp, in PPM residues 17-19 with tryptophan at residue 19, the tyrosine at 
the entrance to the pocket at residue 86 and the arginine behind the tryptophan at 
position 124. In this predicted model the loop containing the conserved triplet from 97- 
99 crosses the tryptophan 19 residue giving an area of the molecule with a high degree of 
conservation.
There are two disulphide bridges. One is shared with other lipocalins and links the C- 
terminal region beyond the a-helix to the strand labelled E in the Figures. This is shown
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S-S C-terminal
\ \  \
N-terminal Thr 97-Asp 98-Tyr 99 Trp 19 Tyr 86
Figure 5.1: Rainbow model of the modelled proposed structure of PP14. 
The N-terminal is in red and the C-terminal in blue. Significant areas of 
the molecule are indicated, further details are given in the text.
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N-terminal Thr 97-Asp 98-Tyr 99 Trp 19 Tyr 86
a-helix Arg 124 S-S C-terminal
S-S
Figure 5.2: Rainbow model of the modelled proposed structure of PPM. 
This figure is identical to Figure 5.1 but rotated 90° around a vertical axis 
through the centre of the molecule. The N-terminal is in red and the C- 
terminal in blue. Significant areas of the molecule are indicated, further 
details are given in the text.
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best on Figure 5.2. The other disulphide bridge links the strands labelled G and H and 
appears to stabilise the loop at the entrance to the binding pocket.
Figure 5.3 lists the sequence of PPM with the significant residues marked to assist in 
interpreting the modelled structure.
Figure 5.4 shows the modelled structure of PPM with the helical regions as cylinders in 
pink and the p-sheets as blue arrows. The structure of p-lactoglobulin is shown below in 
figure 5.5 for comparison. It can be seen from the two Figures that the folding of the 
proteins is similar and the pattern of p-sheets and the a-helix at the C-terminal end are 
present in both molecules.
Figures 5.6 shows the ribbon structure from Figure 5.1 superimposed on the modelled 
postion of the outline of the amino acid structures with progesterone modelled into the 
binding pocket to demonstrate the orientation of the pocket within the molecule. The 
electron densities surrounding the ligand are also shown.
5.3.2 Binding pocket
An analysis of the residues lining the binding pocket shows them to be predominately 
hydrophobic consisting of leucine, valine, alanine and isoleucine. The exceptions to this 
are Glu 55 and Asp 109 which are negatively charged and Asn 90. The dimensions of 
the binding pocket measured from the model are 12.8A by 9.5A by 5.6A, pinched in the 
middle to 4.7A.
5.3.3 Ligand binding
The structures of the three ligands modelled into the binding pocket are shown in Figure 
5.7, 5.8 and 5.9 From these structures it can be seen that progesterone has two polar 
oxygen groups, one at either end, shown in red (Figure 5.7). Hyaluronic acid has one 
nitrogen (shown in blue) and several oxygen groups (shown in red) distributed across the
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molecule (Figure 5.8). Prostaglandin E2 has oxygens at either end and one in the middle 
of the molecule (Figure 5.9). It is important to consider the position of these polar 
groups in relation to the groups within the binding pocket of the molecule with which 
they may interact.
Figures 5.10, 5.11 and 5.12 show progesterone modelled into the binding pocket from 
three different angles. In Figures 5.10 and 5.11 the orientation of the model of PP14 is 
the same as shown in Figure 5.1, with Trp 19 on the left and Tyr 86 on the right marked 
on the Figures. Figure 5.12 shows progesterone from the angle looking down into the 
binding pocket. There is some overlapping of the Van derWaal shells of the PP14 model 
and progesterone in these Figures. This is due to amino acids in front or behind the 
molecule overlapping in the pictures. However it can be seen from the spacing of the 
amino acid side chains and Figure 5.12 that progesterone fits into the pocket.
Figures 5.13 and 5.14 demonstrates the orientation of the progesterone molecule within 
the ribbon diagrams of the PPM model. This shows the oxygen groups (shown in red) 
of the progesterone molecule and their position. Also marked on this diagram are the 
three amino acids lining the binding pocket which may interact with these oxygen 
molecules, Glu 55, Asn 90 and Asp 109. From this Figure it can be seen that these 
residues are all in the same regions as the oxygen molecules.
Figures 5.15 and 5.16 show hyaluronic acid modelled into the binding pocket. Although 
this molecule fitted well from a size and shape perspective, the charged groups in the 
centre of the molecule caused clashing interactions with the hydrophobic amino acids in 
these regions.
Prostaglandin E2 was too large to fit in the pocket. Although it looks a similar size to 
the other two molecules it's double side chain meant that the interactions with the amino 
acids lining the pocket were too close.
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Figure 5.3: Amino acid sequence of PPM. The significant residues are shown in bold, 
the regions forming the strands and a-helix are labelled A-H and a , the residues 
mentioned in the text: Trp 19, Tyr 86, Arg 124 are shaded lightly and the cysteine 
residues are shaded heavily. The residues lining the binding pocket are in italics and the 
residues which have homology with MUP or RBP are indicated by *
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Figure 5.4: The structure of PP14 with oc-helical regions shown as 
barrels in pink, (3-sheets are shown as arrows in blue. The structure of P- 
lactoglobulin (Nagata et al., 1991) is shown below in Figure 5.5 for 
comparison of the two structures.
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Figure 5.6: The ribbon model of PP14 super-imposed over the amino 
acid structure. Progesterone is shown in the binding pocket to show the 
size and position of the pocket.
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Figure 5.7, 5.8 and 5.9: Three possible ligands for PP14, 5.7:
progesterone, 5.8: hyaluronic acid, 5.9: prostaglandin E2. Hydrophobic 
parts of the molecules are coloured in turquoise and charged groups in 
red and blue.
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Figures 5.10, 5.11, 5.12: Progesterone modelled into the binding pocket 
of PP14 shown from three different angles.
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Asp 109
Glu 55 Asn 90
Figure 5.13: Progesterone modelled into the rainbow ribbon model of 
PP14 showing the orientation of the charged groups in the progesterone 
structure and the possible interactions with Glu 55, Asn 90 and Asp 109 
in the binding pocket of PP14.
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Asp 109
Asn 90 Glu 55
Figures 5.14: Progesterone modelled into the rainbow ribbon model of 
PP14, looking into the binding pocket, showing the orientation of the 
charged groups in the progesterone structure and the possible interactions 
with Glu 55, Asn 90 and Asp 109 in the binding pocket of PPM.
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Figures 5.15 and 5.16: Hyaluronic acid modelled into the binding pocket 
of PP14.
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5.4 DISCUSSION
Molecular modelling is a technique used in conjunction with X-ray crystallography to 
elucidate the molecular structure of proteins. X-ray crystallography is required to 
definitively determine the crystalline structure of a protein. However much useful 
information can be gained from predicting the structure of a protein by aligning the 
amino acid sequence with that of another protein where homology of sequence exists and 
structural homology is anticipated. X-ray crystallography is a time-consuming and 
lengthy technique. In the case of PP14 it was anticipated that the recombinant protein 
might require a co-factor or ligand to be active, and that studies on this activity would be 
held up due to a lack of information on possible ligands.
Therefore, in view of the known structural homology between other members of the 
lipocalin family, molecular modelling by the alignment of amino acid sequences was 
possible, and used as a tool to predict the molecular structure of PP14 From this it was 
hoped that information would be gained about the binding pocket, in order to predict 
likely ligands. X-ray crystallography studies are currently underway to complement the 
work reported here.
The results of the molecular modelling of PP14 show that, from the proposed model, 
PP14 is predicted to exhibit the typical structural features of the lipocalin family. Some 
aspects of the model merit particular mention. The P-sheet folding pattern common to 
all the lipocalins is present and the predicted secondary structure shows similarity with 
the structure of beta-lactoglobulin. The a-helix at the carboxyl end is present with the 
disulphide bridge linking region beyond the helix into the rest of the molecule. There is 
also a second disulphide bond linking the 6th and 7th P-sheets. This bond is found in a 
few of the other lipocalins, but is not a strongly conserved feature.
The Trp residue which is conserved in all lipocalins so far identified is at position 19 in 
PPM. This residue in this model is positioned at the bottom of the binding pocket, on
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the first (3-strand. The regions on either side show some partial homology with other 
members of the family. This area is crossed by a loop formed of residues that also share 
homology with other lipocalins.
Of particular interest is residue 86, a tyrosine residue which is directly adjacent to the 
opening and has freedom of movement. This suggests that it could pivot to close the 
binding pocket after the ligand has entered. This closing action may only be possible 
after a conformational shift when the ligand has been bound and the tyrosine residue is 
then able to move to a different conformation to complete the binding site at the opening 
of the pocket. The second disulphide bridge which is not common to all lipocalins 
stabilises the p-sheets which interact with this Tyr residue, indicating that the 
conformation of this part of the molecule may be important.
The binding pocket is extremely hydrophobic, all the amino acid residues lining it are 
hydrophobic with the exception of Glu 55, Asn 90 and Asp 109. These residues may 
interact with charged groups on the ligand. From the proposed structure the pocket is 
elongated, pinched in the middle, with a bulge at each end..
Three ligands were modelled into the pocket. Progesterone and prostaglandin E2 both 
have immunosuppressive activty and are found in the endometrium. Hyaluronic acid may 
bind to adhesion molecules that are involved in the interaction between the trophoblast 
and the decidua during pregnancy, and has a two ring structure that may fit the bulged 
sections of the binding pocket.
Of the three ligands, the best fit was progesterone, due to its size and shape and the 
positioning of its charged groups. However a systematic analysis of a range of ligands 
would need to be carried out before it could be claimed that the ligand for PP14 is in fact 
progesterone.
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Hyaluronic acid, while fitting well into the pocket from a structural point of view, has 
many charged groups which did not match the predominately hydrophobic environment 
of the binding pocket.
Prostaglandin E2 did not fit into the pocket due to the two side chains that are part of the 
structure of this molecule.
These results predict that the ligand for PPM is a hydrophobic molecule with a polar or 
charged group on either end. The structure of the ligand may be in two parts linked by a 
narrower part, to fit the bulges and pinched middle section of the binding pocket of 
PPM. Progesterone comes close to fulfilling these criteria, and may be the ligand, but 
many other molecules could also fit this description.
The activity of PPM is likely to be associated with either the section of the molecule at 
the back of the binding pocket, or the section around the entrance to the pocket. The 
model predicted here could be used to design peptides from these parts of the molecule 
which could mimic the activity of PPM.
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5.5 CONCLUSION
The predicted molecular structure for PPM, a lipocalin, has been proposed. This 
modelled structure demonstrates that this molecule has a binding pocket and shares areas 
of conservation with other members of the lipocalin family. The ligand for PPM is still 
unknown, although progesterone fits into the pocket there is not yet enough evidence to 
claim that it is the ligand for PPM.
This structural information will help in further work to discover the co-factor or ligand 
that PPM binds. This is particularly relevant to the expression of PPM as an active 
recombinant protein. The model also provides information that may be useful in the 
investigation of the mode of action of the molecule.
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CHAPTER SIX: CLINICAL STUDIES
6.1 INTRODUCTION
Placental protein 14 (PPM) is the most abundant protein product released from epithelial 
cells into the lumen of the endometrium in the secretory phase of the menstrual cycle and 
during the first trimester of pregnancy (Olajide & Chard, 1992). Although the exact role 
of this protein has yet to be elucidated it may be involved in the regulation of the 
maternal immune system to protect the fetus from adverse immune responses (Bolton et 
al., 1987) or play a part in paracrine interactions between the endometrium and 
trophoblast (Seppala et al., 1994).
The traditional way to study the development of the endometrium is by taking an 
endometrial biopsy (Noyes et al, 1950). This involves the removal of a small sample of 
endometrial tissue from the patient and the subsequent histological examination of the 
specimen. This method has significant disadvantages. The first and probably most 
important is that it is an uncomfortable and often painful procedure for the patient, 
particularly if she is nulliparous (Li et al, 1990), there is also a risk of disrupting an early 
pregnancy (Li et al, 1993a). The histological examination of the tissue is a subjective 
evaluation, requiring an experienced observer, although recently semi-quantitative 
methods have been described using morphometric analysis (Li et al., 1988), and 
therefore a more objective measure of endometrial status may be obtained. In addition 
the histological examination of a biopsy gives no information about the functional 
secretory status of the endometrium. Immunohistochemical and in situ hybridisation 
techniques can be carried out on biopsy specimens yielding further information about the 
presence of proteins within the tissue. These techniques, however, give no information 
about proteins secreted into the endometrial environment. Because of these problems, 
endeavours have been made to develop alternative non-invasive methods of studying the 
endometrium. There is some evidence to support the theory that the main abnormality in 
the endometrium of infertile subjects involves the secretory activity of the glandular
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epithelium. In this respect PPM levels in plasma have been measured by a number of 
investigators in a wide range of women; (Joshi et al, 1986; Julkunen et al, 1986b). 
However plasma PPM concentrations may not accurately reflect the situation in the 
endometrium (Wood et al, 1990) and many studies have found no significant correlation 
between plasma PPM and endometrial morphology (Than et al, 1988; Edwards, 1988).
PPM secreted from the glandular endometrium can be recovered from uterine luminal 
fluid (Bell & Dore-Green, 1987; Bell, 1988). Sampling this fluid or flushing out the 
uterine cavity provides the opportunity for a more direct measurement of the secretions 
of the endometrium, and therefore its functional status. This study investigates the 
potential of the technique of uterine flushing with particular application to the study of 
PPM concentrations in fertile women, infertile women and women with recurrent 
miscarriage. It also compares results from the techniques of uterine flushing and 
endometrial biopsy in the recurrent miscarriage patients.
6.1.1 Collaborators
This study was part of a collaboration with Mr. T.C. Li from the Jessop Hospital for 
Women, Sheffield and his clinical and laboratory staff teams. The technique of uterine 
flushing was developed by Mr. Li as part of the study and the uterine flushings, 
endometrial biopsies and plasma samples were obtained by the clinical staff at the 
hospital. The biopsy samples were processed by staff at the Department of Biomedical 
Sciences, University of Sheffield, and analysed by Mr. Li..
6.1.2 Purpose of the study
1. To establish the levels of PPM present in uterine flushings from fertile women 
throughout the menstrual cycle.
2. To compare the levels of PPM measured in uterine flushings from fertile women 
with those measured in plasma samples taken immediately afterwards.
3. To compare the levels of PPM in uterine flushings and plasma from patients with 
unexplained infertility with the levels found in fertile women.
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4. To compare the levels of PPM in uterine flushings and plasma from patients with 
recurrent miscarriage with the levels found in fertile women.
5. To compare the levels of PPM in uterine flushings from women with recurrent 
miscarriage with the dating of their endometrial biopsies and so establish if PPM 
levels measured in uterine flushings have a diagnostic value in the study of 
endometrial function.
6 . To investigate whether the PPM levels had any value in predicting the success of 
recurrent miscarriage patients in their next attempted pregnancy.
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6.2 SUBJECTS AND METHODS
6.2.1 Ethical aspects
Informed consent was obtained from all subjects participating in this study. Approval for 
the study was obtained from the local Ethics Committee.
6.2.2 Fertile subjects
Twenty-three healthy fertile women were recruited as a control group from the 
gynaecological outpatient clinic, Jessop Hospital for Women. To be included in the 
study the women had to fulfill the following criteria:
1. Aged between 20 and 40 years (range 24-40, median = 32 years).
2. Regular cycles between 25 and 35 days.
3. Previously fertile (parity ranged from 1 to 4, median = 2)
4. Had not taken any steroid hormones in the two months before the study.
5. No known history or evidence of uterine pathology.
Twenty of the women had been previously sterilised by tubal ligation (87%), the 
remaining 3 (13%) were using the condom as contraception during the study.
6.2.3 Infertile subjects
Eighteen women with unexplained infertility were recruited from the infertility outpatient 
clinic, Jessop Hospital for Women. The patients were defined as having unexplained 
infertility if they had been trying to conceive for more than 18 months without success, 
and without a cause for this lack of fertility being discovered. The range of duration of 
infertility was 3 to 10 years (median 5 years). The women all had regular menstrual 
cycles ranging from 25 to 35 days, and evidence of ovulation from one or two plasma 
progesterone levels over 5.8ng/ml (18nmol/l) in the luteal phase of the cycle (WHO, 
1984). They all had normal thyroid function tests, normal plasma prolactin
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concentrations, normal hysterosalpingogram and normal tubes by laparoscopic 
investigation. All the partners of the women had previously undergone semen analysis. 
The results of these analyses were compared with the parameters measured in semen 
analyses taken from a group of fertile men from the local population of Sheffield, as 
recommended by Dunphy et al., (1991). Any couples where the male partner's semen 
was defined as abnormal based on this comparison were excluded from the study.
6.2.4 Recurrent miscarriage subjects
35 women were recruited from the recurrent miscarriage clinic, Jessop Hospital for 
Women. Recurrent miscarriage was defined as three or more consecutive pregnancy 
losses with normal karotype before 20 weeks gestation. 25 of the women were primary 
miscarriage patients (nulliparous) and 10 were secondary miscarriers (at least one live 
birth, av=l).
6.2.5 Timing of sample collection
All the women collected early morning plasma or urine samples from day nine of their 
cycle counting from the first day of bleeding of their last menstrual period. Luteinising 
hormone (LH) was measured in these specimens by immunoradiometric assay (Li et al., 
1992) and the day on which the LH surge occurred was designated as day LH+0. The 
LH surge was defined as a rapid rise in plasma LH to a peak of > 20iu/l followed by a fall 
to basal plasma level within 3 days. All plasma samples and uterine flushings were timed 
according to the LH surge.
6.2.6 Uterine flushings
Uterine flushings were carried out as an out-patient procedure. A bivalve speculum was 
inserted in the vagina and the cervix exposed and cleaned with physiological saline. A 
size eight Foley catheter was passed through the the cervix into the uterine cavity and the 
balloon was inflated with 1.5ml of physiological saline. The cavity was gradually flushed 
twice with 2ml of physiological saline. The same flushing procedure was repeated a 
further four times making a total of 10ml of saline. The fluid obtained was mixed,
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pooled and stored at -20°C until assayed for PPM. In most cases several flushings were 
taken from each women, with a minimum interval of 48 hours between samples.
6.2.7 Endometrial biopsy samples
Endometrial biopsies were taken from the recurrent miscarriage patients. All the 
biopsies were taken on day LH +1 of the cycle, immediately after the uterine flushing. 
The biopsy was taken using a Sharman's curette from the fundus and upper part of the 
body of the uterus. The specimens were fixed in 2% glutaraldehyde in sodium 
cacodylate buffer (pH 7.4) for 4-6 hours, then washed in buffer, dehydrated and 
embedded in JB-4, a plastic polymer. They were then sectioned at 2pm and the sections 
stained with acid Fuchsin and Toluidine Blue then examined by light microscopy. All the 
endometrial biopsies were studied histologically and analysed by two different methods: 
the dating criteria of Noyes et al., (1950) and morphometric analysis (Li et al., 1988). 
Endometrial biopsy samples were considered retarded if the histological dating results 
were >2 days behind the chronological dating.
6.2.8 Plasma samples
Immediately after the uterine flushing and endometrial biopsy, if taken, a 10ml blood 
sample was taken. The samples were collected in tubes containing lithium heparin and 
centrifuged at 1500g for 10 minutes to obtain plasma which was stored at -20°C until 
subsequent PPM assay.
6.2.9 PP14 assay
The PPM assay was carried out as described in Appendix II. Quality controls at 50ng/ml 
and 10 ng/ml were included in each assay. For assays measuring the PPM content of 
plasma the quality controls were made by spiking normal male plasma with PPM purified 
as described in chapter 2. For assays measuring the PPM content of uterine washings 
the quality controls were made up in the same way but diluted in assay buffer (phosphate 
buffer, pH 7.5, 2% horse serum, 0.1% sodium azide). Plasma samples and plasma 
quality controls were diluted 1:1 with assay buffer before measurement, this eliminated
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some non-specific variation observed when neat serum was assayed. Uterine flushings 
were diluted with assay buffer if necessary until the sample could be measured from the 
standard curve. Parallelism of response has already been established for this assay with 
plasma and amniotic fluid (Bolton et al, 1983), this was found to hold true for uterine 
flushings diluted with assay buffer. The working range of the assay was taken as 
between 3 ng/ml and 100 ng/ml and the inter-assay and intra-assay coefficients of 
variation (CV) were less than 10%. The detection limit of the assay was 3ng/ml. Each 
sample was assayed in duplicate at least twice and the average of the measurements 
taken.. Assays where the quality controls indicated that the inter-assay CV was more 
than 10% were excluded, likewise individual sample measurements with an intra assay 
CV of more than 10% were discarded.
6.2.10 Statistical analysis
Where four or more samples were measured on the same LH day the geometric mean 
was calculated. The uterine flushing and plasma PP14 results from one infertile patient 
were more than two standard deviations outside the mean. Since this result may indicate 
some underlying pathology the results from this patient were excluded from the 
calculation of the mean. All the original data points are shown on each graph, the 
summary graphs show the adjusted data.
The geometric means from the results from fertile women were compared with those 
from infertile women and from women suffering from recurrent miscarriage using 
Student's /-test. The level of statistical significance was chosen at P<0.05.
The correlation between levels of PPM measured in uterine flushings and in plasma 
samples was analysed using regression analysis.
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6.3 RESULTS
6.3.1 PP14 levels in uterine flushings and plasma samples from fertile women
A total of 60 uterine flushings were carried out on fertile women and 53 plasma samples 
taken between days LH -3 and LH +14 of the menstrual cycle.
The concentrations of PPM measured in uterine flushings from fertile women are shown 
in Figure 6.1. PPM was detectable in two samples taken on day LH -3. Between day 
LH -1 and LH + 5 the levels of PPM measured were mostly below or just above the 
detection limit of the assay. After day LH +6 the PPM levels started to rise rapidly. The 
mean PPM concentrations in uterine flushings were: day LH +4 = not detectable, LH +6  
= 9.6 ng/ml, LH +7 = 178.9 ng/ml, LH +8 = 1228.1 ng/ml, LH +10 = 17529.1 ng/ml, LH 
+12 = 14861.5 ng/ml.
The concentrations of PPM measured in the plasma samples from fertile women are 
shown in Figure 6.2. PPM was detectable in all plasma samples and the levels rose 
during the secretory phase of the menstrual cycle although there was a small drop at day 
LH +8 . The mean concentrations in the plasma samples were: day LH +4 = 13.3 ng/ml, 
LH +6 = 9.3 ng/ml, LH +7 = 26.8 ng/ml, LH +8 =14.5 ng/ml, LH +10 = 36.9 ng/ml, LH 
+12 = 51.4 ng/ml.
The correlation between levels of PPM in uterine flushings and plasma samples taken 
immediately afterwards is shown in figure 6.3. There is a significant (P<0.0005) 
correlation between PPM levels measured in the uterine flushings and plasma samples 
(>=0.64; n=53). The concentration of PPM in uterine flushings rose more rapidly than 
that measured in plasma samples although both rose during the menstrual cycle to reach 
a peak in the late secretory phase. At this stage the levels of PP14 detected in uterine 
flushings are over 100 times greater than those measured in plasma samples.
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Figure 6.1: The concentration of PPM in uterine flushings
(n=60) obtained from 23 fertile women with regular menstrual 
cycles. On days where there were four or more results the means 
are represented by the closed squares. The dotted line indicates 
3 ng/ml, the detection limit of the assay.
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Figure 6.2: The concentration of PPM in plasma samples (n=53) 
obtained from 20 fertile women with regular menstrual cycles. On 
days where there were four or more results the means are 
represented by the closed squares. The dotted line indicates 
3 ng/ml, the detection limit of the assay.
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Figure 6.3: The relationship between the concentration of PPM 
in uterine washings (x-axis) and the concentration of PPM in 
plasma samples (y-axis) taken immediately afterwards from fertile 
women (n=53). The dotted lines indicate 3 ng/ml, the detection 
limit of the assay. (r=0.64, P<0.0005)
6.3.2 PP14 levels in uterine flushings and plasma samples from infertile women
A total of 49 uterine flushings and 48 plasma samples were taken from infertile women 
between days LH -1 and LH +12 of the menstrual cycle.
The concentrations of PPM measured in uterine flushings from infertile women are 
shown in Figure 6.4. PPM was undetectable in two samples taken before day LH +7. 
On day LH +7 PPM was undetectable in 5 out of 17 samples (29%) compared to 1 out 
of 7 samples (13%) in fertile women. After day LH +7 the PPM levels started to rise 
rapidly. The mean PPM concentrations in uterine flushings were: LH +7 = 327.7 ng/ml, 
LH +10 = 3055.3 ng/ml, LH +12 = 5368.1 ng/ml.
The concentrations of PPM measured in the plasma samples from infertile women are 
shown in Figure 6.5. As with the samples from fertile women PPM was detectable in all 
plasma samples and the levels rose during the secretory phase of the menstrual cycle. 
The mean concentrations in the plasma samples were: LH +7 = 25.1 ng/ml, LH +10 =
48.2 ng/ml, LH +12 = 57.0 ng/ml.
Figure 6.6 shows the comparison between the levels of PPM measured in uterine 
flushings and in plasma samples from fertile and infertile women. The mean levels of 
PPM in uterine flushings from infertile women were significantly lower than the levels 
measured in fertile women on day LH +10 (p>0.005)and day LH +12 (p>0.005). There 
was no significant difference seen between the levels measured on day LH +7. There 
was also no significant difference observed between the levels measured in the plasma 
samples on days LH +7 and LH +12, however on day LH +10 the plasma levels of PPM 
from infertile women were significantly higher than those measured in fertile women 
(P<0.05).
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Figure 6.4: The concentration of PPM in uterine washings
(n=49) obtained from 18 infertile women with regular menstrual 
cycles. On days where there were four or more results the means 
are represented by the closed squares. The dotted line indicates 
3 ng/ml, the detection limit of the assay.
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Figure 6.5: The concentration of PPM measured in plasma 
samples (n=48) obtained from 18 infertile women with regular 
menstrual cycles. On days where there were four or more 
results the means are represented by the closed squares. The 
dotted line indicates 3 ng/ml, the detection limit of the assay.
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Figure 6.6 : Comparison of the average levels of PPM
measured in uterine flushings (top graphs) and plasma samples 
(bottom graphs) from fertile and infertile women. The closed 
squares indicate the samples from fertile women, the open 
squares the samples from infertile women. The error bars 
represent the standard error of the mean for each set of samples. 
* indicates statistical significance.
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6.3.3 PP14 levels in uterine washings from recurrent miscarriage patients
Figure 6.7 shows the levels of PPM measured in uterine flushings from recurrent 
miscarriage patients on day LH +7 of the menstrual cycle. The levels of PPM measured 
in uterine flushings from fertile women are also shown for comparison. There was no 
significant difference between the levels measured in uterine flushings from fertile women 
and recurrent miscarriage pateints, however the range of values measured in the flushings 
from recurrent miscarriage patients was wider than that of the fertile women (<3- 
5000ng/ml, recurrent miscarriage, <3,-1540.7ng/ml, fertile women,) and the number of 
women with undetectable PPM was higher in the recurrent miscarriage group (n=19, 
54%) compared to the fertile group (n=l, 13%).
The PPM levels measured in uterine flushings from women with primary and secondary 
miscarriage were compared. The data is summarised in table 6 .1. The proportion of 
samples containing detectable PPM was similar for both groups (primary, 44%; 
secondary, 50%) as were the means (primary, 58.4ng/ml; secondary, 65.1ng/ml).
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Figure 6.7: Comparison of levels of PPM measured in uterine
flushings from 7 fertile women and 19 recurrent miscarriage patients. 
The dotted line indicates the detection limit of the assay 3ng/ml. The 
mean values are indicated by the lines. There was no significant 
difference between the levels for each group of women.
155
PP1
4 
(ng
/m
l)
10000
1000
100
6 7542 3
Histological dating (days from LH surge)
Figure 6.8 : The relationship between PP14 concentrations in 
uterine flushings from recurrent miscarriage patients and the 
dating of endometrial biopsies taken on the same occasion.
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PP14 Detectable 
(number of patients)
PP14 Undetectable 
(number of patients)
Primary miscarriage 11 14
Secondary miscarriage 5 5
Table 6.1: Comparison of the detection and levels of PPM in uterine flushings 
from primary and secondary miscarriage patients. Average PPM levels: 
Primary miscarriage = 58.4ng/ml, S.E.M. = 31.2; Secondary miscarriage = 
65.1ng/ml, S.E.M.= 40.3. Detection limit of the assay was 3ng/ml.
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6.3.4 Relationship between endometrial biopsy analysis and PP14 levels in uterine 
washings in recurrent miscarriage patients
Figure 6.8 shows the levels of PPM measured in uterine flushings taken from recurrent 
miscarriage patients immediately before an endometrial biopsy was taken, and the LH 
dating of that biopsy as assessed histologically by the method of Noyes (1950) or by 
morphometric analysis (Li et al., 1988). PPM was detectable in only 2 (17%) of the 
samples taken from women with retarded endometrium (n=12) but in women with 
normal endometrium PPM was detected in 15 samples (65%, n=23). These data are 
summarised in Table 6.2. In the samples with detectable PPM the mean levels were 
higher in the samples from women with normal endometrium than in the samples from 
those with retarded endometrium, however the difference between the two groups did 
not achieve significance.
6.3.5 Subsequent pregnancy outcome of recurrent miscarriage patients related to 
PP14 levels
Data were collected on the pregnancy outcome of the patients included in this study and 
related back to the levels of PPM measured in uterine flushings taken during a previous 
menstrual cycle. 19 of the women subsequently became pregnant (54%). Of these 
women 14 had successful pregnancy leading to a live birth (74%) and 5 miscarried 
(26%). The levels of PPM measured in the uterine flushings in these women are 
summarised in table 6.3. 4 of the 12 women with no detectable PPM miscarried (33%) 
compared with 1 of the 7 women with detectable PPM (14%). In the samples with 
detectable PPM the mean levels of PPM measured in the women who had a live birth 
were higher than the levels in the woman who miscarried but the numbers of patients are 
too small for this to be significant.
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Histological dating PP14 Detectable 
(number of patients)
PP14 Undetectable 
(number of patients)
Normal (>LH+5) 14 9
Retarded (<LH+5) 2 10
Table 6.2: Detection of PPM in uterine flushings from recurrent miscarriage 
patients. Mean PPM levels: Normal endometrium = 683.2ng/ml; S.E.M. = 
359.4; Retarded endometrium = 127.1ng/ml; S.E.M. = 102.4. Detection limit 
of the assay was 3ng/ml.
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PP14 Detectable PP14 Undetectable
Live Birth 6 8
Miscarriage 1 4
Table 6.3: Detection of PPM in uterine flushings and subsequent pregnancy 
outcome. Mean PPM levels: Live birth = 1179.1ng/ml, S.E.M = 961.9; 
Miscarriage = 229.4ng/ml. Detection limit of the assay was 3ng/ml.
160
6.4 DISCUSSION
The measurement of PPM in plasma samples has been shown to have limited use as a 
method of assessing endometrial function (McRae et a l, 1991). This study investigated 
the use of the technique of uterine flushing coupled with the measurement of PPM as a 
potentially useful way of investigating the local secretory activity of the endometrium.
6.4.1 PP14 levels in plasma samples and uterine flushings from normal, fertile 
women
PPM levels were measured in plasma and uterine flushings from 23 proven fertile 
women. The results from the plasma samples confirmed previous studies (Joshi et al., 
1980; Julkunen et a l, 1986b), showing a general trend of rising plasma PPM 
concentrations during the secretory phase of the menstrual cycle, with average levels 
doubling between days LH +7 and LH +12.
The PPM levels observed in the uterine flushings showed a more pronounced pattern. In 
the two samples taken on day LH -3 PPM was detectable, then the average levels 
dropped with the majority of samples between days LH -1 and LH +5 containing no 
detectable PPM. At day LH +7 onwards the levels of PPM began to rise exponentially, 
with an mean doubling time of 13.7 hours between days LH +7 and LH +12. By day LH 
+10 the levels of PPM in the uterine flushings were in the pg/ml range. The volume of 
fluid in the uterine cavity has been estimated as no more than 0.2ml (Casslen, 1986) 
therefore flushing the cavity with 10ml of fluid as was the case in this study would dilute 
this fluid by a factor of 50. Therefore the PPM levels actually in the undiluted uterine 
fluid can be estimated to average 875pg/ml at day LH+10. This is over lOOOx higher 
than the mean PPM levels measured in plasma samples at this time in the cycle. It may 
also be significant that the concentrations reached from day LH +7 onwards during the 
ped-implantation period are in the range at which PPM is biologically active as shown in 
chapter 3. This points to a possible role for PPM in the process of implantation.
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There is a significant correlation between the levels of PPM measured in plasma samples 
and that measured in uterine flushings taken on the same occasion in fertile women. 
Although it has been suggested that the endometrium may not be the only source of 
PPM (Seppala et al., 1987) the increase in plasma PPM observed during the secretory 
phase of the menstrual cycle is likely to be due to seepage of PPM from the uterine 
cavity into the plasma.
6.4.2 PP14 levels in plasma samples and uterine flushings from infertile women
PPM levels were measured in plasma samples and uterine flushings from infertile women 
and compared to those observed in fertile women. There was no significant diffference 
in the mean plasma levels between the two groups of women on days LH +7 and LH +12 
but on day LH +10 the mean levels in the samples from infertile women were just 
significantly higher than the mean levies in the fertile women. In the uterine flushings on 
day LH +7 there was no significant difference in mean PPM levels between the two 
groups while on days LH +10 and +12 the mean levels of PPM in the uterine flushings 
from infertile women were significantly lower than those measured in flushings from 
fertile women.
Abnormalities in the secretory ability of the endometrium have been implicated as a cause 
of unexplained infertility (Li et al., 1990). The lower levels of PPM in the uterine 
flushings from infertile women as compared to the levels of PPM in the flushings from 
fertile women may be a reflection of this. The plasma levels did not show up this 
difference, confirming that plasma levels of PPM are not sensitive enough to reflect 
changes in the local endometrial environment.
6.4.3 PP14 levels in uterine flushings from recurrent miscarriage patients
The levels of PPM measured in uterine flushings from recurrent miscarriage patients was 
compared to the levels measured in flushings from fertile women on day LH +7, the day 
of implantation. There was no significant difference between the mean levels from the 
two groups, however the range of PPM levels measured was wider in the samples from
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women with recurrent miscarriage. This indicates that the secretory function of the 
endometrium in these patients may be out of phase, either ahead or behind the LH 
dating, leading to both higher and lower PPM levels than those observed in fertile 
women.
The data was also analysed to see if there was a difference in the PPM levels measured 
in uterine flushings from primary and secondary miscarriage patients. There was no 
difference observed between these groups. PPM was equally likely to be detected and 
there was no significant difference in the mean PPM levels measured or the S.E.M 
between the two groups.
The relationship between the levels of PPM measured in the uterine flushings and the 
histological dating of biopsy samples taken immediately afterwards was investigated. 
There was not a clear correlation between the PPM levels and the histological dating, 
instead there appear to be three groups of patients, all but two patients fit into one of 
three categories. The first group have normal endometrial development and also secrete 
measurable quantities of PPM. The second group have retarded endometrial 
development and PPM cannot be detected in their uterine flushings. In both these 
groups the PPM levels reflect the histological endometrial development. In the third 
group of pateints this is not the case. These patients have apparently normal endometrial 
development as assessed histologically, but they do not have detectable levels of PPM in 
their uterine flushings.
This implies that PPM is a marker of endometrial secretory function, rather than 
endometrial development alone.
The pregnancy outcome of the recurrent miscarriage patients was compared with the 
levels of PPM in the uterine flushings to see if PPM had any predictive value. The 
numbers of patients were too low to draw any firm conclusions. However, it appears 
that although a lack of PPM does not make a patient more likely to miscarry, the
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detection of PP14 in uterine washings raises the probability that the pregnancy will be 
successful. 80% of patients who had detectable PPM in their uterine flushings went on 
to have a successful pregnancy outcome compared to 66% of those without detectable 
PPM. This is likely to be due to PPM secretion being a marker of endometrial 
development and secretory ability, although it may be a more direct effect.
When the study was initially designed LH +7 was picked as the day to study because it is 
around the time of implantation. The results from the fertile women show that PPM 
secretion is only just detectable on this day and differences between these levels and 
those in infertile women only become significant later in the secretory phase. This may 
also be true for recurrent miscarriage patients and studies are currently underway to 
extend this work in this way.
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6.5 CONCLUSION
From these results it would seem that PP14 measurement in uterine flushings is a more 
effective assessment of endometrial function than plasma PPM measurement. In infertile 
patients PPM measurements may be able to identify women with secretory dysfunction. 
This may also be true for women with recurrent miscarriage, and a lack of PPM may 
indicate either endometrial retardation or secretory dysfunction. Further studies into 
PPM and other secretory molecules in uterine flushings may distinguish between 
histological and secretory endometrial development and provide a non-invasive way of 
investigating the local uterine environment from a structural and a functional perspective.
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CHAPTER SEVEN: FINAL DISCUSSION AND
CONCLUSIONS
7.1 INTRODUCTION
7.1.1 Leukocytes in the decidua
In Chapter 1 the presence in the decidua of NK-like large granular lymphocytes (LGLs) 
and macrophages was described. Both these cell populations appear to be specifically 
recruited, and are likely to have a role in the process of normal pregnancy. One function 
that has been suggested for the LGLs is that of surveillance of aberrant trophoblast, 
thereby controlling the invasion of the fetal tissue. These LGLs appear to be activated, 
which may be important for their function, but there does not appear to be a upregulation 
of the responses usually associated with immunologically activated cells. Therefore there 
appears to be a tightly regulated system that allows these activated cells to exist 
alongside the semi-allogenic fetus without a rejection response occurring. However if 
decidual LGLs are exposed to exogenous interleukin-2 they are then able to lyse 
trophoblast cells. They also release y-interferon (y-IFN), a cytokine which enhances the 
expression of MHC antigens, and may increase the susceptibility of the fetal tissue to this 
recognition process.
Activated lymphocytes release interleukin-2, which further stimulates the proliferation of 
lymphocytes in a positive feedback mechanism. The presence in the decidua of activated 
LGLs that do not appear to secrete IL-2 is intriguing. One explanation is the proposal 
that immunomodulators in the decidua suppress the immune response, preventing the 
upregulation of the immune response.
7.1.2 Immunomodulation
While the observation that decidual tissue contains immunosuppressive activity is 
generally accepted, there is disagreement and controversy about which molecules are
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responsible. Transforming growth factor-P, an immunosuppressive cytokine, has been 
suggested as one of the molecules involved. More controversial is the suggested role of 
placental protein 14 (PP14), to which immunosuppressive activity has also been 
attributed (Bolton et al, 1987). PP14 is a major secretory product of the endometrium 
during the second half of the menstrual cycle and the decidua during the first trimester of 
pregnancy.
The study of immunomodulators from decidual tissue including PPM may have 
important clinical applications, not only in the field of reproduction, but also in the study 
or treatment of diseases which involve upregulated inflammatory responses, such as 
rheumatoid arthritis.
7.1.3 Placental protein 14
Most previous studies into PPM have involved either the measurement of the molecule 
in plasma or serum in a clinical context, or investigations into the immunosuppressive 
activity of the molecule.
The aim of this thesis was to broaden the knowledge of PPM and develop a number of 
ways of studying this molecule that would provide tools for future investigations. 
Studies were carried out to extend previous investigations of the activity, structure and 
clinical relevance of PPM. In addition a number of new methods of studying PPM were 
developed. These included the U937 bioassay, the expression of PPM as a recombinant 
protein and the technique of uterine flushing as a method to study PPM in a clinical 
context.
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7.2 PURIFICATION OF PP14 AND INVESTIGATION OF ACTIVITY
The purification method described in Chapter 2 yielded active PPM at a purity of 97% in 
mg quantities. One key factor in the success of this method in recovering active protein 
may have been the maintenance of all stages of the method at 4°C. This could explain 
why some other investigators have failed to prepare active PPM using methods which 
were carried out at room temperature.
The purified protein was investigated for its ability to suppress the response of peripheral 
blood mononuclear cells to IL-2. This is relevant because of the principal role of IL-2 in 
the immunological environment of the endometrium. The fact that PPM blocks the 
proliferative response of PBMCs to IL-2 confirms its potential role in the 
immunomodulation of this environment.
PPM may mediate its action by acting on monocyte-macrophages to suppress the release 
of DL-1. The suppression of the growth of the IL-1 dependent cell line U937 by PPM 
would seem to confirm this theory.
However, the main point of the investigation into the suppression of U937 growth by 
PPM was the potential this observation provided for the development of a bioassay for 
PPM. The lack of reproducibility was a serious disadvantage of the previous methods of 
investigating the activity of PPM. This was a natural consequence of the variation from 
one person to another of the response of blood cells to mitogens or PHA. The U937 
assay provides a rapid, simple method for the further investigation of PPM. This assay 
can be used for the study of the stability of PPM, as demonstrated in Chapter 3. Other 
applications are the study of interaction of PPM with receptors and the binding of PPM 
to a co-factor or ligand.
The assay also enables the activity of PPM to be defined in terms of Unit/ml. An 
arbitrary definition was made that 1 Unit of activity is the amount of PPM activity
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required to suppress by 50% the growth of 1 x 105 U937 cells. The U937 assay 
described is not specific for PP14, but it can be made specific by the use of the 
immunoabsorbent gel.
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7.3 EXPRESSION OF RECOMBINANT PP14 AND MOLECULAR 
MODELLING
The expression of a protein in a recombinant form is an important development towards 
the use of that protein as a therapeutic molecule. Although pure recombinant PPM was 
not obtained, the cloning and expression of the cDNA coding for PPM in E. coli 
provides the basis for a source of recombinant protein in the future. The optimisation of 
the expression and growth conditions has been achieved. Once the optimisation of the 
purification of the fusion protein, and the cleavage reaction have also been carried out a 
source of recombinant PPM will be available.
An important factor in the activity of the recombinant preparation will be the requirement 
or otherwise of a co-factor or ligand for activity.
With this in mind, the molecular modelling of PPM has been carried out using a 
computerised modelling programme. The enabled the investigation of the structure of 
PPM and the binding pocket of the molecule. It also provided an opportunity to 
anticipate which co-factors or ligands may fit into the binding pocket.
Progesterone emerged as a potential ligand for PPM, fitting the binding pocket and 
having charged groups at either end which could interact with the charged amino acids 
that are present in those specific areas of the molecule.
In addition the modelled structure of PPM predicted that the molecule shares many 
structural features with other members of the lipocalin family. As the mode of action of 
these other members is discovered this may assist with investigations into the mode of 
action of PPM. The model showed two possible receptor binding sites, one at the back 
of the binding pocket, the other at the entrance of the binding pocket.
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7.4 CLINICAL STUDIES
The clinical data presented here demonstrates the importance of PP14 measurements in 
uterine flushings as a technique for investigating the local environment of the 
endometrium.
The levels of PPM measured in uterine flushings from fertile women showed a pattern of 
secretion consistent with the previously reported immunohistochemical data. This 
pattern of secretion is observed in plasma PPM measurements but the levels in uterine 
flushings are more directly representative of the secretory activity of the endometrium.
Infertile women had lower levels of PPM and women suffering from recurrent 
miscarriage often did not secrete PPM at all on day LH +7. The measurement of PPM 
in these patients may diagose endometrial secretory dysfunction.
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7.5 EXTENSION OF THE KNOWLEDGE OF PP14
This thesis has described a number of investigations into the immunomodulatory protein
PPM.
The overall understanding of this molecule was advanced in several key areas:
1. PPM suppresses the proliferative response of peripheral blood mononuclear cells to 
IL-2. This is directly relevant to the situation in decidual tissue where an activation 
of lymphocytes by IL-2 may cause trophoblast lysis and fetal demise.
2. The suppression of growth of the cell line U937 can be used as the basis for a 
bioassay for PPM. This assay is reproducible, rapid and simple. It provides a 
method of expressing the specific activity of PPM.
3. PPM has been expressed in a recombinant form, this is vital for any therapeutic 
application of the molecule. The availability of recombinant PPM will also assist in 
the study of the activity of the molecule by providing an alternative source of pure 
protein.
4. The predicted molecular model of PPM reveals that it is similar in structure to the 
other members of the lipocalin family. This identifies it as a carrier of small 
hydrophobic molecules. This characteristic could be exploited and PPM used to 
carry a variety of molecules by modifying the amino acids inside the binding pocket.
5. PPM measurement in uterine flushings provides a more accurate reflection of the 
secretory activity of the endometrium than plasma PPM measurement. Reduced 
levels of PPM are found in the flushings of infertile women, while in recurrent 
miscarriage patients PPM is often absent in flushings in the peri-implantation period.
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7.6 FUTURE STUDIES
As previously mentioned the investigations and results described in this thesis provide 
new methods by which to study PP14.
Some aspects of the studies need completion. A complete investigation of the stability of 
the activity of PP14, using the bioassay, would be one such study. The completion of the 
purification of recombinant PP14 is another.
The modelled molecular structure of PP14 can be used to investigate a wider and more 
extensive range of ligands. Solving the structure of PP14 by X-ray crystallography 
would be a useful confirmation of the data presented here.
An investigation into the levels of PP14 found in recurrent miscarriage patients later in 
the menstrual cycle would demonstrate whether these women, like those with 
unexplained infertility, secrete subnormal amounts of PP14. The technique of uterine 
flushing and subsequent PP14 measurement is more sensitive to changes in the uterine 
environment than the measurement of PPM in plasma. This technique may be able to 
detect endometrial dysfunction, or the response of the endometrium to hormone 
therapies.
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APPENDIX I REAGENTS, SUPPLIERS AND 
EQUIPMENT
Li Reagents
All reagents unless otherwise indicated were obtained from Sigma, Poole, Dorset, U.K.; 
BDH, Poole, Dorset,U.K.; or Fisons, Loughborough, Leicestershire, U.K.
DEAE Sepharose Fast Flow 
Hexyl agarose 
Superdex 200 HR 
Hiload Q Sepharose 
Protein assay 
Molecular weight markers 
Lymphopaque 
AIM V medium 
Scintillation fluid 
mRNA extraction kit:
Phenol
Chloroform
First-Strand cDNA synthesis kit 
Restriction enzymes
Taq Polymerase 
T4 Ligase 
GeneClean 
Agarose
Disposable plastics
Pharmacia Biochemicals, Hertfordshire, U.K. 
ACL chromatography, Isle of Man 
Pharmacia Biochemicals, Hertfordshire, U.K. 
Pharmacia Biochemicals, Hertfordshire, U.K. 
Pierce, Chester U.K.
Biorad, Hertfordshire, U.K.
Nycodenz, Sweden 
Gibco, Paisley U.K.
Wallac, Milton Keynes, Hertfordshire, U.K. 
Stratagene, Cambridge, U.K.
Appligene, Chester-le-Street, Co. Durham, U.K. 
New Brunswick Scientific, Hatfield, U.K. 
Pharmacia Biochemicals, Hertfordshire, U.K. 
Northumbria Biologicals Limited, Cranlington, 
Northumbria, U.K.
Promega, Southampton, U.K.
Promega, Southampton, U.K.
Bio 101. California, U.S.A.
BRL, Gaithersburg, Maryland, U.S.A.
Fisons, Leicester, U.K.
Sarstedt Leicester, U.K.
Alpha, Eastleigh, Hampshire, U.K.
Costar, Buckinghamshire, U.K.
Nitrocellulose membranes 
(Hybond C)
Filter papers 
Glutathione Agarose 
Yeast extract 
Tryptone 
Agar
125I-NaOH
3H-Thymidine
Donkey anti-rabbit Amerlex
I.ii Equipment
Gamma counter 
Beta counter 
Cell harvester 
Centrifuges
Dri-Block
SDS-PAGE equipment 
Power supplies
Agarose gel electrophoresis 
Balances
Western blot equipment 
Vortex Mixer 
Water Bath 
Rotary evaporator
Amersham, Little Chalfont, Buckinghamshire, 
U.K.
Whatman, Maidstone, Kent
Pharmacia Biochemicals, Hertfordshire, U.K.
Oxoid, Unipath Ltd, Basingstoke U.K.
Difco, Detroit, Michagen, U.S.A.
Difco, Detroit, Michagen, U.S.A.
ICN Flow, Oxfordshire, U.K.
ICN Flow, Oxfordshire, U.K.
Amersham Little Chalfont, Buckinghamshire, U.K.
LKB
LKB
ICN Flow 
Centaur 2 (MSE)
Beckman JA-21 
Techne
Biorad MiniProtean II
Pharmacia EPS 500/400
Hoefer, PS 500XT, (Hoeffer Scientific
Instruments), San Francisco, U.S.A.
Biorad Model 200/2.0.
Biorad mini and miniwide sub DNA cell
Mettler AJ100
Hoefer TE Series Transphor
MT20, Chiltern
Grant Cambridge
Hetovac
Pipettes
Oligonucleotide synthesiser 
Thermal cycler 
Spectrophotometer
Eppendorf,
Applied Biosystems 392 DNA/RNA synthesiser 
Coy Tempcycler, Flowgen 
Ultraspec 4050 LKB
APPENDIX n  PP14 RADIOIMMUNOASSAY
n.i Iodination of PP14
PPM was measured using the method of Bolton et. al. (1983). PPM was iodinated by 
the chloramine T method. lOpg of PPM purified by the method described in chapter 2 
in lOpl of iodination buffer (50mM phosphate buffer, pH 7.5) was placed in a 12mm x 
75mm polystyrene tube. To this was added lmCi of 125I-NaOH in lOjil, followed by 1.7 
pg of chloramine T in lOpl of iodination buffer. After exactly 30 seconds the reaction 
was stopped by the addition of 5 mg of cysteine in lOOpl of iodination buffer, followed 
by 10 mg Nal in 1ml of assay buffer (50mM phosphate, pH 7.5, containing 1% BSA and 
0.1% sodium azide). The tracer was separated from the free iodine by applying it to a 
10ml G25 column. The fractions containing protein were further purified on a 1ml 
column of concavalin A, to which PPM binds. Damaged PPM passes through and the 
bound PPM was eluted with 0.2M mannose in assay buffer.
The binding of the tracer was titrated against the polyclonal antibody. The dilution of 
antibody which gave 50% binding of the tracer was picked to use in the assay.
n.ii PP14 radioimmunoassay
lOOpl of each sample or standard (200-1.5ng/ml) was placed in a tube in duplicate. To 
this was added lOOpl of PPM tracer diluted to lng/ml in assay buffer and lOOpl of 
polyclonal antibody diluted to give 50% binding of the tracer. Zero standard tubes 
containing assay buffer instead of sample, non-specific binding tubes containing assay 
buffer instead of sample and antibody and totals tubes containing tracer only were also 
set up. All tubes were mixed and left at room temperature overnight. Next lOOpl of 
Amerlex antirabbit magnetic separating reagent was added to each tube except the totals 
tubes, the tubes were mixed and left to stand for 20 minutes. After centrifuging at 2000g 
for 10 minutes at room temperature the unbound fraction in the supernatant was 
aspirated and the bound fraction in the pellet counted in a gamma counter. The
detection limit of the assay was 3ng/ml and the inter- and intra-assay variation less than 
10%.
APPENDIX m  MONOCLONAL ANTIBODIES
m.i Subcloning of monoclonal antibodies
A cell line producing monoclonal antibodies against PPM was subcloned. The cloning 
medium was RPMI supplemented with 20% FCS, 10% human endothelial cell 
supplement (HECS), 200mM Penicillin, 200jig/ml streptomycin and 2mM glutamine. 
Cells were diluted in this medium to concentrations of 320,160,80,40,20,10,5, and 2.5 
cells /ml. lOOfxl of each dilution was placed in a row of wells in a 96 well plate. The 
wells were all topped up with an additional lOOpl of cloning medium. A few hours later 
the wells were inspected microscopically and a note made of the number of cells present 
in each well. The plates were incubated for about a week until colonies of cells had 
grown. The cells were then subcultured into 24 well plates in RPMI + medium (RPMI, 
10% fetal calf serum, 200mM penicillin, 200pg/ml streptomycin, 2mM glutamine).
After 3-4 days a portion of the supernatant was removed and tested for antibody activity 
against PPM. lOOpl of iodinated PPM diluted to lng/ml was mixed with lOOpl of cell 
supernatant. After overnight incubation the bound tracer was separated from the 
unbound using Amerlex anti-mouse solid phase. Radioactivity was found in the bound 
fraction in clones secreting the antibody. Clones that tested positive were expanded into 
25cm2 flasks. 3-5 clones were selected, based on the extent of their binding to PPM, the 
fact that they originated from one cell only (as recorded when the wells were scored for 
cell numbers), and speed of growth. These clones were tested for subtype using a 
Serotec subclone kit and found to be subtype IgGla. A portion of the expanded cells 
were frozen in liquid nitrogen in a freezing medium of 10% DMSO, 90% FCS. These 
clones were maintained as a stock cell line and expanded to produce monoclonal 
antibodies as required.
Ill.ii Production and purification of monoclonal antibodies
The subcloned cells were expanded into 225cm2 flasks in RPMI + medium. The cells 
were grown on to exhaustion, removed by centrifugation and up to 5 litres of 
supernatant mixed with an equal volume of saturated ammonium sulphate at 4°C. After 
1 hour the suspension was centrifuged at 10,000g for 30 minutes at 4°C. The pellet 
containing the antibodies was resuspended in approximately 200mls of water and 
dialysed overnight against two changes each of 4 litres of PBS.
After centrifuging to remove any insoluble material the dialysed solution was applied to a 
5ml Protein G column. After washing the column with 2 column volumes of PBS the 
antibodies were eluted with glycine-HCl (0.1M, pH 2.7). The eluted antibodies were 
collected as 1 ml fractions in tubes containing lOOpl of2M Tris pH 9.0 to protect against 
denaturation due to the low pH. The antibody concentration was measured using a RID 
kit and the antibodies were stored at -20°C until required.
APPENDIX IV SDS-PAGE ELECTROPHORESIS AND WESTERN BLOTTING
IV.i SDS-PAGE
SDS-PAGE was carried out using the Biorad mini-protean system. 12% gels were 
prepared by mixing the following reagents to make the separating gel:
8.1 ml acrylamide/bisacrylamide solution (30%, 29:1 w/w)
1.9 ml water
5.0 ml separating gel buffer (1.5M Tris-HCl, pH 8.8)
5 ml Ammonium persulphate (0.1%)
25pi TEMED
This mixture was poured in to the gel mould and overlayed with water saturated butanol 
to speed up the polymerisation which is inhibited by air. After it had set (approximately 
1 hour) a stacking gel was poured consisting of the following reagents:
3.2ml acrylamide/bisacrylamide solution (30%, 29:1 w/w)
6.8ml water
5.0ml stacking gel buffer (0.5M Tris-HCl, pH 6.8)
5 ml Ammonium persulphate 
25pi TEMED
A comb to form the well was inserted into the stacking gel immediately after it had been 
poured and the gel was left to set for 1 hour.
After loading the samples the gels were electrophoresed for 1 hour at 150V then stained 
in 0.25% Coomassie Brilliant Blue stain for 1 hour. The gels were destained in 
methanol:water:acetic acid (5:5:1).
IV.ii Western blotting
After running the gels some lanes were blotted. The lanes were sliced from the rest of 
the gel which was then stained. Nitrocellulose membrane was cut to the same size as the 
gel and placed on top of it. The gel and membrane were sandwiched between four 
pieces of filter paper soaked in separating buffer, placed in a semi-dry blotting apparatus 
and a current of 10-15mA/cm2 of gel was applied for 20 minutes.
The nitrocellulose membrane was removed and the free binding sites were blocked by 
incubation in blotto (PBS, 2.5% skimmed milk powder, 0.1% sodium azide) overnight 
with shaking on a plate shaker at room temperature. The membrane was then incubated 
for 2 hours in blotto containing the primary antibody. After three ten minute washes in 
blotto with shaking the membrane was placed in blotto containing the secondary 
antibody conjugate (anti-rabbit alkaline phosphatase or anti-mouse alkaline phosphatase 
1/10000 dilution). The membrane was incubated for two hours with shaking, the washed 
twice for 10 minutes with blotto then washed twice in substrate buffer (lOOmM Tris- 
HCl, pH 9.5, lOOmM NaCl, 50mM MgCl2). The substrate (BCIP/NBT, 1.5mg/3mg) 
was added to the membrane in substrate buffer and incubated for 30 minutes or until 
colour development was observed.
APPENDIX V PROTEIN ASSAY
Total soluble protein was measured using a Pierce BCA protein kit adapted for use in 
microtitre plates.
lOpl of samples or standards in duplicate were placed in the wells of a microtitre plate. 
200pl of assay reagent (bicinchoninic acid and copper sulphate) was added to all wells. 
After shaking the plate on a plate shaker for 30 seconds the plate was covered and 
incubated at 37°C for 30 minutes. The colour development was read at 540nm in a plate 
reader. The standard protein used was albumin at concentrations in. the range 200pg/ml- 
2000pg/ml.
